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Abstract 
Peptidases of Leishmania are acknowledged virulence factors.  It is hypothesised 
that peptidases are crucial for the survival of Leishmania in its hosts and that many 
could be potential targets for new antileishmanial drugs.  As such, the investigation 
of peptidase activity in live Leishmania promastigotes was proposed as a valuable 
approach by which to increase knowledge on particular peptidases.  In order to 
complete this investigation, it was decided to use short peptidyl fluorogenic 
substrates, which only fluoresce once the bond linking the peptide to the 
fluorescent moiety is cleaved.  These allow detection of peptidase activity by 
quantifying the release of the fluorescent moiety. 
Detection of peptidase activity in live Leishmania using the fluorogenic substrate 
Bz-R-AMC proved fruitful, enabling study of the activity of the serine peptidase 
oligopeptidase B (OPB) in live L. major promastigotes.  OPB is a member of the 
Family S9 peptidases, the prolyl-oligopeptidases, which are taxonomically 
restricted to plants, bacteria and trypanosomatid flagellates.  In African and 
American trypanosomes, OPB has been shown to have important roles: OPB is a 
virulence factor in Trypanosoma cruzi, mediating entry into host cells, and OPB is 
released into the serum by African trypanosomes, where it cleaves host blood 
factors. 
In this study, the inhibition profile of L. major OPB has been determined and OPB 
has been localised to the cytosol, the site of hydrolysis of Bz-R-AMC.  
Immunoprecipitation of OPB confirmed that OPB was the sole peptidase 
responsible for the hydrolysis of Bz-R-AMC and anti-OPB antibodies were found to 
inhibit the hydrolysis of Bz-R-AMC.  Inhibitors of OPB could also kill Leishmania 
promastigotes, suggesting OPB could be a valuable drug target. 
However, genetic manipulation of OPB was successful, with mutants over-
expressing OPB and Dopb null mutants produced.  OPB is thus not essential for 
the growth of promastigote L. major, though the Dopb null mutants did have a 
defect in metacyclogenesis, in survival in macrophages and a reduced ability to 
induce lesions on the footpads of mice.  A role in amastigote differentiation or 
survival in macrophages was also suggested.  OPB is thus likely to be a virulence 
factor, though not essential, and thus not suitable as a primary drug target.   iii 
A number of avenues require further investigation, including the need for re-
expression of OPB in the Dopb null mutants to confirm that lack of OPB is indeed 
responsible for the phenotypic deficiencies of the null mutants.  Other important 
areas requiring attention are investigation of the role of OPB in amastigote 
differentiation or survival, investigation of the reported release of OPB by 
promastigotes, and identification of the physiological substrate of OPB. iv 
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DCI      3,4-dichloroisocoumarin 
DFP      diisopropyl phosphofluoridate 
DMSO    dimethyl sulfoxide 
DTT      dithiothreitol 
E-64      trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane 
E-64d  (2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methylbutane 
ethyl ester 
EDTA     ethylenediamine tetra acetic acid 
ED50      effective dose to kill 50% 
EF-1a     elongation factor 1a from T. brucei  
GFP      green fluorescent protein 
GPI      glycoinositol-phospholipid 
h      hour 
HEK cells    human embryonic kidney cells 
HIFCS    heat inactivated foetal calf serum 
HRP      horseradish peroxidase 
HYG      hygromycin B 
IC50      inhibitory concentration for 50% inhibition 
IFN-a     interferon a 
IFN-g      interferon g 
IL      interleukin 
iNOS      inducible nitrogen oxide synthaseaa 
K11777    N-methyl-piperazine-Phe-homoPhe-vinylsulfone-phenyl 
kb      kilo base 
kDa      kilo dalton 
Ki      inhibition constant; binding efficiency of inhibitor 
KO      knock out 
l      litre 
LaOPB    OPB from L. amazonensis 
LB      Luria-Bertani 
LD50      lethal dose to kill 50%  xvi 
L. inf.      Leishmania infantum 
L. maj.    Leishmania major 
L. mex.    Leishmania mexicana 
LPG      lipophosphoglycan 
LUC      ectopic luciferase-expressing Leishmania 
µ      micro 
m      milli / metre 
M      molar 
min      minute 
MHC      major histocompatibility complex 
MMP      matrix metalloprotease 
MØ      macrophage 
ms      millisec 
MVT      multivesicular tubule 
n      nano 
nd      not done 
NO      nitric oxide 
OD      optical density 
OPB      oligopeptidase B 
PBS      phosphate buffered saline 
PCMB     p-chloromercuribenzoic acid 
PCR      polymerase chain reaction 
pefabloc    see AEBSF 
PEM      peritoneal exudate macrophage 
PG      phosphoglycan 
P.I.S.      pre-immune serum 
PMA      phorbol 12-myristate 13-acetate 
PMN      polymorphonuclear neutrophil granulocytes 
PMSF     phenylmethylsulfonyl fluoride 
POP      prolyl oligopeptidase 
PPG      proteophosphoglycan 
PSG      promastigote secretory gel 
PV      parasitophorus vacoule 
sec      second 
SAT      streptothricin acetyltransferase 
SDS-PAGE    sodium dodecylsulphate polyacrylamide gel electrophoresis 
SEM      standard error of the mean 
sp      subpassage number 
Suc      3-carboxy-propionyl 
TbOPB    OPB from T. brucei 
TcOPB    OPB from T. cruzi 
TcgOPB    OPB from T. congolense 
TeOPB    OPB from T. evansi 
Th      T helper cell 
TLCK     N-tosyl-L-lysyl-chloromethylketone 
TNF-a     tumour necrosis factor a 
TGF-b     transforming growth factor b 
TPCK     N-tosyl-L-phenylalanyl-chloromethylketone 
TSE      trypomastigote soluble extract 
U      unit 
VL      visceral leishmaniasis 
WHO      World Health Organisation 
WT      wild type 
Z      benzoyloxycarbonyl       1 
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1.1 Leishmania 
1.1.1 Causative agent of leishmaniasis  
Leishmania are obligate intracellular protozoa of the order Kinetoplastida and 
family Trypanosomatidae.  They are the causative agent of leishmaniasis, which is 
endemic in various tropical and subtropical regions (Herwaldt, 1999a).  Around 20 
species of Leishmania are able to infect humans and 30 phlebotomine sand fly 
species have been identified as vectors (Desjeux, 2004).  Leishmaniasis is a 
complex of diseases, which may be classified into four clinical forms:  
i) Visceral leishmaniasis (VL), also known as kala azar, causes life-threatening 
systemic infection.  Symptoms include fever, severe weight loss, anaemia, hepato-
splenomegaly, pancytopenia and hypergammaglobulinaemia.  Most cases of VL 
are caused by L. donovani, particularly in the Indian subcontinent and Eastern 
Africa.  In the Mediterranean and the New World VL is due to L. infantum and  
L. chagasi, which are now generally accepted to be one species (Olliaro et al., 
2002).   
ii) Localised cutaneous leishmaniasis (CL) is the most common form and causes 
1-200 skin lesions, generally confined to the bite site.  It is caused mainly by  
L. major, L. tropica and L. aethiopica in the Old World and by L. mexicana complex 
species, L. guyanensis and L. panamensis in the New World.  The lesions usually 
self heal within a few months, though they can cause disfiguring scars.  It can 
generally be resolved without recourse to drugs (Desjeux, 2004).   
iii) Diffuse cutaneous leishmaniasis is a chronic progressive form characterised by 
disseminated cutaneous lesions, which are non-ulcerative (Herwaldt, 1999a), due 
to a defective cell-mediated immune response (Desjeux, 2004).  The lesions are 
comparable to those of leprosy and, unlike those of localised CL, do not self-heal.  
It is caused by L. aethiopica in the Old World and L. mexicana complex species, 
particularly L. amazonensis, in the New World. 
iv) Mucocutaneous leishmaniasis is a metastatic complication of cutaneous 
leishmaniasis caused by L. braziliensis subspecies.  Sores develop on the naso-
oropharyngeal mucosal membranes with consequent disfigurement (Herwaldt, 
1999a).   Chapter 1      3 
Leishmaniasis is endemic in 88 countries worldwide, 66 in the Old World and 22 in 
the New World (Desjeux, 2001), as shown in Figure 1.1.  The disease burden is 
very high, with an estimated prevalence of 12 million people infected and 350 
million people at risk.  There is substantial under-reporting of the number of cases, 
but it is estimated that there are 1-1.5 million new cases of CL and 500,000 of VL 
annually (www.who.int/entity/leishmaniasis).  Over 90% of cases of VL occur in 
Bangladesh, Brazil, India, Nepal and Sudan; 90% of cases of CL occur in Algeria, 
Afghanistan, Brazil, Iran, Iraq, Peru, Saudi Arabia and Syria (Herwaldt, 1999a). 
1.1.2 Life cycle 
Leishmania alternate between their mammalian host and the digestive tract of 
female phlebotomine sand flies.  Most Leishmania species (those of subgenus 
Leishmania) are suprapylarian parasites, restricted to the midgut of the sand fly, 
but the New World Viannia subgenus parasites are peripylarian parasites, entering 
the hindgut before moving forward to the midgut (Kamhawi, 2006).   
When a sand fly bites an infected mammal it takes up a bloodmeal containing 
Leishmania amastigotes.  These amastigotes must differentiate into promastigotes 
to survive in the sand fly.  Six stages of promastigotes have been described, which 
Leishmania differentiate into sequentially as they move anterially through the 
midgut (Rogers et al., 2002).  Amastigotes transform into procyclic promastigotes, 
which then develop into nectomonad promastigotes, then leptomonad 
promastigotes and finally metacyclic promastigotes, which are the stage infective 
to mammals.  There are also haptomonad promastigotes and paramastigotes, 
both of which have been found only in low numbers, and for neither of which stage 
has the precursor form been definitely determined (Rogers et al., 2002; Kamhawi, 
2006).  Only two of the six stages identified have been shown to be actively 
replicative: i) procyclic promastigotes, in the abdominal midgut, the bloodmeal 
phase, and ii) leptomonad promastigotes, in the thoracic midgut and foregut, the 
sugarmeal stage (Gossage et al., 2003).  This life cycle is illustrated in Figure 1.2. 
The development of Leishmania within the sand fly, from amastigote to infective 
metacyclic promastigotes, has been found to take 6-9 days, depending on the 
species (Kamhawi, 2006).  Metacyclic promastigotes accumulate at the stomodeal 
valve for transmission.  The thoracic midgut is filled by promastigote secretory gel 
(PSG) which contains mostly leptomonad and metacyclic promastigotes and which Chapter 1      4 
 
 
 
 
Figure   1.1 Distribution of cutaneous and visceral leishmaniasis worldwide.   
A = cutaneous leishmaniasis, B = visceral leishmaniasis.   
Maps from World Health Organisation (www.who.int/leishmaniasis/leishmaniasis_maps).   
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Figure   1.2 Life cycle of Leishmania in sand fly. 
A = schematic representation of a Leishmania infected phlebotomine sand fly, illustrating time-
dependant appearance of distinct morphological forms of promastigotes within the midgut.  
Thoracic midgut is filled with promastigote secretory gel (PSG) and the stomodeal valve is held 
open by this PSG.  (From Kamhawi, 2006). 
B = digenic life cycle of Leishmania.  Parasite replication only occurs at three points: i) amastigotes 
in the parasitophorous vacuole of macrophages, ii) procyclic promastigotes in the sand fly 
abdominal midgut and iii) leptomonad promastigotes in the sand fly thoracic midgut.  The growth 
phases are linked by various non-dividing stages as is shown.  (From Gossage et al., 2003). 
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blocks the midgut, forcing open the stomodeal valve (Rogers et al., 2002).  The 
presence of the PSG plug and a heavy infection with Leishmania is associated 
with a reduced ability to take in blood, numerous attempts to feed and thus more 
chances for transmission.  It has been found that around 1000 metacyclic 
promastigotes are regurgitated into the mammalian host when a sand fly feeds, 
with most coming from behind the stomodeal valve (Rogers et al., 2004).  The 
PSG plug has also been shown to be regurgitated into the mammalian host and it 
has been found that the main component of this, filamentous proteophospho-
glycan (fPPG), enhances disease progression (Rogers et al., 2004). 
When metacyclic promastigotes are injected into the mammalian host 
polymorphonuclear neutrophil granulocytes (PMN) are the first cells recruited to 
the bite site, appearing within 10-24 hours post infection (Muller et al., 2001).   
L. major promastigotes were found to be chemotactic for neutrophils, attracting 
them to the bite site (van Zandbergen et al., 2004).  Leishmania promastigotes are 
phagocytosed by PMN and inhibit spontaneous apoptosis of the PMN, prolonging 
the cell lifespan until the point when macrophages are recruited to the bite site, 
normally within 1-2 days after infection.  Macrophages then phagocytose the 
infected PMN (Aga et al., 2002).  This has been suggested to be a “Trojan horse” 
by which the parasite can infect the macrophage silently, without activating the 
antimicrobial functions of the macrophage (Laskay et al., 2003).  PMN can be 
infected by promastigote Leishmania, but the parasites stay as this form: they do 
not transform into an amastigote, the mammalian replicative stage of the parasite 
(van Zandbergen et al., 2004), nor multiply (Laskay et al., 2003), until they are 
within the parasitophorous vacuole (PV) in a macrophage.  Amastigotes are 
aflagellate and round-oval in shape with a diameter of approximately 4 µm 
(Herwaldt, 1999a).  Amastigotes reside within PVs within the macrophage and 
these vacuoles differ depending on the species of Leishmania: they can be tightly 
or loosely fitted around the amastigotes, and one vacuole can harbour a single 
amastigote or multiple amastigotes (Rittig and Bogdan, 2000).  For example,  
L. mexicana and L. amazonensis PVs are large and contain many amastigotes, 
whilst L. major, L. infantum and L. donovani produce only small vacuoles which fit 
closely around the amastigotes (Handman and Bullen, 2002), as illustrated in 
Figure 1.3.  The amastigotes multiply within the PV and are released to infect 
further cells.  The mechanism of the release is not fully characterised.  The 
macrophage was presumed to burst due to the physical pressure of large numbers  Chapter 1      7 
 
 
 
 
Figure   1.3 Amastigotes within parasitophorous vacuoles in mouse peritoneal exudate 
macrophages.  A = PEM infected with L. mexicana, B = PEM infected with L. infantum.  Infected 
PEM were stained with Giemsa’s stain.  False colour image.  Scale = 10 µm. 
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of amastigotes, but recent evidence suggests that the parasite may induce the 
exocytosis machinery of the macrophage to enable release (Rittig and Bogdan, 
2000).   
1.1.3 Ultrastructure of Leishmania  
The ultrastructure of Leishmania differs from that of other kinetoplastids and also 
shows variation between the different life cycle stages of the parasite (Clayton et 
al., 1995).  The various forms of the Leishmania life cycle were initially 
characterised according to their dimensions, flagellar morphology, kinetoplast 
(mitochondrial DNA) position and the relative distance from the nucleus to the 
basal body of the flagellum (Clayton et al., 1995).  The characteristic shapes of the 
stages are maintained by an array of cross-linked subpellicular microtubules 
underneath the plasma membrane (McConville et al., 2002).   
The ultrastructure of the promastigote and amastigote stages of Leishmania is 
illustrated in Figure 1.4.  Promastigotes are motile cells with long thin bodies, of 
size up to 5 µm by 20 µm, with a flagellum up to 20 µm, whilst amastigotes are 
non-motile ovoid cells of approximately 4 µm diameter with only a remnant 
flagellum. 
1.1.3.1  Specialised organelles 
Leishmania contain many of the organelles found in higher eukaryotes, but they 
also contain a number of special organelles.   
The surface membrane of Leishmania is covered in a distinct glycocalyx made of 
glycolipids.  This glycocalyx is thick on promastigote stages and thin on 
amastigotes and is thought to enable survival of the promastigote in the sand fly 
(Turco et al., 2001).  The main surface molecule is the hyperglycosylated form of 
glycoinositol-phospholipid (GPI), lipophosphoglycan (LPG).  GPI-linked proteins, 
including the GPI-linked surface metallopeptidase GP63, and proteophospho-
glycans (PPGs) are also present on the surface of Leishmania (McConville et al., 
2002).  The role of LPG in virulence in mammalian hosts is dependant on the 
species.  LPG is essential for the survival of L. major and L. donovani 
promastigotes in the sand fly (Sacks et al., 2000) and for L. major infection of 
macrophages and mice (Spath et al., 2000).  However, L. mexicana parasites  Chapter 1      9 
 
 
 
 
 
Figure   1.4 Schematic representation of the main organelles of Leishmania in both 
promastigote and amastigote form.  Promastigote on the left and amastigote on the right.  The 
flagellar pocket is at the anterior end of the cell.  Taken from Besteiro et al., 2007. Chapter 1      10 
lacking LPG are still infective to macrophages and mice (Ilg et al., 2001).  The role 
of all surface molecules containing phosphoglycan (PG) has also been 
investigated in L. major, with a lack of PGs on promastigotes confirmed to lead to 
a defect in macrophage infectivity.  However, there was no effect on the infectivity 
of amastigotes (Capul et al., 2007).  This is probably due to amastigotes having a 
much reduced glycocalyx, lacking GPI-anchored macromolecules, having instead 
a surface layer of free GPIs and host-derived glycophospholipids (McConville et 
al., 2002). 
Both promastigotes and amastigotes secrete a large quantity of soluble PPG.  
These form, individually or after self association, large filamentous structures.  
PPG structures may lead to promastigote aggregation and the transmission of 
large clusters of promastigotes in the sand fly bite (McConville et al., 2002), with 
PPG known to be the main component of the PSG plug in the sand fly, which, as 
has been stated earlier, is regurgitated into the mammalian host and enhances 
disease progression (Rogers et al., 2004). 
The subpellicular microtubules below the cell membrane form the cytoskeleton 
and restrict vesicular transport to the only region of the cell not subtended by the 
microtubules: the flagellar pocket at the anterior end of the cell (Clayton et al., 
1995).  The flagellar pocket is an invagination of the plasma membrane, with the 
junction between the cell membrane and the flagellum being formed of 
desmosome-like tight junctions (de Souza, 2002).  The flagellar pocket is the 
single location for endo- and exo-cytosis, for integration of membrane proteins into 
the cell membrane, and is accessible to large macromolecules (Landfear and 
Ignatushchenko, 2001), for example secreted LPG and PPG, and endocytosed 
MHC class II molecules (De Souza Leao et al., 1995). 
The flagellum contains a classical 9 + 2 microtubule doublet axoneme as well as 
the trypanosomatid-specific paraflagellar rod (Bastin et al., 2000).  The flagellum is 
thought to have a number of functions.  It is responsible for the motility of 
promastigote Leishmania, and is known to mediate attachment of Leishmania to 
the sand fly gut epithelium (Killick-Kendrick et al., 1974a; Killick-Kendrick et al., 
1974b).  It is also postulated to act as an environmental sensor and to be involved 
in signalling (Bastin et al., 2000).  The amastigote stage has a much shortened 
flagellum which does not emerge from the flagellar pocket, making this stage 
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The flagellum of Leishmania is anchored into the cell by a basal body, which is 
physically linked to the mitochondrion.  A second basal body, lying perpendicular 
to the major one, develops during cell division.  In T. brucei, the basal bodies are 
necessary for kinetoplast division (Ogbadoyi et al., 2003), whilst in L. donovani 
duplication and segregation of kinetoplasts have been observed despite a lack of 
basal body duplication (Selvapandiyan et al., 2004). 
The kinetoplast is a disc shaped structure, comprising the condensed 
mitochondrial DNA (Liu et al., 2005).  The kinetoplast DNA (kDNA) represents  
10-20% of the total cell DNA and is composed of a few dozen maxicircles and 
thousands of minicircles (Stuart, 1983).  The maxicircles have some of the 
functions of higher eukaryote mitochondrial DNA, encoding genes for the 
respiratory complexes.  The minicircles are responsible for the network structure of 
kDNA (Stuart, 1983) and encode guide RNAs which mediate the editing of the 
maxicircle transcripts to form functional mRNA, by insertion of uridylate residues to 
precise sites (Liu et al., 2005).  In T. brucei, the kinetoplast is attached to the 
mitochondrial membrane by unilateral filaments and to the basal body via 
exclusion zone filaments.  These filaments constitute the tripartite attachment 
complex (TAC), which may mediate interactions between the mitochondrion and 
the cytoskeleton (Ogbadoyi et al., 2003).  It has been postulated that the TAC is 
present in Leishmania and the other trypanosomatids (Ogbadoyi et al., 2003), 
though this has not been confirmed. 
In Leishmania there is a single mitochondrion which extends throughout the cell.  
In dividing promastigotes the mitochondrion is a symmetrical organelle, extending 
from both sides of the kinetoplast region and joined at the posterior end of the cell.  
In contrast, in non-dividing promastigotes the mitochondrion is asymmetric, 
extending from one end of the kinetoplast past the nucleus to the cell posterior 
(Simpson and Kretzer, 1997), as shown in Figure 1.4.  In amastigotes the 
mitochondrion is in the form of a complex network extending throughout the cell 
(Coombs et al., 1986).  In addition to the mitochondrion, Leishmania produce 
energy within specialised organelles called glycosomes, which contain the 
glycolytic enzymes responsible for converting glucose to 3-phosphoglycerate (de 
Souza, 2002).  Glycosomes are small, spherical organelles, belonging to the 
peroxisome family (Michels et al., 2006).  Leishmania also contain 
acidocalcisomes, spherical organelles preferentially located at the periphery of the Chapter 1      12 
cell, which are believed to be storage organelles for a number of elements 
including phosphorus, calcium, magnesium, sodium and zinc (de Souza, 2002). 
As with other eukaryotes, Leishmania contain a single Golgi apparatus, located 
between the nucleus and the flagellar pocket and consisting of a stack of 3 to 10 
cisternae and a polymorphic trans-Golgi network.  The endoplasmic reticulum (ER) 
consists of the nuclear envelope and a system of cisternae that are often closely 
associated with the plasma membrane (McConville et al., 2002).  The ER provides 
some of the membranes necessary for the biosynthesis of endosomes and 
lysosomes.  In promastigotes the endocytic pathway has been shown to consist of 
three parts: i) a network of tubular endosomes close to the flagellar pocket, ii) a 
population of multivesicular bodies also in the flagellar pocket region of the cell, 
and iii) an unusual multivesicular tubule (MVT) running along the anterior-posterior 
axis of the cell (Waller and McConville, 2002).  The MVT is the terminal 
compartment of the endocytic pathway, forming the mature lysosome and so is 
known as the MVT-lysosome (Ghedin et al., 2001; Mullin et al., 2001; McConville 
et al., 2002).  The lytic capacity of the MVT increases as the promastigotes reach 
the stationary phase of growth (Mullin et al., 2001).  In Leishmania amastigotes 
there is an extended lysosomal compartment comprising one or more large 
vesicles that have been termed megasomes, which were originally found only in  
L. mexicana group species (Pupkis et al., 1986; Ueda-Nakamura et al., 2001), but 
have recently been identified in L. chagasi amastigotes (Alberio et al., 2004).  
Megasomes make up 5-15% of the amastigote cell volume depending on the 
species (Alberio et al., 2004).  The large increase in lysosomal capacity with the 
appearance of megasomes in amastigotes coincides with the large increase in 
expression of cysteine peptidases resident in these cells (Waller and McConville, 
2002).  In addition to the cysteine peptidases, megasomes also contain a number 
of other enzymes, including arylsulfatase, b-glucuronidase, DNAse and RNAse 
(Pupkis et al., 1986).   
The lysosome of Leishmania is postulated to have a number of functions.  For 
example, it may be involved in nutrient acquisition, evasion of the immune system 
and regulating the levels of endogenous proteins (Waller and McConville, 2002).  
Lesion amastigotes have been found to degrade host macromolecules (Schaible 
et al., 1999) and to influence the immune system by degrading host MHC class II 
complexes, thus governing the range of peptides which can associate with MHC 
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1.1.4 Treatment of leishmaniasis 
The drugs currently available for treating leishmaniasis are the pentavalent 
antimonials, i.e. sodium stibogluconate (Pentostam) and meglumine antimonate 
(Glucantime); amphotericin B and its lipid formulations; pentamidine; miltefosine 
and paromomycin (Croft and Coombs, 2003).  All current drugs have their 
limitations, with all except miltefosine requiring parenteral administration, 
necessitating long hospitalisation.  In addition, the drugs available are not equally 
effective against all types of leishmaniasis. 
1.1.4.1  Visceral leishmaniasis 
For visceral leishmaniasis, the pentavalent antimonials have been the first line 
treatment for over 60 years (Croft and Coombs, 2003).  Antimonials are toxic 
drugs, giving rise to musculoskeletal pain and gastrointestinal side effects, with 
potential for serious adverse effects including cardiac arrhythmia and pancreatitis.  
High levels of resistance to these drugs have been reported in endemic regions, 
particularly around the focus of infection in Bihar, India (Sundar and Rai, 2002).  
Due to its toxicity, pentamidine has generally only been used as a second line 
therapy following ineffective antimonial treatment.  Treatment failures with 
pentamidine have also been reported in India (Sundar and Rai, 2002).  
Amphotericin B is highly effective at treating antimony-resistant cases, but is also 
toxic, with infusion related fever and chills, nephrotoxicity and first-dose 
anaphylaxis reported.  It has, however, replaced antimonials as a first line 
treatment in some areas of Bihar (Chappuis et al., 2007).  The lipid formulation, 
AmBisome, has much reduced toxicity, but its high cost has limited its use in 
developing countries until recently (Croft and Coombs, 2003).  The WHO 
announced a price reduction in May 2007 for AmBisome in VL-endemic countries, 
which reduced treatment cost from around $2,800 to $200 (Chappuis et al., 2007). 
Miltefosine was licensed for use in India in 2002 (Davies et al., 2003).  It is an alkyl 
phosphocholine which was originally designed as an anti-cancer drug and was 
found to have anti-leishmanial activity against L. donovani and L. infantum in a 
mouse model (Croft et al., 1987; Kuhlencord et al., 1992; Croft et al., 1996).  
Miltefosine has been shown to be safe for both adults and children in India and 
although gastrointestinal side effects are common, these do not generally prevent 
completion of treatment (Sundar et al., 2002; Sundar et al., 2003).  However, it Chapter 1      14 
was found to be a possible teratogen in animal studies (Herwaldt, 1999b), so its 
use in women of child-bearing age has to be carefully monitored (Sundar et al., 
2002).  Miltefosine has the advantage of being orally administered, but it has a 
long half life in the body, which may influence the development of resistance 
(Guerin et al., 2002), and such resistance has been generated in a laboratory 
setting (Seifert et al., 2003; Perez-Victoria et al., 2006; Seifert et al., 2007).  In 
addition, it has not been established whether miltefosine will be as effective 
against L. infantum/chagasi as it is against L. donovani (Croft and Coombs, 2003).  
Paromomycin, an aminoglycoside antibiotic, was identified as an anti-leishmanial 
in the 1960’s, but was only licensed for use in India in 2006 following development 
co-ordinated by WHO/TDR (www.who.int/tdr).  Paromomycin was found to be as 
effective as amphotericin B when trialled (Sundar et al., 2007).  It has drawbacks: 
it has to be administered by intramuscular injection, it causes reversible damage to 
the inner ear in 2% of patients, and it may produce mild injection pain (Chappuis et 
al., 2007), but it does have the major advantage of being low cost, as it is out of 
patent . 
1.1.4.2  Cutaneous leishmaniasis 
Since cutaneous leishmaniasis often self-heals, drug treatment is not always 
necessary, and is normally only used if there is a risk of mucocutaneous 
leishmaniasis.  For patients with relapsing or disfiguring lesions or diffuse or 
mucocutaneous leishmaniasis, systemic treatment with pentavalent antimonials is 
most commonly used (Davies et al., 2003).  Treatment failures have been 
documented for New World cutaneous leishmaniasis (Lawn et al., 2003) and it is 
known that there is a difference in the susceptibility of different Leishmania 
species to pentavalent antimonials; L. donovani and L. braziliensis are more 
sensitive compared to L. major, L. tropica and L. mexicana (Croft et al., 2002).  
Pentamidine is successfully used to treat cutaneous and mucocutaneous 
leishmaniasis (Sundar and Rai, 2002), and amphotericin B, particularly liposomal 
amphotericin B, is often used as a first line treatment for travellers and as a 
second line treatment after relapse (Schwartz et al., 2006).   
Miltefosine is currently undergoing clinical testing against New World species of 
Leishmania.  It is effective against L. panamensis, less so against L. mexicana, 
and shows a large variation in its efficacy against L. braziliensis (Soto et al., 2004; Chapter 1      15 
Soto et al., 2007).  Miltefosine has also been tested against Old World cutaneous 
species and found to give similar cure levels as antimonials (Mohebali et al., 2007).  
Topical treatment with paromomycin has been found to be effective against both 
Old and New World species (Schwartz et al., 2006; Mohebali et al., 2007), with 
ointments of paromomycin combined with methylbenzethonium having increased 
effectiveness compared to those combined with urea (Arana et al., 2001). 
1.1.4.3  Effect of immunosuppression 
Increased levels of HIV prevalence in Leishmania-endemic countries has led to 
increasing numbers of co-infected patients, with 34 countries currently reporting 
co-infection (www.who.int/leishmaniasis).  HIV-Leishmania co-infection leads to 
worse outcomes for the patient for both diseases.  Both HIV-co-infected patients 
and immunosuppressed patients respond slowly to treatment and in most cases 
relapses occur (Olliaro et al., 2002).  Non-antimonial treatment is thought to be 
preferred in immunocompromised patients: AmBisome and miltefosine have been 
shown to be effective in mouse models of VL-infected immunodeficient mice, 
where antimonial treatment was ineffective (Escobar et al., 2001).  Amphotericin B 
has been shown to be more effective than pentavalent antimonial treatment in HIV 
co-infected patients (Sundar and Rai, 2002), with antimonials also associated with 
pancreatitis in immunosuppressed patients (Bryceson, 2001).  Co-infected or 
immunosuppressed patients are also believed to be likely to develop resistance to 
anti-leishmanial drugs if given in monotherapy, a resistance which could then 
spread throughout the community, meaning combination therapy is desirable 
(Bryceson, 2001). 
1.1.4.4  Future treatment options 
New treatments for leishmaniasis are needed, but development is hampered by 
the lack of funds available for costly drug development for what is seen as mostly a 
developing world disease (Guerin et al., 2002).   
A number of potential anti-leishmanial drugs have been identified and are at 
various stages of development.  Those furthest through development are 
sitamaquine and the azoles.  Sitamaquine is an 8-aminoquinoline which was 
identified by the Walter Reid Army Institute of Research, but is being developed by 
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of success in Phase I/II trials against visceral leishmaniasis in Brazil and Kenya 
(Croft and Coombs, 2003), but further toxicological testing is underway after 
unanticipated nephrotoxicity was found in trials.  The azoles were discovered as 
antifungal drugs and several, including ketoconazole, itraconazole and fluconazole, 
have entered clinical trials for both cutaneous and visceral leishmaniasis (Singh et 
al., 2006).  They inhibit the formation of ergosterol, which is the major sterol in 
Leishmania, compared to cholesterol in the mammalian cell (Urbina, 1997).  There 
are suggestions from clinical trials that they are more effective against L. major and 
L. mexicana than L. donovani and L. braziliensis (Croft et al., 2002). 
Research into potential drugs continues, with a more rational approach to drug 
design being taken (Davis et al., 2004).  Fundamental research into Leishmania-
specific drug targets is one of the most promising areas.  Through a rational 
approach to identifying drug targets, several have already been proposed and 
investigated, including cysteine peptidases, the metabolism of trypanothione and 
sterol biosynthesis enzymes and protein kinases (Croft & Coombs, 2003).  
However, the recent availability of the genomes of three Leishmania species and 
powerful bioinformatic tools has identified Leishmania-specific genes, making 
them attractive potential drug targets (Peacock et al., 2007), and will hopefully lead 
to identification of the parasite factors responsible for disease tropism and 
pathology of the disease which may be good potential targets (Ivens et al., 2005).  
As early branching eukaryotes, the organisation of their cells show extensive 
differences from that of mammalian cells (as described in Section 1.1.3), 
suggesting that there will be ample basis for identifying novel proteins, structures 
and processes that may be exploitable as drug targets (Barrett et al., 1999). 
1.1.5 Potential for vaccination 
Vaccination has been a focus of research for many years, since it is known that 
patients who have recovered naturally from cutaneous infection maintain residual 
parasites indefinitely, but are resistant to reinfection (Handman, 2001).  This 
suggests that vaccination is a viable prospect for preventing infections.  A form of 
vaccination, leishmanisation, was practised for decades in the Middle East and 
Soviet Union (Selvapandiyan et al., 2006).  This was controlled infection, inducing 
lesions on unexposed areas of skin, in order to prevent future lesions on visible 
skin, particularly the face.  The procedure holds risks, however, with the potential 
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discontinued (Handman, 2001; Chappuis et al., 2007).  Killed Leishmania vaccines 
have also been investigated, but no preparations of killed parasites have shown 
protective efficacy (Chappuis et al., 2007).  
Latterly, strategies using live-attenuated parasites, recombinant DNA, peptides, 
purified parasite proteins and non-protein antigens have been investigated 
(Handman, 2001; Selvapandiyan et al., 2006).  It is hoped that the recent creation 
of a promising multi-epitope subunit vaccine will lead to progress, since it has 
shown efficacy against L. major and L. infantum infections in animal models 
(Skeiky et al., 2002; Coler et al., 2007) and its efficacy is being tested in human 
trials (Coler and Reed, 2005).  There is also an increasing number of genetically 
altered parasites which are being tested as candidate live attenuated vaccines 
(Alexander et al., 1998; Papadopoulou et al., 2002; Uzonna et al., 2004), although 
their efficacy in humans has yet to be investigated. 
1.2 Interaction Between Leishmania and Host Cells 
1.2.1 Invasion of macrophages  
The entry of Leishmania into macrophages is thought to involve both silent entry 
through the “Trojan Horse” of infected neutrophils, as described in Section 1.1.2, 
and direct entry into macrophages.  The binding of Leishmania promastigotes to 
macrophages is thought to be primarily through the complement receptors type 1 
(CR1) and type 3 (CR3), which bind to complement components attached to 
molecules on the parasite plasma membrane (Antoine et al., 1998).  The CR1 
binds the C3b fragment of complement and CR3 binds iC3b, with the latter  
thought to be the more important (Mosser and Rosenthal, 1993).  Bound iC3b on 
the parasite surface prevents complement lysis, with GP63 on the parasite surface 
being responsible for rapid conversion of C3b to iC3b (Cunningham, 2002; 
Denkers and Butcher, 2005).  Amastigote binding to macrophages is not 
dependant on serum and involves different receptors than binding of 
promastigotes (Mosser and Rosenthal, 1993).   
Leishmania are thought to be taken up by conventional phagocytosis, with 
elongated pseudopodia advancing tunnel-like along the parasites (Rittig and 
Bogdan, 2000), into a phagosome which then merges with endosomes and 
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promastigotes are phagocytosed, LPG on the parasite surface inhibits phagosome-
endosome fusion (Desjardins and Descoteaux, 1997; Dermine et al., 2000).  Since 
promastigotes are acid labile but amastigotes are not (Bogdan and Rollinghoff, 
1999), delaying the development of this organelle promotes survival, allowing 
promastigote-amastigote differentiation to be completed (Bogdan and Rollinghoff, 
1999).  Amastigote survival in the acidic PV is thought to be due to the protective 
effects of the abundance of cell surface and secreted glycoconjugates produced by 
this stage (Sacks and Sher, 2002). 
The phagolysosome has features of lysosomal compartments, being positive for 
the lysosomal-associated membrane proteins LAMP-1 and LAMP-2, having acidic 
pH and containing acidic hydrolases normally found in lysosomes (Russell et al., 
1992).  They are seen as being a mixed organelle, also having features of late 
endosomes, since they contain the late-endosome associated proteins rab7p and 
macrosialin (Lang et al., 1994; Courret et al., 2002).  Fusion with endocytic 
organelles is believed to occur in a sequential manner, with endosomes fusing 
prior to lysosomes (Duclos and Desjardins, 2000).  A “kiss and run” fusion 
hypothesis has been proposed for the biogenesis of phagosomes, with organelles 
joining their plasma membranes to form a fusion pore, which allows exchange of 
molecules between organelles; the pore then closes and the organelles separate 
(Duclos and Desjardins, 2000).  This process would allow gradual acquisition of 
molecules and size selection based on the size of the pore. 
1.2.2 Survival of Leishmania 
In order to survive within macrophages Leishmania must achieve silent infection, 
avoiding activating the anti-microbial respiratory burst and evading immune 
responses (Bogdan and Rollinghoff, 1999).  Induction of a Th1 immune response 
is associated with clearance of Leishmania infection, whilst a Th2 response leads 
to persistence.  The regulatory cytokines TGF-b and IL-10 have also been 
suggested as important as immunosuppressive signalling molecules in Leishmania 
infections (Olivier et al., 2005).  The release of both cytokines has been found to 
be induced by infection of macrophages by Leishmania and mice constitutively-
expressing IL-10 cannot control Leishmania infection (Olivier et al., 2005).  
Leishmania have also been shown to inhibit production of the Th1 response-
promoting cytokines IL-1, IL-12 and TNF-a (Bogdan and Rollinghoff, 1999; Olivier Chapter 1      19 
et al., 2005).  Recent In vivo studies using L. major and L. donovani have found 
that pro-inflammatory cytokines were actually induced in early infection, with the 
induction being higher in L. major infections, suggesting one possible reason for 
the differences in pathology associated with the two species (Olivier et al., 2005).  
An analysis of the genes expressed by macrophages following infection by  
L. chagasi has also revealed a general trend for genes encoding Th1-type 
responses to be down-modulated, whilst genes involved in an anti-inflammatory, 
Th2-type response were upregulated (Rodriguez et al., 2004).  Leishmania thus 
modulate the immune system by both down-regulating Th1 response and up-
regulating Th2 responses. 
The primary receptor used for uptake of Leishmania into macrophages is thought 
to be protective for the parasite, as uptake of complement opsonised L. major via 
CR3 leads to inhibition of IL-12 release, while uptake via other receptors induces 
IL-12 release (Schonlau et al., 2000).  Uptake of L. major or L. mexicana 
amastigotes also suppresses IL-12 production, though this is not dependent on 
opsonisation by complement (Weinheber et al., 1998).  IL-12 is a Th1 response-
initiating cytokine which activates natural killer (NK) cells, which in turn produce 
interferon (IFN)-g which activates macrophages and is important for early control of 
infection (McMahon-Pratt and Alexander, 2004).   
Binding of complement by L. major and L. donovani has also been found to increase 
parasite survival by leading to a reduction of the respiratory burst of macrophages 
when complement-opsonised promastigotes were phagocytosed (Mosser and 
Rosenthal, 1993).  IFN-g induces macrophages to produce inducible nitrogen oxide 
synthase (iNOS) and nitric oxide (NO) production, which are known to be effective at 
killing Leishmania (Olivier et al., 2005).  L. major have been found to interfere with 
the induction of iNOS, and purified LPG alone is able to suppress iNOS expression 
and NO production (Proudfoot et al., 1996).  The inhibition of iNOS has been shown 
to involve abnormal protein kinase C activity (Olivier et al., 2005). 
1.2.2.1  Neutrophils in Leishmania infection 
As well as their role as “Trojan horses” for the infection of macrophages (as 
detailed in Section 1.1.2), PMN are also important in the survival of Leishmania 
due to their production of cytokines.  In mouse models it has been found that 
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killing, whilst neutrophils from sensitive mice were not.  The neutrophils induced 
different cytokine profiles: TNF-a was induced by neutrophils from resistant mice, 
whilst TGF-b was induced by neutrophils from sensitive mice (Ribeiro-Gomes et 
al., 2004).  PMN from L. major-infected resistant mice have been found to produce 
not only TNF-a, but also other Th1 response-associated cytokines, particularly 
IFN-g, whereas susceptible mice did not (Chen et al., 2005).  Depletion of PMN 
from resistant mice led to a reduction in the expression of Th1 cytokines by 
macrophages.  Depletion of neutrophils in sensitive mice led to an increase in the 
levels of IL-4, a key Th2 response-promoting cytokine, with an exacerbation of 
infection (Chen et al., 2005).  However, depletion of PMN from sensitive mice has 
also been found to be beneficial; with impairment in the development of footpad 
lesions in L. major infected BALB/c mice and less IL-4 produced (Tacchini-Cottier 
et al., 2000).  It is suggested that the strains used or the method of depletion of 
neutrophils used could be responsible for this difference (Chen et al., 2005).  In  
L. donovani-infected mice, neutrophils have also been implicated in the protective 
response against Leishmania.  Depletion of neutrophils from BALB/c mice led to 
increased numbers of parasites in the spleen and bone marrow, with an increase 
of levels of IL-10 and IL-4 in the serum, with impairment of the protective Th1 
immune response (McFarlane et al., 2008).  The response of neutrophils is 
therefore implicated as one of the mechanisms of protection against L. major 
(Chen et al., 2005) and L. donovani (McFarlane et al., 2008).   
1.2.2.2  Leishmania and antigen presentation 
Leishmania-specific CD4
+ T cells have been found to have an essential role in the 
immune responses of infected mammalian hosts (Antoine et al., 1998).  CD4
+ T 
cells recognise peptides bound into MHC class II molecules on the plasma 
membrane of macrophages.  Infection of mouse macrophages by Leishmania does 
not inhibit the induction of MHC class II molecules by IFN-g, nor does it reduce the 
number of molecules expressed (Antoine et al., 1998).  L. mexicana-infected 
macrophages were found to have MHC class II both on their surface and in the 
parasitophorous vacuole (Russell et al., 1992).  After infection, intracellular MHC 
class II molecules were redistributed to the periphery of most PVs (Lang et al., 
1994), suggesting that the PV is where parasite molecules are processed and 
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MHC class II molecules and to degrade these within their megasomes, due to the 
cysteine peptidases found in these organelles (De Souza Leao et al., 1995). 
Leishmania infections have also been shown to elicit a MHC class I dependent 
CD8
+ T cells response.  This was thought to be unlikely since, classically, MHC 
class I molecules present antigens from the cytoplasm but it has been found that 
the phagosome, and most likely the PV, can process exogenous antigens for MHC 
class I molecules (Houde et al., 2003), providing a mechanism for the presentation 
of Leishmania antigens. 
1.2.2.3  Manipulation of dendritic cells 
Monocyte derived dendritic cells (DCs) are essential to induce a protective Th1 
immune response against Leishmania (Favali et al., 2007).  DCs have been found 
to be infected with Leishmania, though it appears that only amastigotes can 
successfully invade and persist (Ghosh and Bandyopadhyay, 2004).  Langerhans 
cells (skin DCs) are thought to be a safe haven in early infection with Leishmania 
as, although parasites cannot multiply within them, Langerhans cells can not kill 
the parasite easily, presumably due to the absence of iNOS in these cells (Bogdan 
and Rollinghoff, 1998).   
DC distribution in L. donovani infected mice has been found to be altered, with 
migration of Langerhans cells reduced by L. major LPG, and in vitro the mobility of 
splenic DCs is inhibited by L. major secreted products.  Alteration of migration of 
DCs is thought to affect the host immune response, as the DCs normally migrate 
to lymphoid organs to present antigens to T cells, thereby activating the primary 
immune response (Ghosh and Bandyopadhyay, 2004).   
Different parasite strains appear to have different effects on DCs, principally on the 
release of IL-12, which promotes the development of a Th1 response.  L. major 
strains which had led to self-healing lesions induced IL-12 production, whilst  
L. major strains which had caused multiple subcutaneous nodules in patients and 
L. tropica or L. donovani isolates did not induce IL-12 production (McDowell et al., 
2002).  Reduction of IL-12 may thus be part of the reason for some of the 
differences seen in the immune response and the pattern of disease (Sacks and 
Sher, 2002).  L. mexicana has also been shown to inhibit DC IL-12 production, and 
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Leishmania can also delay the maturation of DCs and their migration to the 
lymphoid organs, which is thought to promote establishment of the infection before 
the acquired immune response can start (Brandonisio et al., 2004).  Monocyte-
derived DCs exposed to L. amazonensis had altered DC differentiation and 
produced less IFN-g, making the DCs less effective at inducing adaptive immune 
responses (Favali et al., 2007). 
1.2.3 Nutrient acquisition by Leishmania  
To survive within their host cell, Leishmania must acquire nutrient sources from 
the macrophage.  A number of ligands have been shown to be taken up by 
endocytosis and delivered to the parasitophorous vacuole (PV) through the 
endosomal system, with increased efficiency of uptake with increasing age of 
infection (Russell et al., 1992).  The ligands were also detected within the flagellar 
pocket and megasomes of amastigotes, illustrating that Leishmania can take up 
molecules delivered from the endosomal system. 
As well as molecules delivered to the PV via endocytosis, molecules from the host 
cell cytosol are delivered to the PV.  Two mechanisms have been demonstrated 
whereby molecules can be delivered from the cytosol: firstly via an organic anion 
transporter on the vacuole membrane, and secondly via the autophagic pathway 
(Schaible et al., 1999).  Autophagy is a self-digestion process whereby cells 
degrade proteins and organelles in the cytoplasm, by sequestration into a double-
membrane vesicle, which normally fuses with the lysosome to allow the 
degradation of the cargo by hydrolases (Reggiori and Klionsky, 2005).  Delivery of 
molecules to the PV via autophagy may provide nutrients to Leishmania in addition 
to those delivered via fusion with endosomes (Schaible et al., 1999), particularly 
purines which Leishmania are unable to synthesize (Hassan and Coombs, 1988).   
Although there is no evidence of other transporters in the PV membrane, a 
number of other transporters have been identified on lysosomal membranes 
(Pisoni and Thoene, 1991) and it is likely that these would also be found on the PV 
membrane.  If present, these would allow the movement of monosaccharides, 
nucleosides, amino acids, sulphate and phosphate from the cytosol into the PV 
(Burchmore and Barrett, 2001).   
The various methods of nutrient acquisition by the PV are illustrated in Figure 1.5. Chapter 1      23 
 
 
 
 
 
 
 
Figure   1.5 Nutrient acquisition by Leishmania via interaction with the endosomal and 
autophagosomal systems of the macrophage and lysosomal membrane transporters.  
Adapted from Duclos and Desjardins, 2000. 
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The hydrolases present in the PV ensure that most macromolecules delivered to 
this organelle are rapidly degraded to low molecular weight solutes (Burchmore 
and Barrett, 2001).  These solutes ought to be ideal nutrient sources for 
Leishmania, with amastigotes being able to use fatty acids, amino acids and 
glucose as carbon sources (Hart and Coombs, 1982) and amastigotes taking up 
glucose, proline and polyamines through transporters with acidic pH optima 
(Burchmore and Barrett, 2001). 
A number of proteins characterised as peptidases or involved in proteolysis were 
detected in an analysis of the L. donovani secretome.  These enzymes could be 
involved in degradation of host proteins for the nutrient needs of the parasite.  
Several Leishmania peptidases have been identified as potential virulence factors 
for survival in the host and this secretion into the PV may be an additional survival 
mechanism (Silverman et al., 2008). 
1.3 Peptidases 
1.3.1 Peptidase biochemistry 
Peptidases are responsible for the degradation of proteins or oligomeric peptides 
by hydrolysis of peptide bonds.  Enzymes which cleave peptide bonds have 
previously also been described as proteases or proteinases (Barrett and 
McDonald, 1986).  It was determined in 1936 that there were two types of 
peptidases, endopeptidases and exopeptidases (Bergmann and Ross, 1936),  
endopeptidases being those peptidases which cleave bonds within the polypeptide 
chain, exopeptidases cleaving bonds from the amino or carboxyl ends.  
Peptidases are numerous and diverse; they represent around 2% of all gene 
products (Rawlings and Barrett, 1999) and range from monomers of around 10 
kDa to multimeric complexes of several hundred kDa (Sajid and McKerrow, 2002).   
Although only a single peptide bond is cleaved during a catalytic reaction, the 
surrounding amino acids in the substrate also play a role in determining peptidase 
specificity, as do the sequences flanking the catalytic amino acid residues on the 
peptidase.  The convention used to identify substrate and peptidase residues was 
determined in 1967 by Schechter and Berger, with the substrate residues 
designated as P and the corresponding residues of the enzyme as S (Schechter 
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C-terminal side of the cleavage site and as non-prime if on the N-terminal side.  
Thus, a five residue substrate cleaved between the third and fourth amino acids 
would be designated as P3P2P1-P’1P’2.   
The naming of peptidases varies from that of other enzymes.  The naming of 
enzymes is usually on the basis of the reactions they catalyse, but the specificities 
of peptidases are typically almost impossible to rigorously determine or describe in 
a simple name (Rawlings and Barrett, 1999) and peptidases all effectively catalyse 
the same reaction: the hydrolysis of a peptide bond (Barrett et al., 2001).  Instead, 
the peptidases were divided into groups on the basis of the catalytic mechanism 
used (Hartley, 1960), based on the active site residue that provides the 
nucleophilic attack during the catalytic reaction.  Six main types are now 
recognised: serine, cysteine, metallo-, aspartic, threonine and glutamic 
peptidases, but there are also a few peptidases of unknown catalytic type.  In 
serine, cysteine and threonine peptidases, the catalytic nucleophile is the reactive 
group of an amino acid side chain, a hydroxyl group in serine or threonine 
peptidases or a sulfhydryl group in cysteine peptidases.  For aspartic and metallo-
peptidases the nucleophile is an activated water molecule.  The mechanism of 
action of glutamic peptidases has not been fully determined (Fujinaga et al., 2004).  
In the early 1990s, peptidases were classified by both sequence data and 
crystallographic data in a scheme that brought together sets of peptidases that 
were similar both in their molecular structure and their evolutionary origin 
(Rawlings and Barrett, 1993).  This classification system was used to create the 
MEROPS database of peptidases and peptidase inhibitors, using a hierarchical 
classification system (Rawlings et al., 2008; http://merops.sanger.ac.uk).  Related 
peptidases are grouped into a family, families believed to have had a common 
ancestor are grouped into clans and the clans are grouped into types based on 
their active site residue (Rawlings et al., 2008). 
1.3.2 Types of peptidases 
Most serine peptidases have a catalytic triad of three amino acids: serine, 
aspartate and histidine, acting as nucleophile, electrophile and base respectively.  
The order of the amino acids varies between the clans (Rawlings and Barrett, 
1994b).  A number of mainly bacterial serine peptidases, however, utilise serine 
and lysine as their catalytic residues (clans SE and SF; Barrett and Rawlings, 
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peptidases with high specificity and digestive enzymes with broader substrate use, 
such as trypsin and chymotrypsin.   
Cysteine peptidases have also been known previously as thiol peptidases.  Their 
activity depends on a catalytic dyad of cysteine and histidine residues (Rawlings 
and Barrett, 1994a).  As with the catalytic triad of the serine peptidases, the order 
of the cysteine and histidine residues differs between the different families of 
cysteine peptidases.  A wide variety of cysteine peptidases have been described, 
with the best known and largest family being the papain family (family C1, clan 
CA).  These enzymes are generally lysosomal or secreted and include the major 
mammalian cysteine peptidases, cathepsins B, H, K, L and S (Rawlings and 
Barrett, 1994a).  They have been shown to mediate extracellular matrix turnover, 
antigen presentation, and processing events.  Furthermore, they might constitute 
potent drugs targets for osteoporosis, arthritis, immune-related diseases, 
atherosclerosis and cancer, as well as for numerous parasitic infections (Lecaille 
et al., 2002).  Clan CD cysteine peptidases appear to be more specific in their 
function and include the caspases, peptidases involved in inflammatory disease 
and apoptosis (Mottram et al., 2003). 
Metallo-peptidases are a vast group of enzymes that use a metal ion in the 
catalytic process, usually zinc, but also cobalt or manganese (Rawlings and 
Barrett, 1995a).  Examples of eukaryotic metallo-peptidases are regulatory 
peptidases and matrix degradation enzymes, e.g. elastases and collagenases. 
Aspartic peptidases need two aspartate residues for catalytic activity and are the 
simplest subclass of peptidases known.  Family A1 of aspartic peptidases has one 
aspartate residue in each half of a bilobed protein, whilst family A2 consists of 
peptidases of a single lobe, again containing only one aspartate residue and which 
are therefore thought to be active as a homodimer (Rawlings and Barrett, 1995b).  
Aspartic peptidases are often secreted, with eukaryotic aspartic peptidases 
including digestive enzymes and intracellular lysosomal peptidases, though there 
are also a number of intramembrane peptidases (Rawlings and Barrett, 1995b). 
Threonine peptidases were recognised more recently, with the discovery of the 
mechanism of action of the 26S proteasome (Seemuller et al., 1995).  The active 
site threonine residue is at the amino terminal end of the peptidase and a second 
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(Seemuller et al., 1995; Bochtler et al., 1999).  Non-proteasome threonine 
peptidases have also been identified (Bochtler et al., 1999). 
Glutamic peptidases were identified in 2004 (Fujinaga et al., 2004), with only one 
family so far recognized.  Their activity is not fully determined, but is likely to 
depend on a glutamine and glutamic acid catalytic dyad 
(http://merops.sanger.ac.uk/).    
1.3.3 Peptidase inhibitors as drugs 
Peptidase inhibitors can be classified as two types: low molecular weight 
peptidomimetic inhibitors and protein inhibitors.  Inhibition can occur by two 
mechanisms: irreversible trapping reactions, which alter conformation and 
covalently bind the enzyme to prevent its participation in further reactions, and 
reversible reactions, where the inhibitor blocks the active site of the peptidase, 
either directly or indirectly (competitive or allosteric inhibition), but the inhibitor can 
dissociate from the enzyme (Fear et al., 2007).  Peptidases are increasingly being 
seen as potential drug targets (Rawlings, 2007), and it has been estimated that 
14% of human peptidases are being investigated by pharmaceutical companies 
(Southan, 2001).  Therapeutically, peptidase inhibitors have been successfully 
introduced to treat HIV, hypertension, pancreatitis and multiple myeloma.   
The HIV protease retropepsin cleaves some unique bonds, post phenylalanine 
residues, which has eased the task of designing selective inhibitors for the viral 
protease (Patick and Potts, 1998).  There are eight inhibitors of the HIV protease 
that have been approved for use, with several more in clinical trials (Fear et al., 
2007).  They are commonly used in combination therapy with reverse 
transcriptase inhibitors, though they have also been found to be effective when 
used in monotherapy (Arribas et al., 2005).  The introduction of protease inhibitors 
to combination therapy was associated with a substantial increase in the survival 
rates of people diagnosed with AIDS (Schwarcz et al., 2000).  
Inhibitors of angiotensin-converting enzyme (ACE) inhibit the renin-angiotensin 
system and reduce blood pressure by decreasing peripheral vascular resistance.  
They have been used clinically since 1977 (Fear et al., 2007).  ACE inhibitors have 
the advantage of better tolerability, limited side effects and a favorable metabolic 
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proteinuria and stabilise renal function, meaning they are also used for the 
treatment of diabetic nephropathy (Fear et al., 2007).   
Acute pancreatitis is commonly treated with peptidase inhibitors, as these are 
considered to reduce damage to the pancreas, lessen systemic complications and 
reduce mortality.  However, meta-analysis has shown that protease inhibitors only 
reduce mortality in patients with moderate to severe disease (Seta et al., 2004). 
The proteasome inhibitor bortezomib is used to treat multiple myeloma and 
relapsed mantle cell lymphoma and is being investigated for other non-Hodgkin’s 
lymphoma types.  It causes cancerous cells to arrest in the G2/M phase of the cell 
cycle and to undergo apoptosis (Barr et al., 2007).  Other proteasome inhibitors 
are also being investigated in clinical trials for multiple myeloma. 
1.3.4 Peptidases as potential drug targets 
As described previously, peptidases have been successfully exploited as drug 
targets and so other such enzymes are being investigated as therapeutic targets.  
Diseases for which peptidase inhibitors are being investigated include numerous 
infectious diseases, particularly viruses; various forms of cancer; diabetes mellitus; 
various inflammatory diseases and Alzheimer’s disease (Rawlings, 2007). 
Several inhibitors of viral peptidases are being tested in clinical trials, including two 
against the hepatitis C virus NS3/4A serine peptidase and two against picornavirus 
3C serine peptidase (Fear et al., 2007).  Additionally, the 3CL cysteine peptidase 
of severe acute respiratory virus (SARS) is known to be similar to the C3 
peptidase of picornaviruses and in vitro the anti-picornavirus peptidase inhibitors 
were effective against SARS.  SARS patients treated with the HIV protease 
inhibitors lopinavir and ritonavir in combination have also been shown to have 
better clinical outcomes (Fear et al., 2007).  Inhibitors of the peptidases of 
cytomegaloviruses, herpes simplex viruses and rotaviruses are also being 
developed. 
Serine, cysteine and metallo-peptidases are implicated in cancer metastasis and 
so inhibitors of these enzymes are being investigated.  Inhibitors of specific zinc 
matrix metalloproteases (MMP) have been researched as anti-cancer agents since 
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effects and a lack of specificity (Fingleton, 2006).  Despite the failure of many 
clinical trials, phase III trials of more specific MMP inhibitors are continuing for 
pancreatic, non-small-cell lung and renal cell carcinomas (Coussens et al., 2002).  
Inhibitors of other peptidases are also being investigated as anti-cancer agents, 
with inhibitors of the serine peptidase urokinase plasminogen-activating enzyme 
being evaluated in phase I clinical trials and a wide variety of inhibitors of 
cathepsin B, which is over-expressed in cancer cells, are being researched, 
though none have yet reached clinical trial (Fear et al., 2007).  
Inhibitors of the serine peptidase dipeptidyl peptidase IV are proposed for treating 
diabetes mellitus.  This peptidase degrades peptides involved in stimulating 
pancreatic beta cells to produce insulin and several inhibitors are in clinical trial to 
assess their enhancement of the insulin response (McIntosh et al., 2006). 
In inflammatory diseases, peptidase inhibitors have been investigated for use as 
anticoagulants, by binding to the serine peptidase thrombin; to minimise 
reperfusion injury; to reduce cerebral inflammation due to MMP-2 and -9 after 
stroke injury; for the reduction of atherosclerosis caused by MMP, cathepsins S, K, 
L and neutrophil elastase; to inhibit pulmonary inflammation, caused by elastase, 
collagenase and cathepsin G; and to reduce gastrointestinal inflammation by 
inhibiting trypsin (Fear et al., 2007).   
The aspartic peptidases b- and g-secretase are involved in the formation of the 
plaques found on the brain in Alzheimer’s disease and inhibition of these 
peptidases is being explored as a new treatment option.  Inhibitors of b-secretase 
are yet to enter clinical trial, whilst inhibitors of g-secretase have been found to be 
well tolerated in phase I trials (Siemers et al., 2005) and are being evaluated in 
phase II trial (Fear et al., 2007). 
The peptidases of various protozoan parasites are thought to be promising drug 
targets.  Cysteine and serine peptidases of Plasmodium have been found to 
mediate invasion of erythrocytes by merozoites and the rupture of erythrocytes by 
schizonts, with inhibitors of both blocking these processes.  Inhibitors of cysteine 
peptidases and aspartic peptidases have also been found to block P. falciparum 
development.  Peptide-based inhibitors of falcipain, a cathepsin L-like cysteine 
peptidase found in the food vacuole of malaria, have been shown to cure 80% of 
murine malaria (Rosenthal, 1999).  The proteasome of P. falciparum is also a Chapter 1      30 
promising drug target, with the multiple myeloma drug bortezomib being a potent 
inhibitor of the erythrocytic stage of both drug-sensitive and resistant P. falciparum 
strains, inhibiting parasite development and multiplication (Reynolds et al., 2007). 
Peptidyl proteasome inhibitors have also been found to be effective anti-African 
trypanosomal agents, suggesting inhibition of the proteasome would be a good 
target for treatment of T. brucei (Nkemgu et al., 2002).  The T. brucei lysosomal 
cathepsin L-like cysteine peptidase trypanopain is also a potential drug target, with 
several inhibitors of trypanopain killing cultured bloodstream form T. brucei and the 
most effective inhibitors protecting mice from an otherwise lethal infection in an in 
vivo model of acute infection (Troeberg et al., 2000).  For T. cruzi the lysosomal 
cysteine peptidase cruzipain is being investigated as a therapeutic target, since 
cysteine peptidase inhibitors which target cruzipain have shown ability to rescue 
mice from acute lethal infections of T. cruzi and have cured mice in the chronic 
stage of disease (Engel et al., 1998).  An inhibitor of cruzipain is in the early 
stages of clinical trials (Jaishankar et al., 2008). 
1.3.5 Peptidases in Leishmania 
A total of 154 peptidases were found to be present in the L. major genome (Ivens 
et al., 2005), with examples of serine, cysteine, aspartic, threonine and metallo-
peptidases, as well as one peptidase of unknown catalytic type.  The peptidases 
make up around 1.8% of the genome and are illustrated in Figure 1.6.   
1.3.5.1  Aspartic peptidases 
Two aspartic peptidases were found in the L. major genome sequence (Ivens et 
al., 2005), one with sequence similarity to presenilin 1 (PS1), which is a multi-pass 
membrane peptidase, and the other which has sequence similarity to an 
intramembrane signal peptide peptidase (SPP).  PS1 cleaves type I membrane 
proteins, which are membrane proteins which have a single transmembrane 
domain, with the carboxyl end of the protein in the cytoplasm.  In L. major PS1 is 
potentially involved in autophagy.  SPP cleaves the transmembrane domains of 
signal peptidases (Besteiro et al., 2007). 
However, a soluble peptidase inhibited by aspartic peptidase inhibitors and which 
could cleave a substrate specific for the aspartic peptidase cathepsin D, has been  Chapter 1      31 
 
Figure   1.6 Clans and families of L. major peptidases.  Nomenclature is based on the MEROPS 
database (http://merops.sanger.ac.uk/).  Numbers in brackets represents the estimated number of 
peptidases in each family.  Figure taken from Besteiro et al., 2007. Chapter 1      32 
reported in L. mexicana (Valdivieso et al., 2007).  An aspartic peptidase inhibited 
by pepstatin A has also been demonstrated to be present in soluble extracts of  
L. amazonensis, being found to be at its highest level in promastigotes and in the 
early stages of differentiation to amastigotes in vitro (Alves et al., 2005).  These 
results suggest that either one of the peptidases found in L. major is actually a 
soluble peptidase or there may be species-specific differences in the peptidases 
present. 
1.3.5.2  Threonine peptidases 
Twenty-one threonine peptidases were found in the L. major genome, though all 
are classified as proteasome subunits (Besteiro et al., 2007).  The proteasome is a 
multisubunit, multicatalytic peptidase responsible for degradation of ubiquitinated 
proteins in the cytosol (Silva-Jardim et al., 2004).  Sequences of both types of 
threonine proteasomes were found in L. major, i.e. the eukaryotic-type 20S and 
the bacterial-type hslV proteasomes (Gille et al., 2003).  The finding of numerous 
proteasome subunits in L. major is to be expected, as at least 10 subunits of 
varying size were found in L. mexicana (Robertson, 1999) and at least 6 subunits 
were found in L. chagasi (Silva-Jardim et al., 2004), based on electrophoresis of 
purified proteasomes. 
As with the malarial and T. brucei proteasomes, the proteasome of Leishmania is 
a potential therapeutic target, as the use of specific inhibitors has shown the 
proteasome to be necessary for growth of L. mexicana promastigotes and 
amastigotes in vitro (Robertson, 1999).  Proteasome inhibitors also inhibited the 
growth of L. chagasi promastigotes and reduced amastigote survival within 
macrophages (Silva-Jardim et al., 2004).  In addition, two HIV protease inhibitors, 
which inhibit the proteasome, have been shown to be leishmanicidal against  
L. major and L. infantum promastigotes (Savoia et al., 2005). 
1.3.5.3  Metallo-peptidases 
16 families of metallo-peptidases were identified in L. major (Besteiro et al., 2007), 
though only those of clan MA, family M8 (the leishmanolysin or GP63 family), have 
been comprehensively studied.  GP63 is the major glycosyl phosphatidyl inositol 
(GPI)-anchored surface protein of Leishmania promastigotes and aids the uptake 
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converts this to its breakdown products, which interact with macrophage 
complement receptors, facilitating the uptake of the promastigotes by 
macrophages.  GP63 is also thought to prevent lysis of the parasites by binding 
and breaking down C3 and to protect amastigotes from degradation in the 
parasitophorus vacuole of macrophages (Yao et al., 2003), and has also been 
found to protect L. amazonensis and L. major from various antimicrobial peptides 
(Kulkarni et al., 2006). 
Four members of the leucyl aminopeptidase family (clan MF, family M17) were 
found in the L. major genome (Ivens et al., 2005).  One of these, leucyl 
aminopeptidase (Lap), has been investigated in L. major, L. amazonensis and  
L. donovani (Morty and Morehead, 2002).  The substrate specificity of recombinant 
Lap was determined, with zinc found to be the likely natural cofactor and  
L-Leu-AMC (7-amino-4-methylcoumarin) the best substrate for the Lap enzymes 
of all three Leishmania species.  Both metal ion chelators and anti-Lap IgG 
inhibited the activity of recombinant Lap and by using anti-Lap IgG, Lap was found 
to be responsible for the majority of the L-Leu-AMC hydrolysis in soluble parasite 
extracts, though other, unidentified, aminopeptidases in addition to Lap were 
responsible for L-Cys-AMC and L-Met-AMC hydrolytic activity (Morty and 
Morehead, 2002).  Malaria Lap has shown promise as a drug target (Nankya-
Kitaka et al., 1998; Howarth and Lloyd, 2000), but this has not been investigated 
for Leishmania.  
There were six methionine aminopeptidases found in the L. major genome (clan 
MG, family M24), and two specific methionine aminopeptidase inhibitors have 
previously been found to inhibit the growth of L. donovani to a similar extent as the 
antileishmanial drug pentamidine (Zhang et al., 2002). 
Aside from these examples, the specific metallo-peptidases of Leishmania have 
not been investigated, though unidentified metallo-peptidases inhibited by 1,10 
phenanthroline were found in soluble extracts of L. amazonensis.  This peptidase 
or peptidases had higher activity in promastigotes and in the early hours of 
differentiation to amastigotes in vitro than in amastigotes (Alves et al., 2005). Chapter 1      34 
1.3.5.4  Cysteine peptidases 
L. major was found to have members of four clans of cysteine peptidases, with 
enzymes of eight families of clan CA, three families of clan CD and one family 
each of clans CF and PC (Ivens et al., 2005). 
The peptidases of the papain family (clan CA, family C1) are the most extensively 
studied peptidases of Leishmania, comprising the cathepsin-L like peptidases CPA 
and CPB, and the cathepsin-B like peptidase CPC, all of which are lysosomal.  
There is one copy of CPA and CPC in Leishmania, whilst CPB is found in a 
tandem array of genes, with eight genes in L. major and 19 in L. mexicana, the 
species primarily used for characterisation of the peptidase.  Both the copy 
number of CPB genes and the sequences of the genes vary between the different 
Leishmania species (Hide et al., 2007).  Neither CPA nor CPC are essential for 
survival of L. mexicana in the host, with no defect in the ability of CPA null mutants 
to infect mice (Souza et al., 1994), and whilst CPC null mutants had a reduced 
infectivity to macrophages, there was no defect in the growth of lesions in mice 
(Bart et al., 1997).  However, CPB has been found to be a virulence factor, with 
deletion of the CPB array leading to slower appearance of small lesions in mice 
(Mottram et al., 1996b).  In addition, double null mutants for CPB and CPA did not 
produce lesions in mice, suggesting exacerbation of the phenotype (Alexander et 
al., 1998).  The CPA/CPB double null mutants have a defect in autophagy, which 
is thought to lead to their defect in differentiation to metacyclics and amastigotes 
(Williams et al., 2006). 
The use of an inhibitor specific to cathepsin L-like cysteine peptidases, K11777, 
has shown that these peptidases are necessary for the growth of L. tropica and  
L. major promastigotes and for the growth of lesions of L. tropica in mice, 
indicating the potential of the peptidases as a drug target (Mahmoudzadeh-
Niknam and McKerrow, 2004).  Inhibitors of all three peptidases have also been 
tested and found to inhibit promastigote growth, infection of macrophages and 
development of lesions in mice, being selective for parasite cysteine peptidases 
over mammalian peptidases (Selzer et al., 1999).  These peptidases have also 
been suggested to have a role as virulence factors by modulating the immune 
response.  Splenocytes from mice infected with L. mexicana CPA/CPB double null 
mutants increased their production of Th1-type response cytokines, and reduced 
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infected with L. mexicana CPB null mutant promastigotes controlled the infection 
with a Th1-type response (Buxbaum et al., 2003), with multiple CPB isoforms 
being necessary to restore a Th2-type response (Denise et al., 2003).  CPC has 
also been shown to have a role in the exacerbation of disease, as L. chagasi CPC 
cleaved the cytokine TGF-b from its precursor form to the active form, which aids 
survival in macrophages and inhibits Th1-type cytokines (Somanna et al., 2002).  
In addition, CPA and CPB have been shown to be antigens in human disease, as 
sera from leishmaniasis patients reacts with recombinant L. major CPA and CPB 
(Rafati et al., 2001).   
In addition to these well characterised papain family enzymes, L. major contain 
many other clan CA peptidases.  There are 22 members of the calpain family, 
which in higher eukaryotes are central in calcium-regulated functions including 
signal transduction, cell differentiation and in apoptosis.  Their role in L. major has 
yet to be elucidated (Besteiro et al., 2007).  L. major also has numerous enzymes 
involved in ubiquitination; with 19 ubiquitin hydrolases (families C12 and C19), one 
small ubiquitin-like modifier (SUMO)-specific peptidase (family C48) and one 
otubain (family C65).  These ubiquitination-associated genes work in partnership 
with the proteasome (discussed in Section 1.3.2.2), and the number of genes 
present indicates a nonlysosomal cytosolic protein degradation
 system is important 
(Ivens et al., 2005).  Two members of the C51 family of d-alanyl-glycyl 
endopeptidases or peptidoglycan amidases are present in L. major, which contain 
CHAP (cysteine, histidine-dependent amidohydrolases/peptidases) domains.  In 
bacteria, these enzymes are involved in cell division, growth and cell lysis 
(Bateman and Rawlings, 2003), but are as yet uninvestigated in Leishmania.  
There are also two members of the C54 family, the ATG4 peptidases, which have 
a key role in the autophagic pathway, with the ATG4 peptidase processing ATG8 
and being crucial for autophagosome function.  Null mutants for one of the 
isoforms, ATG4.2, have been produced.  They have a defect in both autophagy 
and in differentiation to metacyclic promastigotes, again suggesting autophagy is 
necessary for this differentiation (Besteiro et al., 2006). 
Members of three clan families of CD cysteine peptidases were found in L. major:  
GPI8 from family C13, metacaspase from family C14 and separase from family 
C50.  GPI8 is the catalytic component of the GPI:protein transamidase complex 
which adds GPI anchors to prescursor GPI-anchored proteins in the
 endoplasmic 
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mutants being able to differentiate into amastigotes and establish infections in 
purified macrophages and mice (Hilley et al., 2000).  Metacaspases are 
evolutionary distant orthologues of metazoan caspases which have been identified 
only in plants, fungi, protozoa and some bacteria (Gonzalez et al., 2007).  
Metacaspases are thought to have a key role in inducing programmed cell death 
(PCD) in plants and yeast and the L. major metacaspase has been shown to 
complement a PCD phenotype in yeast (Gonzalez et al., 2007).  Two 
metacaspase genes have been identified in L. donovani, which were localised to 
acidocalcisomes and found to have a trypsin-like specificity for cleavage of 
substrates.  The L. donovani metacaspases are suspected to have a role in PCD, 
as they were upregulated in parasites undergoing PCD and promastigotes over-
expressing metacaspase 1 were more sensitive to hydrogen peroxide-induced 
PCD (Lee et al., 2007).  In L. major there is only one metacaspase gene, which 
was located in punctate structures in the cytoplasm in interphase cells, but was 
concentrated in the kinetoplast when this was segregating and was localised in the 
nucleus during mitosis.  It was not possible to generate metacaspase null mutants, 
suggesting it is essential for the correct segregation of the nucleus and kinetoplast, 
and it is a potential drug target, particularly with the absence of metacaspase from 
mammals (Ambit et al., 2008).  In higher eukaryotes separase is a major regulator 
of the metaphase-to-anaphase transition.  Little is known about chromosome 
segregation in Leishmania, but separase is likely to have a crucial role in the 
parasite’s cell cycle control mechanisms (Besteiro et al., 2007). 
The clan CF, family C15 cysteine peptidase that was found in L. major was 
pyroglutamyl peptidase I (PPI), which removes N-terminal l-pyroglutamyl residues 
(l-pGlu), post-transcriptional modifications conferring relative aminopeptidase 
resistance that are essential to the modified peptides’ biological activity in some 
cases.  The L. major PPI has been previously cloned and expressed as a 
recombinant enzyme, which had pyroglutamyl peptidase activity.  It was possible 
to generate LmjPPI null mutants, which were able to differentiate to metacyclic 
promastigotes and successfully infect murine macrophages.  It is thought that PPI 
could regulate I-pGlu-modified peptides which are necessary for differentiation of 
metacyclic promastigotes since over-expression of PPI caused a defect in 
metacyclogenesis (Schaeffer et al., 2006).  
Only one member of the family C56, clan PC was found in L. major, Pyrococcus 
furiosus protease 1 (PFP1).  This is a multimeric cysteine peptidase, which forms Chapter 1      37 
a doughnut-shaped hexamer, made up of a trimer of dimers.  This peptidase has 
limited taxonomic distribution, with homologues being found in certain bacteria, 
archaea and plants.  A PFP1-like protein is expressed in L. major, but not in other 
species of Leishmania or trypanosomes.  Pseudogenes of PFP1 have been found 
in L. mexicana, L. braziliensis and L. infantum.  The expression of PFP1 in  
L. major suggests it may contribute to the disease tropism that distinguishes  
L. major from other Leishmania species, or it may be becoming a pseudogene, 
albeit more slowly than in other species (Eschenlauer et al., 2006). 
1.3.5.5  Serine peptidases 
The trypsin/chymotrypsin family (S1) is one of the most abundant groups of serine 
peptidases, but none were identified in L. major (Ivens et al., 2005).  Seven other 
serine peptidase families were identified.  There is one subtilisin-like serine 
peptidase, which has a signal peptide and is likely to be part of the secretory / 
endosomal system, involved in the processing of secreted proteins.  The subtilisin-
like peptidases of Plasmodium are thought to be potential drug targets (Withers-
Martinez et al., 2004).  The other poorly characterised serine peptidases are: one 
lysosomal serine carboxypeptidase, a homologue of which has previously been 
characterised in T. cruzi (Parussini et al., 2003); two members of the signalase 
family, type-I signal peptide peptidases, which cleave signal peptides from proteins 
in the endoplasmic reticulum (Tuteja, 2005); a 26S regulatory subunit of the 
proteasome; a nucleoporin and a rhomboid-like protein (Ivens et al., 2005). 
There are also six members of the prolyloligopeptidase family (S9), including 
prolyloligopeptidase (POP), peptidyl-dipeptidase IV and oligopeptidase B (OPB).  
OPB has been shown to be a virulence factor in T. cruzi, mediating entry into host 
cells (Caler et al., 1998) and the OPB of African trypanosomes is released into the 
host serum, where it cleaves host blood factors (Morty et al., 2005a).  T. cruzi POP 
is also involved in entry of parasites to host cells, with inhibitors preventing host 
cell invasion (Grellier et al., 2001).  A likely Leishmania OPB was described in  
L. amazonensis in 1998 (de Andrade et al., 1998) and subsequently in L. major in 
1999 (Morty et al., 1999a).  The L. amazonensis OPB was later cloned, 
sequenced and found to be 90% identical to L. major and L. infantum OPB and 
84% identical to L. braziliensis (de Matos Guedes et al., 2007).  Whether OPB has 
a virulence role in Leishmania, as in trypansomes, was unknown; addressing this 
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As well as these defined serine peptidases, three other unidentified serine 
peptidase activities have been investigated in L. amazonensis.  Firstly, a 68 kDa 
soluble serine peptidase was found which could cleave haemoglobin, bovine 
serum albumin (BSA), ovalbumin, arginine-containing peptide substrates and 
insulin, being found to prefer to cleave insulin after hydrophobic residues or 
glutamate residues (da Silva-Lopez and Giovanni-De-Simone, 2004).  The activity 
was inhibited by N-tosyl-L-phenylalanyl-chloromethylketone (TPCK) and antipain, 
inhibitors of chymotrypsin-like and trypsin-like peptidases respectively.  This 
peptidase was subsequently localised to vesicular structures close to the flagellar 
pocket, morphologically similar to those of the endocytic/exocytic pathway 
(Morgado-Diaz et al., 2005). 
Secondly, a secreted serine peptidase has been characterised.  This 56 kDa 
peptidase appears to be present as a homodimer and could also cleave a number 
of substrates, including haemoglobin, BSA, ovalbumin, fibrinogen, collagen type II 
and arginine-containing peptide substrates, again cleaving substrates after 
hydrophobic residues (Silva-Lopez et al., 2005).  This activity was only fully 
inhibited by aprotinin, but also partially by benzamidine, TPCK and 
phenylmethylsulfonyl fluoride (PMSF); aprotinin and benzamidine are inhibitors of 
trypsin-like peptidases, whilst TPCK is an inhibitor of chymotrypsin-like inhibitors.  
This peptidase was found to be secreted through the flagellar pocket, being 
predominantly located in the flagellar pocket and in endocytic/exocytic vesicles in 
promastigotes, and in megasomes as well as the flagellar pocket in amastigotes 
(Silva-Lopez et al., 2004). 
Finally, an unidentified serine peptidase activity, inhibited by PMSF, has also been 
found in soluble extracts of L. amazonensis, with higher activity in promastigotes 
and in the early hours of differentiation to amastigotes in vitro than in amastigotes 
(Alves et al., 2005). 
Investigation of the effect of serine peptidase inhibitors on the survival of 
Leishmania has shown that TPCK and benzamidine both reduce viability and 
induce morphological changes in the L. amazonensis promastigotes (Silva-Lopez 
et al., 2007), suggesting serine peptidases could be useful potential drug targets.   Chapter 1      39 
1.4 Aims of Project 
The peptidases of Leishmania described above, particularly those identified by the 
genome but so far not explored, have been deemed to be a fruitful line of research 
for in depth characterisation and investigation of their potential use as drug 
targets.  Thus, the research described in this thesis had the following four aims: 
1)  to develop an assay to characterise peptidase activity in live Leishmania 
promastigotes and to identify the major peptidase(s) involved, 
2)  to fully characterise the identified peptidase(s), 
3)  to evaluate its (their) potential as an antileishmanial target using specific 
inhibitors and genetic manipulation, and 
4)  to determine the value of the luciferase reporter gene for identifying the 
presence of Leishmania in infected macrophages. 
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2.1 Cell Culture 
2.1.1 Leishmania spp promastigote culture 
Leishmania promastigote parasites (L. mexicana MNYC/BZ/M379, L. major 
MHOM/IL/80/Friedlin and L. infantum JPC clone M5, MCAN/ES/98/LLM-877), were 
maintained in culture in HOMEM medium (Invitrogen, Paisley, UK, ref 041-946-
99M), with 10% (v/v) heat-inactivated foetal calf serum (HIFCS; Labtech 
International, Ringmer, UK).  Starting inoculation was ~10
5 cells/ml and cells were 
sub-passaged once grown to stationary phase, ~3 x 10
7 cells/ml, after around  
1 week.  Cultures were grown at either 25° C ( L. mexicana and L. major) or 27° C  
(L. infantum), with air as the gas phase, in phenolic-style lidded flasks.   
To start initial cultures, amastigotes were isolated from either a footpad lesion on  
a BALB/c mouse (L. mexicana and L. major) or from a Golden hamster spleen  
(L. infantum), by either Mrs Susan Baillie or Mrs Denise Candlish (both University of 
Glasgow), and differentiated by inoculation into HOMEM with 10% (v/v) HIFCS into 
promastigotes.  Leishmania were used in experiments up to sub-passage 20. 
When necessary, antibiotics were added to the cultures of generated transgenic  
cell lines as follows: hygromycin B at 50 µg/ml, neomycin (G418, Geneticin) at  
12.5 to 50 µg/ml (both Calbiochem, Nottingham, UK) and nourseothricin at 75 µg/ml 
(Hans Knoll Institute, Jena, Germany). 
Stabilates of Leishmania were made by diluting 500 µl of mid log phase cells with 
500 µl of a mixture of 30% glycerol / 70% HIFCS in a 1.5 ml cryotube, slow cooling 
these stabilates using an isopropanol bath to –80° C , storing them overnight at  
–80° C and then indefinitely in liquid nitrogen. 
2.1.2 Growth of Leishmania spp axenic amastigotes 
L. mexicana promastigotes were transformed to axenic amastigotes by a 1 in 10 
dilution of stationary phase promastigotes into Schneider’s Drosophila medium 
containing 10% (v/v) HIFCS, 0.3% (v/v) Hemin (from a 2.5 mg/ml stock in 50 mM 
NaOH), at pH 5.5 and in a 32.5° C incubator with 5%  CO2.  They were maintained 
by weekly subpassage, of 1 in 10 dilution in the same medium, in vented lidded 
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amastigotes was transferred into 9 ml of HOMEM medium, with 10% (v/v) HIFCS 
and incubated at 25° C with air as the gas phase. 
2.1.3 Growth of THP-1 cells 
The human monocytic cell line THP-1 was originally cultured from the blood of a 
boy with acute monocytic leukaemia (Tsuchiya et al., 1980).  THP-1 cells (a gift of 
Dr Vanessa Yardley, LSHTM, UK), were maintained in RPMI 1640 medium (PAA 
Cell Culture, Yeovil, UK), with 10% (v/v) HIFCS, 100 U/ml penicillin and 100 µg/ml 
streptomycin (Sigma-Aldrich, Poole, UK), and incubated at 37° C with 5% CO 2.  
They were sub-passaged twice-weekly, splitting the flask 1 in 4 with medium, with  
a starting inoculum of ~10
5 cells/ml in vented lidded flasks.  
2.1.4 Isolation of L. major metacyclic promastigotes 
Isolation of L. major metacyclic promastigotes was completed based on the  
method of Sacks (Sacks et al., 1985).  L. major promastigotes were counted, then 
centrifuged for 10 minutes at 1000 g at room temperature.  They were washed in 
PBS, recentrifuged and resuspended at 2 x 10
8 parasites/ml in PBS.  Sterile  
peanut agglutinin was added to the cell suspension at a final concentration of  
100 µg/ml.  The tube was mixed and incubated stationary for 30 min at room 
temperature.  The supernatant was carefully removed from the pellet and the 
number of metacyclic promastigotes in this supernatant were counted.  The 
metacyclic promastigotes were then adjusted to the desired concentration for use.  
In order to calculate the percentage of metacyclic promastigotes in a culture of 
stationary phase cells, the number of metacyclic promastigotes found after the 
incubation with peanut agglutinin was compared to the initial concentration of  
2 x 10
8 parasites/ml.  Two replicates were completed per parasite line. 
2.1.5 Determination of cell densities 
2.1.5.1  Promastigote parasites 
An equal volume of culture and 1% formaldehyde in PBS were combined and 10 µl  
of the fixed cells was pipetted onto a Neubauer haemocytometer and left to settle to 
the bottom at room temperature.  Five of the large squares were counted, and the 
count multiplied by 10
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2.1.5.2  Axenic amastigote parasites 
Amastigotes were separated by passage through a 26 gauge needle.  10 µl of cells 
were then pipetted onto a Neubauer haemocytometer and left to settle to the 
bottom at room temperature.  5 of the large squares were counted, and the count 
multiplied by 5 x 10
4 to give the number of cells present in 1 ml of culture. 
2.1.5.3  THP-1 cells 
10 µl of THP-1 cells were pipetted onto a Neubauer haemocytometer and left to 
settle to the bottom at room temperature.  Five of the large squares were counted, 
and the count multiplied by 5 x 10
4 to give the number of cells in 1 ml of culture. 
2.1.6 Harvest, lysis and fractionation of cells 
Parasites or macrophage cells were harvested by centrifugation at 1300 g at room 
temperature for 10 min, washed twice in PBS and either used immediately or  
stored at -80° C until used.  Two methods were used  to lyse cells.  Cells were  
either lysed by resuspension to the required concentration of cells per ml in lysis 
buffer (50 mM Tris/HCl pH 8.0, 0.25% (v/v) Triton X-100, 20% (v/v) glycerol), or by 
sonication of cells suspended in PBS, using a Soniprep 150 (MSE Ltd, Lower 
Sydenham, UK) on full power 3 times for 30 sec with 10 sec in between.  As 
necessary, the following peptidase inhibitors were included, either singly or in 
combination, to prevent peptidase activity in the lysates: 10 µM E-64 (trans-
epoxysuccinyl-L-leucylamido(4-guanidino)butane), 400 µM 1,10-phenanthroline,  
2 µM pepstatin A, 1 mM phenylmethylsulphonyl fluoride (PMSF), 10 µM antipain,  
10 µM leupeptin and 2 mM ethylenediamine tetra acetic acid (EDTA). 
To separate lysates into membrane and soluble fractions, the lysate was spun at 
37500 g for 1 h at 4° C.  The supernatant (soluble fraction ) was separated from the 
pellet (membrane fraction), and the pellet was washed with PBS, recentrifuged  
and then resuspended in the same volume as before in lysis buffer.   
2.1.7 Differentiation of THP-1 cells 
THP-1 cells can be differentiated from a suspension of monocytic cells to attached 
macrophage like cells by the addition of phorbol esters (Tsuchiya et al., 1982; Chapter 2      44 
Wang et al., 1996).  Based on these methods and that of Ogunkolade et al. for the 
infection of THP-1 cells with Leishmania (Ogunkolade et al., 1990), 20 nM phorbol 
12-myristate 13-acetate (PMA, Sigma-Aldrich, Poole, UK), from a stock of 100 µM 
was added to THP-1 cells diluted to a concentration of 5 x 10
5 cells/ml.  Cells were 
added to the wells of a 12 well plate and left to adhere for 2 or 3 days at 37° C with 
5% CO2.  THP-1 cells were then treated as mouse macrophages for infection with 
Leishmania promastigotes or immunofluorescence (Sections 2.2.2 and 2.6.5.2). 
2.2 Infectivity of Leishmania spp 
2.2.1 Harvest of peritoneal exudate macrophages (PEM) 
Female CD1 mice were culled, the abdomen was degloved and 10 ml of RPMI 
1640 medium containing 1% (v/v) gentamicin and 1% (v/v) penicillin/streptomycin 
was injected into the abdomen under the sternum using a 21 gauge needle.  The 
mice were shaken to detach the macrophages into the medium.  A 26 gauge needle 
was then used to extract the medium from the side of the abdomen.  The PEM were 
centrifuged at 1000 g for 10 min at 4° C, then resuspended in fresh RPMI  1640 
medium with 10% (v/v) HIFCS and counted.  The PEM were adjusted to 5 x 10
5 
cells/ml in the same medium, 100 µl of this was added to each well of Nunc 16-well 
Lab-tekÔ tissue culture slides (Fisher Scientific, Loughborough, UK) and these 
were incubated at 37° C with 5% CO 2 overnight.  PEM were generally infected with 
Leishmania the day following extraction, but they could be infected up to one week 
after extraction.  
2.2.2 Infectivity in vitro in PEM 
PEM were infected with cultured promastigotes or axenic amastigotes.  Stationary 
phase promastigotes, metacylic promastigotes or axenic amastigotes were counted 
as detailed above (Sections 2.1.5.1 and 2.5.1.2) and diluted in RPMI 1640 with  
10% (v/v) HIFCS to the relevant concentration for the desired ratio.  100 µl was 
added to the 16-well chamber slides already containing PEM.  Slides were 
incubated at 32.5° C ( L. mexicana), or 37° C ( L. major or L. infantum) with 5% CO2.  
Parasites were left to infect overnight then the slides were washed at least twice 
with RPMI 1640 and the macrophages were re-covered with 200 µl RPMI 1640  
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The slides could be stopped at this 24 h point, or kept for up to 1 week at the 
relevant temperature to determine how the infections changed over time.  Slides  
left to incubate for over four days had their medium replaced at this point. 
When stopped, slides were fixed with 100% methanol for around 1 min and  
stained with 10% Giemsa’s stain (VWR International, Lutterworth, UK) for 10 min.  
The percentage of macrophages infected and, if necessary, the number of 
amastigotes per macrophage were determined by light microscopy.  
2.2.3 Assessment of infectivity in BALB/c mice 
Groups of 5 or 6 female BALB/c mice were inoculated in the footpad with 5 x 10
5 
stationary-phase L. major promastigotes resuspended in 20 µl of PBS, pH 7.4.   
The thickness of the footpad was measured weekly until the footpad was 5 mm 
thick, at which stage the mice were culled. 
2.3 Testing the Effectiveness of Anti-Leishmanial Drugs 
2.3.1 Alamar blue tests with promastigote cells 
L. major cells were diluted to a concentration of 2 x 10
6 cells/ml in HOMEM  
medium with 10% (v/v) HIFCS for use.   
Drugs were initially tested from a starting concentration of 10 µM, with an 
appropriate serial dilution.  Drugs were made up in HOMEM medium with 10%  
(v/v) HIFCS, at twice the desired final concentration. 
Tests were completed in 96 well plates, with 100 µl of the appropriate drug 
concentration added to the wells, and then 100 µl Leishmania was added to the 
drugged wells and to control wells.  Control wells contained either 100 µl of 
HOMEM with 10% (v/v) HIFCS, for water soluble drugs, or 100 µl of a matched 
serial dilution of the liquid in which the drugs were made up in, for example DMSO 
or ethanol, in HOMEM with 10% (v/v) HIFCS. 
Plates were incubated for 5 days at 25° C, with air  as the gas phase.  After 5 days, 
20 µl sterile resazurin solution (0.0125% (w/v) resazurin salt (Sigma, Poole, UK) in 
PBS, filter sterilised), was added and the plates incubated for a further 24 h.   Chapter 2      46 
Plates were read using an EnVision plate reader (Perkin Elmer, Beaconfield, UK)  
at emission wavelength of 535 nm, excitation of 620 nm, with a general mirror.  
LD50 values were determined by comparison to the control wells, using GraFit 5 
data analysis software (Erithacus Software, Horley, UK). 
2.3.2 Testing of amastigotes within PEM 
PEM were harvested and infected with promastigote L. major as described in 
Sections 2.2.1 and 2.2.2.  PEM were infected at a 7:1 ratio of promastigotes:PEM.  
The un-engulfed promastigotes were washed off at the 24 h time point, and the 
drugs were added.  Drugs were initially tested from a starting concentration of  
10 µM, with a 3-fold serial dilution.  They were made up in RPMI 1640 medium  
with 10% (v/v) HIFCS. 
200 µl of the appropriate drug concentration was added to wells of the chamber 
slides, in triplicate or quadruplicate, with 200 µl of control solution added to control 
wells.  This control solution was either RPMI 1640 with 10% (v/v) HIFCS for water 
soluble drugs, or a matched serial dilution of the solvent in which the drug was 
made up, in RPMI 1640 with 10% (v/v) HIFCS. 
The slides were incubated at 37° C with 5% CO 2 for 5 days, with the drugs 
completely replenished on the 3
rd day.  After the incubation, slides were fixed with 
100% methanol for around 1 min and stained with 10% Giemsa’s stain for 10 min.  
The percentage of macrophages infected was determined by light microscopy and 
IC50 values were determined by comparison to the control wells, using GraFit 5  
data analysis software (Erithacus Software, Horley, UK). 
2.4 Uptake and Cleavage of Fluorescent Molecules 
Observed with Fluorescent Plate Reader 
2.4.1 Basic peptide-AMC cleavage assay 
Either benzoyl-Arg-AMC (Bz-R-AMC), 3-carboxy-propionyl-Ala-Ala-Pro-Val-AMC 
(Suc-AAPV-AMC) or 3-carboxy-propionyl-Ala-Ala-Pro-Phe-AMC (Suc-AAPF-AMC; 
all Bachem, Weil am Rhein, Germany) were used to assess the enzymatic capacity 
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phase (day 3 following sub-passage) and in stationary phase (day 7 following  
sub-passage).  All were made up at a stock concentration of 100 mM as per the 
manufacturer’s instructions. 
Leishmania promastigotes were counted and diluted to the desired concentration 
(typically 6 x 10
6 cells/ml) in HOMEM medium.  100 µl of cell suspension was used 
per well in a black 96-well plate (Greiner Bio-one, Stonehouse, UK).  Control wells 
of the same volume of HOMEM medium were included with every assay, to  
account for the inherent cleavage of the substrate.   
The relevant peptide-AMC was diluted to 10 µM and 100 µl of this was added to 
both parasite and control wells to give a final concentration of 5 µM.   
For each assay, an AMC standard was included.  AMC (Calbiochem, Nottingham, 
UK) was made up as a stock of 1 µM and a two-fold serial dilution in water was 
included on each plate, starting from 50 nM.  The values for the standard were 
converted into a standard curve to assess the fluorescence associated with a 
particular concentration of AMC. 
Fluorescence was read every min for 30 repeats, in an EnVision Multilabel 
Reader (Perkin Elmer, Beaconfield, UK) at emission wavelength of 355 nm, 
excitation of 460 nm and using the general mirror.  The fluorescence readings 
(minus the fluorescence of the control wells) were converted to a concentration of 
AMC released using the AMC standard.  The figures were graphed using Microsoft 
Excel to determine the rate of cleavage of Bz-R-AMC over the 30 min time frame. 
2.4.2 Inhibition of cleavage  
To determine the effect of peptidase inhibitors or other compounds, the basic  
Bz-R-AMC assay was completed as described in Section 2.4.1, with minor 
changes.  The inhibitor under test was made up at 20x the desired concentration.  
10 µl of inhibitor was added to the desired wells of a black 96 well plate.  
Leishmania promastigotes were diluted to a concentration of 6.67 x 10
6/ml and  
90 µl were added to the relevant wells.  The HOMEM control and AMC standard 
were added to the plate as described in Section 2.4.1.  100 µl of 10 µM Bz-R-AMC 
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The following inhibitors and drugs were used, with these starting concentrations:  
20 mM (2S,3S)-trans-epoxysuccinyl-L-leucylamido-3-methylbutane ethyl ester  
(E-64d, the membrane permeable form of E-64), a general clan CA cysteine 
peptidase inhibitor; 10 µM N-methyl-piperazine-Phe-homoPhe-vinylsulfone-phenyl 
(K11777), a more specific cysteine peptidase inhibitor, acting against Clan CA, 
family C1; 1 µM 1,10 phenanthroline and 250 µM EDTA, both metallo-peptidase 
inhibitors; 2 µM pepstatin A, an aspartic peptidase inhibitor; 1 mM phenylmethyl 
sulfonyl fluoride (PMSF) and 100 µM 4-(2-aminoethyl) benzenesulfonyl fluoride 
hydrochloride (AEBSF or pefabloc), both serine peptidase inhibitors; 25 µM  
antipain and 50 µM leupeptin, both inhibitors of serine and cysteine peptidases;  
100 µM MG132 and 100 µM lactacystin, proteasome inhibitors; 100 µg/ml 
cytochalasin D, an inhibitor of actin polymerization; and 100 µM pentamidine, and 
1000 µM of the polyamine CMR compounds 3, 32 and 370, synthesised by 
Caroline Reid in the Department of Chemistry, University of Glasgow, as detailed  
in Section 4.2.6. 
When an inhibitor was found to be effective at preventing cleavage, a serial dilution 
of concentrations was prepared and tested against the cells in order to determine 
an IC50 value for inhibition of Bz-R-AMC cleavage. 
Fluorescence was read every min for 30 repeats, in an EnVision Reader (Perkin 
Elmer) at emission wavelength of 355 nm, excitation of 460 nm and using the 
general mirror.  The fluorescence readings (minus the fluorescence of the control 
wells) were converted to a concentration of AMC released using the AMC standard.  
The figures were graphed using Microsoft Excel to determine the rate of cleavage 
of Bz-R-AMC over the 30 min time frame, with the rates converted to relative 
activities compared to uninhibited cells.  IC50 values were calculated from these, 
using GraFit 5 data analysis software (Erithacus Software, Horley, UK). 
2.5 Molecular Biology Techniques 
2.5.1 Isolation of genomic DNA from L. major 
Genomic DNA was prepared following the “cultured animal cells” protocol of the 
DNeasy tissue kit (Qiagen, Crawley, UK).  DNA was quantified either by running out 
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2.5.4.2) or by analysing a 1 in 100 dilution of DNA using an Eppendorf 
Spectrophotometer.  DNA concentration was calculated using the Beer-Lambert 
Law: concentration (µg/ml) = Abs λ=260nm x sample dilution x 50 µg/ml (where 50 
µg/ml represents the concentration of DNA necessary to obtain 1 unit of 
absorbance at λ=260nm). 
2.5.2 Polymerase chain reactions (PCRs) 
All oligonucleotides were synthesised by MWG-Biotech (Ebersberg, Germany).  
PCR reactions were performed using either Taq DNA polymerase (AB gene, 
Epsom, UK or NEB, Hitchin, UK) or Phusion Hot Start high-fidelity Taq 
polymerase (NEB, Hitchin, UK).  The annealing temperature and elongation time 
used were optimised for each reaction.  A G-Storm GS4 PCR machine was used 
(GRI Ltd, Braintree, UK) for PCR cycles. 
For reactions using Taq polymerase, the following concentrations of reagents were 
used: 2 µl of 10x PCR mix (1.13 mg/ml BSA, 450 mM Tris pH 8.8, 110 mM 
ammonium sulphate, 45 mM MgCl2, 68.3 mM b-mercaptoethanol, 44 µM EDTA  
pH 8.0, 10 mM dCTP, 10 mM dATP, 10 mM dGTP, 10 mM dTTP, water), 10 pmol 
of each oligonucleotide, 50-100 ng of DNA and 0.5 units of Taq polymerase in a 
final volume of 20 µl.  The PCR cycles were: 95° C f or 30 sec, 1 cycle; 95° C for  
30 sec, 56° C for 30 sec, 72° C for y min, 30 cycles;  finally 72° C for 10 min.  The 
elongation time (y) was estimated from the size of the fragment to be amplified, 
based on the assumption that typically around 1 kb was synthesised per min. 
For reactions using the proof-reading polymerase, the following concentrations of 
reagents were used: 4 µl of 5x Phusion GC buffer (NEB, Hitchin, UK), 1 mM of 
dNTPs mix, 10 pmol of each oligonucleotide, 50-100 ng of genomic DNA and  
1 unit of Phusion high-fidelity Taq polymerase, in a final volume of 20 µl.  The PCR 
cycles were: 95° C for 30 sec, 1 cycle; 95° C for 30  sec, 56° C for 1 min, 72° C for  
y min (as above), 35 cycles; finally 72° C for 10 mi n.  The annealing temperature 
was adjusted depending on the melting temperature of the oligonucleotides in use.   
2.5.3 Oligonucleotides used 
Oligonucleotides are shown in Table 2.1.  Sequences are written in 5’ ® 3’ sense.  
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oligonucleotides contain restriction sites, the restriction site is underlined, with the 
corresponding restriction enzyme named.  For site-directed mutagenesis, the codon 
that has been modified is underlined and the mutated nucleotide indicated in bold.  
Table   2.1 Oligonucleotides used in this study. 
Oligonucleotide  Forward 
/ Reverse 
Sequence (restriction site / 
codon modified underlined) 
Restriction 
enzyme  
OL2352  F  A CCC GGG ATG TCG TCG GAC AGC TCC 
GTC  Xma I 
OL2353  R  T AGA TCT TTA CCT GCG AAC CAG CAG GCG  Bgl II 
OL2395  F  C AAG CTT CTC CTT CTC GGT GGC ACT TG  Hind III 
OL2415  R  CC GTT GGG CAC GCA TGT ACC GTC GAC G  Sal I 
OL2356  F  G CCC GGG GAG TCG TGA ACA TTA ACT CC  Xma I 
OL2459  R  G AGA TCT CGG TAG CGG GAG AGA GAA GG  Bgl II 
OL2520  F  GAG CAC CTC AAC AAG GAG AAG GTC TAC 
TTC CAG GCG CGC   
OL2521  R  GCG CGC CTG GAA GTA GAC CTT CTC CTT 
GTT GAG GTG CTC   
OL2550  F  GCC TGC GAG GGG CGT GGC GCC GGT GGC 
CTG C   
OL2551  R  G CAG GCC ACC GGC GCC ACG CCC CTC 
GCA GGC   
OL1853  F  CTG GAT CAT TTT CCG ATG   
OL1854  R  TGA TAC CAC TTA TCG CAC TT   
M13 Forward  F  GTA AAA CGA CGG CCA G   
M13 Reverse  R  GGA AAC AGC TAT GAC CAT G   
T3  F  AAT TAA CCC TCA CTA AAG GG   
T7  R  TAA TAC GAC TCA CTA TAG GG   
OL2456  R  CCT CGT TAC CGC TCA TGT CC   
OL816  F  CTG TCA TCT CAC CTT GCT CC   
OL13  R  GGT GAG TTC AGG CTT TTT CA   
OL14  F  CGT CCG AGG GCA AAG GAA TA   
OL17  R  CAG GGA TCA CCG AAA TCT TCA   
OL18  F  CGG GAG CAC AGG ATG ACG CCT   
OL2615  F  CGT GCC GCA TGG CCG CCA AC   
OL2616  R  CGC CGC CGA GGG CGG GAA GG   
OL2702  F  TGA AGA TTT CGG TGA TCC CTG   
OL2703  R  AGG CGT CAT CCT GTG CTC CCG   
OL2704  F  TGA AAA AGC CTG AAC TCA CC   
OL2705  R  TAT TCC TTT GCC CTC GGA CG   
OL2399  F  CAC GGT GCA CCT CGT GGA GTC   
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2.5.4 Cloning of DNA fragments 
Cloning of DNA fragments used two strategies.  One method involved digestion  
by restriction enzymes of both DNA insert and vector recipient, followed by ligation 
of the fragments.  The second involved cloning of PCR products by amplication 
using either Taq polymerase or Phusion high-fidelity Taq polymerase.  Taq 
polymerase adds a single A residue to the 3’ ends of the PCR product, which can 
then be inserted into the pCR2.1-TOPO vector (Invitrogen, Paisley, UK).  Phusion 
polymerase does not add the single A and these fragments can thus be inserted  
into the PCR-Script Amp cloning vector (Stratagene, La Jolla, CA, USA). 
2.5.4.1  Digestion of DNA with restriction enzymes 
Typically, restriction digests used 5 units of restriction enzyme and 1x buffer in a 
total volume of 20 µl per 500 ng of DNA to be digested.  The buffer used was 
provided with the enzyme by the manufacturer (NEB, Hitchen, UK).  For digests 
using multiple enzymes, compatible buffers were chosen.  The reactions were 
incubated at the temperature specified by the manufacturer for 1-4 h on average. 
2.5.4.2  DNA gel electrophoresis and gel extraction 
Analysis was performed using 1% (w/v) agarose gels (Invitrogen, Paisley, UK), in 
0.5 x TBE (20 mM Tris, 20 mM boric acid, 0.5 mM EDTA pH 7.2).  Sybr safe  
DNA gel stain (Invitrogen, Paisley, UK) was added to the agarose gel, at a 1x 
concentration, to allow the visualisation of the DNA by exposure to UV light (Gel  
Doc 2000 (BioRad)).  A 1 kb ladder molecular weight marker (Invitrogen, Paisley, 
UK) was used at a concentration of 1  g per lane to determine the size and 
concentration of the analysed DNA (at this concentration the 1.6 kb marker band is 
composed of 100 ng of DNA, therefore, the concentration of fragments of 
comparable size and intensity are similar).  For PCR sample analysis, 10 µl of the 
reaction were mixed with 2 µl of 6x DNA loading buffer (50% (v/v) glycerol, 0.25% 
(w/v) bromophenol blue in TBE). 
Following PCR reactions or enzymatic digestion, DNA of interest was isolated and 
purified using the Gel Extraction Kit (Qiagen, Crawley, UK) as specified in the 
manufacturer’s instructions.  To be concentrated or when used for transfection,  
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10% 3 M NaAc pH 5.2 and centrifugation at 18,000 g for 30 min.  The DNA pellet 
was washed twice with chilled 70% ethanol.  Once air-dried, the pellet was re-
suspended in a suitable volume of sterile water and kept at -20° C until required. 
2.5.4.3  Ligations 
PCR products generated, as described previously with the Taq DNA polymerase or 
Phusion high-fidelity Taq polymerase, were ligated into the pCR2.1-TOPO vector or 
pPCR-Script vector, respectively, following the manufacturer’s instructions. 
For ligation into the final cloning vector, gel-purified digested DNA fragments and 
100-200 ng of gel-purified digested vector were mixed together at a molecular ratio 
of 7:1 and incubated with 40 units of T4 DNA ligase and 1 µl of 10x T4 DNA ligase 
buffer (both NEB, Hitchin, UK) in a final volume of 10 µl, either overnight at 16° C  
or for 1 h at room temperature. 
These ligations were used to transform heat-shock competent Escherichia coli  
XL-1 blue cells (see Section 2.5.4.5) and transformants were selected on Luria-
Bertani (LB) agar (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl,  
20% (w/v) agar) plates supplemented with the appropriate antibiotics. 
2.5.4.4  Competent cells 
E. coli XL-1 blue cells were plated on an LB agar plate with tetracycline.  One  
colony was used to inoculate 10 ml of LB medium (1% (w/v) tryptone, 0.5% (w/v) 
yeast extract, 1% (w/v) NaCl) and incubated overnight at 37° C.  The overnight 
culture was diluted 1:100 in 50 ml of LB medium and grown at 37° C, until an  
OD=0.7 (at 600 nm).  The cells were transferred to a 50 ml tube and put on ice for 
10 min before centrifugation at 350 g for 15 min.  The cell pellet was resuspended  
in 16 ml of RF1 buffer (100 mM rubidium chloride, 50 mM
 MnCl2.4H20, 30 mM 
potassium acetate, 10 mM CaCl2, 15% glycerol, with a final pH of 5.8, adjusted  
with 0.2 M acetic acid) and incubated on ice for 15 min.  The suspension was 
centrifuged for 15 min at 540 g at 4° C.  The cell pellet was resuspended, with  
careful pipetting, in 4 ml of RF2 buffer (10 mM MOPS pH 6.8, 10 mM rubidium 
chloride, 75 mM CaCl2, 15%
 glycerol, with a final pH of 6.8, adjusted with NaOH)  
and incubated on ice for 1 h.  Heat-shock competent cells were then aliquoted and 
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2.5.4.5  Transformation of competent cells 
Frozen heat-shock competent E. coli cells were placed on ice to defrost.  The DNA 
of interest was added to the cells and incubated with them, still on ice, for 30 min.  
Transformation was performed by incubation of the cells-DNA mix at 42° C for  
45 sec, following which the suspension was placed on ice for a further 2 min,  
100 µl of LB medium was added and the mixture was spread on LB plates, 
containing the relevant antibiotic.  The plates were incubated overnight at 37° C.   
2.5.4.6  Colony screening by PCR 
Bacterial colonies were taken from their plate with a sterile 200 µl pipette tip, 
streaked onto a new LB Agar plate and residual bacteria dipped into a Taq DNA 
polymerase mediated PCR reaction (made up as detailed in Section 2.5.2).  For 
screening the presence of insert in the pPCR-Script or TOPO vector, the T3/T7  
and M13F/M13R oligonucleotide couples were used, respectively.  When using 
different plasmids, the relevant oligonucleotides to be used were determined using 
the Vector-Nti map of the constructs and the “research motif” function of this 
software (Vector-Nti Advance 10, Invitrogen).  Only primers with a level of  
homology higher than 80% were used. 
PCR products were analysed on an agarose gel as detailed in Section 2.5.4.2.  
Clones of interest were selected and the relevant colony was picked from the plate 
and used to inoculate 5 ml of LB medium.  After an overnight incubation at 37° C, 
600 µl of the culture was mixed with 600 µl of a 2% (w/v) peptone, 40% (v/v)  
glycerol solution and placed at -80° C for cryoprese rvation and long term storage. 
2.5.4.7  Plasmid DNA purification 
The bacterial culture of the clones identified by screening were processed with a 
MiniPrep kit (Qiaspin miniprep, Qiagen, Crawley, UK), following the manufacturer’s 
instructions, to extract the plasmid DNA.  The plasmid DNA was eluted in water and 
stored at -20° C until needed.  When a larger amount of DNA was required, for 
example for transfection of Leishmania cells, 100 ml of bacterial culture was grown 
up overnight in LB medium at 37° C and the DNA was e xtracted using either several 
miniprep columns or a MidiPrep kit (Qiagen, Crawley, UK).  The DNA was then 
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2.5.4.8  Plasmid generation 
DNA inserts were transferred between vectors by using single-cutter restriction 
enzymes.  To enable this, the necessary restriction sites were added to the 5’ and  
3’ ends of the oligonucleotides used for PCR amplifications.  Therefore, after a DNA 
fragment was sequenced to confirm its conformity, it could be easily cut from the 
sub-cloning vector by enzymatic digestion.  Restriction enzymes (NEB, Hitchin, UK) 
were used at 10 units per µg of DNA in the appropriate reaction buffer (NEB, Hitchin, 
UK), following the manufacturer’s recommendations.  
Most of the enzymes used generated 5’ or 3’ overhangs.  However, when, during the 
preparation of the vector DNA, there was no other possibility than to use restriction 
enzymes creating blunt-ended fragment, the calf intestinal alkaline phosphatase 
(CIP; NEB) was used, as indicated by the manufacturer, to dephosphorylate the 
digested DNA and prevent the linearised plasmid from religating to itself.    
In order to blunt the ends of fragments, Mung bean Nuclease (NEB) was used after 
digestion to degrade single-stranded extensions from the end of the DNA.   
The plasmids generated in this study are detailed in Table 2.2 and further discussed 
in Chapter 5. 
Table   2.2 Plasmids generated in this study.  
Plasmid number  Purpose 
pGL1640  Over-expression of WT OPB 
pGL1714  Over-expression of active site mutant OPB 
pGL1693  Deletion of OPB – with Hygromycin B phosphotransferase 
pGL1762  Deletion of OPB – with Streptothricin acetyltransferase 
 
2.5.5 DNA sequencing and analysis 
DNA sequencing was performed by the Sequencing Service, University of Dundee 
(www.dnaseq.co.uk/), using
 an ABI 3730 capillary DNA sequencer.  Electro-
phoregrams were then edited and compiled into contigs using ContigExpress and 
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2.5.5.1  Sequence alignments 
Amino acid sequences were imported either from the GeneDB (www.genedb.org)  
or the National Center for Biotechnology Information (NCBI; www.ncbi.nlm.nih.gov/) 
websites into Vector NTI Advance 10.  Alternatively, the amino acid sequences  
were obtained from translation of nucleotide open reading frames (in Vector NTI 
Advance 10).  Alignments were performed using the ContigExpress module of  
the Vector NTI Advance 10 package. 
2.5.6 Site-directed mutagenesis 
Site directed mutagenesis was used to correct a single base alteration in the  
L. major OPB over-expression construct, pGL1640, and to introduce a site-specific 
mutation in the active site of L. major OPB in order to generate an inactive OPB 
over-expression construct, pGL1714.  The mutation chosen altered the active site 
serine to glycine (S577G), with a single point-mutation required, using pGL1640 as 
the template.    
To correct the single base alteration in pGL1640 the oligonucleotides OL2520 and 
OL2521 were used, whilst to generate pGL1714 the oligonucleotides OL2550 and 
OL2551 were used. 
The QuikChange Site-Directed Mutagenesis Kit was used (Stratagene, La Jolla,  
CA, USA).  The reactions contained 1x reaction buffer (provided with the kit), 50 ng 
of plasmid DNA (plasmid carrying the gene to mutate), 125 ng of each forward and 
reverse primer, 1 µl of dNTP mix and 2.5 units of Pfu Turbo DNA polymerase.  The 
following cycle was used: 95° C for 1 min, then 18 c ycles of 95° C for 30 sec, 60° C  
for 1 min and 68° C for 8 min, followed by 10 min at  68° C.  Ten units of  DpnI enzyme 
were added to the completed reaction and this was incubated at 37°C overnight, to 
remove any residual methylated template.  90 µl of E. coli XL-1 Blue 
supercompetent cells were transformed with 10 µl of digested PCR using the heat 
shock method (see 2.6.4.5) and were plated on LB agar plates.  The plates were 
incubated overnight at 37° C.  Plasmid was extracted  from colonies, sequenced and 
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2.5.7 Transfection of Leishmania  
2.5.7.1  Plasmid DNA Preparation 
For integrative constructs, 45 µg of plasmid was digested with the appropriate 
restriction enzymes (see Figures 5.8 and 6.1 for details), separated by gel 
electrophoresis and gel extracted, as described in Section 2.5.4.2.  The digested 
DNA was precipitated with ethanol.  For ectopic constructs, 20 µg of circular  
plasmid was directly precipitated with ethanol.  In both cases, the last washing  
step of the precipitation was done in a sterile Category II cabinet.  The precipitated 
DNA was resuspended in 20 µl of sterile water and used for transfection of 5 x 10
7  
L. major promastigotes. 
2.5.7.2  Electroporation and cloning 
Promastigotes from mid-log phase cultures, at a density of around 1-1.5 x 10
7 
cells/ml were used.  5 x 10
7 L. major and 10-20 µg of purified (digested or not) 
plasmid DNA (in 20 µl water) were necessary for each transfection.  Two methods 
were used.  For the first, cells were counted and the appropriate number were 
centrifuged for 10 min at 1000 g at 4° C and washed with ElectroPoration Buffer 
(EPB, 120 mM KCl, 0.15 mM CaCl2, 10 mM K2HPO4, 25 mM HEPES, 2 mM EDTA,  
2 mM MgCl2 at pH 7.6).  Cells were resuspended at 1 ´ 10
8 cells/ml in 500 µl EPB 
and incubated with the plasmid DNA, in an ice-cold 4-mm gap cuvette (Gene Pulse, 
BioRad, Hemel Hempstead, UK) on ice for 10 min.  Electroporation was done twice 
at 25 µFarads, 1500 Volts (3.75kV/cm), pausing 10 sec between pulses, using a 
BioRad Gene Pulser II machine.   
For the second method, cells were counted, the appropriate number were 
centrifuged for 10 min at 1000 g at 4° C and 5  ´ 10
7 cells were resuspended in  
100 µl of Nucleofector Solution from the Amaxa Human T Cell Nucleofector Kit 
(Amaxa AG, Cologne, Germany).  These were mixed with the plasmid DNA, in a 
cuvette from the Nucleofector kit.  Program U-033 was used to electroporate the 
cells using an Amaxa Nucleofector Device. 
In both cases, the transfected cells were stored on ice for 10 min, then transferred  
to a 25 cm
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20% (v/v) HIFCS and left to recover overnight at 25° C.  Antibiotic selection of 
successful transfectants was started the following day.   
To generate a population of cells, for ectopic expression, antibiotics were added 
directly to the flask of cells (concentrations used are described in Section 2.1.1).   
To generate individual clones, transfected cells were diluted in three steps.  This 
method is based on the calculated transfection efficiency in Leishmania in order to 
dilute the promastigotes to a concentration which will give an average of 0.1 cells/ 
well in the middle dilution.  Firstly 4 ml of cells was added to 20 ml of HOMEM with 
20% (v/v) HIFCS and the relevant antibiotics and mixed.  2 ml of this dilution was 
then added to 22 ml of HOMEM with 20% (v/v) HIFCS and the relevant antibiotics 
and mixed.  2 ml of the second dilution was then added to a further 22 ml of  
HOMEM with 20% HIFCS and the relevant antibiotics and mixed.  Each dilution  
was plated out in a 96 well plate, with one plate per dilution and 200 µl per well.  
Genomic DNA was extracted from drug resistant populations and clones and 
presence of the ectopic construct or correct integration was checked by PCR. 
2.5.8 Species Check of Leishmania by PCR 
Genomic DNA was extracted for the parasites to be checked.  The method used  
was based on that of Schonian et al. (Schonian et al., 2003).  A PCR reaction was 
completed by the method in Section 2.5.2 using primers OL1853 and OL1854 and 
the genomic DNA of interest and standard DNA of known species.  The PCR 
products obtained were digested with Hae III enzyme (Section 2.5.4.1) and then  
the digested DNA was visualised by agarose gel electrophoresis (Section 2.5.4.2) 
and the samples of interest compared to the digestion pattern of the known 
standards to enable identification of the species.   
2.6 Biochemical Methods 
2.6.1 SDS-PAGE 
Cell lysates were mixed with equal volumes of 2x loading buffer and denatured at 
100° C for 5 min.  Protein separation was carried ou t using the polyacrylamide gel 
method described by Laemmli (1970).  Gels used 12% (w/v) polyacrylamide  
(Bio-Rad, Hemel Hemstead, UK) and were run using a Mini-Protean II system  
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immersion in a solution of 0.25% (w/v) Coomassie Brilliant Blue R250, 45%  
ethanol, 9.2% acetic acid for 1 h at room temperature and destained using several 
changes of destain solution (10% (v/v) acetic acid, 12.5% (v/v) methanol).  Gels 
were then washed in water and a picture captured using a Gel Doc 2000 (BioRad).  
Alternatively, gels were used for immunodetection (western immunoblot). 
2.6.2 Antibodies 
2.6.2.1  Production 
Full length recombinant OPB protein was produced in E. coli (by Dr. Gareth 
Westrop, University of Glasgow) and used to raise polyclonal antiserum in a sheep 
using standard procedures. 
2.6.2.2  Affinity Purification 
OPB antiserum was affinity purified using a 5 ml polypropylene column (Pierce, 
Cramlington, UK).  5 mg of recombinant OPB was covalently linked to 500 µl of 
Aminolink Coupling Gel (Pierce), following the manufacturer’s protocol.  The OPB/ 
aminolink resin was then equilibrated with 10 ml of IgG binding buffer (0.14 M NaCl, 
8 mM sodium phosphate buffer pH=7.5, 2 mM potassium phosphate buffer pH 7.5, 
0.01 M KCl).  2 ml of anti-OPB sheep antiserum (final bleed) was then diluted by  
half in IgG binding buffer and incubated overnight at 4° C with the protein/aminolink 
resin.  The resin was washed with 12 ml of IgG binding buffer before eluting the 
bound antibodies with 2.5 ml of Immunopure IgG elution buffer (Pierce).   
A PD-10 Desalting column (GE Healthcare, Chalfont St Giles, UK) was used to 
change the buffer from IgG elution buffer to PBS, as per the manufacturer’s 
instructions.  The purified antibodies were stored at -20° C in aliquots. 
2.6.3 Western immunoblotting 
SDS-PAGE gels were first incubated for 10-15 min in transfer buffer to equilibrate 
(20 mM Tris/HCl, 15 mM glycine, 20% (v/v) methanol).  Separated proteins were 
transferred by electrophoresis to Hybond P (PVDF) membrane (Amersham,  
Chalfont St Giles, UK) using the Mini Protein II transblot module at 100 V for 1 h at 
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at room temperature in PBS-T (0.1% Tween-20 in 1x PBS) with 5% (w/v) low fat 
dried milk powder, then incubated in fresh blocking buffer containing the  
appropriate primary antibody at room temperature for 1 h or overnight at 4° C, both 
with constant, gentle agitation.  
The affinity purified sheep antibody against OPB was used at a 1:20,000 dilution  
and monoclonal anti-luciferase antibody (Calbiochem, Nottingham, UK) was used  
at 1:1000.  Monoclonal anti-GP63 antibody (Button et al., 1991), was used at  
1:100.  Mouse anti-TbEF1a antibody (Upstate, Chandlers Ford, UK), was used at 
1:10,000.  Rabbit anti-HASPB antibody (Flinn et al., 1994) was used at 1:1000. 
The membranes were washed briefly twice in PBS-T, to remove the majority of the 
antibody-milk solution, and then a further 4x in PBS-T, each for 15 min.  After this, 
they were incubated with secondary antibody for 1 h at room temperature in  
PBS-T plus 5% (w/v) low fat milk.  Depending on the primary antibody used, 
secondary antibodies were goat anti-mouse, donkey anti-sheep or goat anti-rabbit 
Horse Radish Peroxidase (HRP)-conjugated antibodies, all at 1:5000 dilution.  
Following incubation with secondary antibody, membranes were washed briefly 
twice in PBS-T, to remove the majority of the antibody-milk solution, and then a 
further 4x in PBS-T, each for 15 min.  The membrane was then incubated with an 
ECL kit (SuperSignal West Pico Chemoluminescent Substrate, Pierce,  
Cramlington, UK) for 5-15 min and were either subsequently exposed to 
autoradiography film for various time intervals and developed using a Kodak M35- 
M Xomat Processor (Kodak, Hemel Hemstead, UK), or were visualised using a 
Molecular Imager ChemiDoc XRS System (Bio-Rad, Hemel Hemstead, UK). 
2.6.4 Immunoprecipitation 
L. major cells were lysed by sonication (see Section 2.1.6) in Binding Buffer A  
(0.1 M sodium phosphate buffer, 0.15 M NaCl, pH 7.4) with the following inhibitors:  
E-64, pepstatin A, 1,10 phenanthroline, PMSF and EDTA (at the concentrations 
described in Section 2.1.6).  The lysate was filter sterilised and incubated  
overnight at 4° C in a 50:50 mix of either lysate:un purified anti-OPB antibody or 
lysate:pre-immune serum. 
A ProPur Protein G Mini Spin kit (Nunc, Roskilde, Denmark) was used.  The 
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(0.2 M glycine/HCl buffer, pH 2.5) and Neutralisation Buffer C (1 M Tris/HCl buffer, 
pH 9.0).  A sample was taken of the lysate mixtures that went on the column, and  
for both mixtures the following samples were collected: flow through from column, 
three washes and two elutions.   
The samples were used in a Bz-R-AMC degradation assay (as detailed in Section 
2.4.1) and were run on an SDS-PAGE gel and transferred for a western  
immunoblot (Sections 2.6.1 and 2.6.3). 
2.6.5 Immunofluorescence Analysis 
2.6.5.1  Fixation of promastigote Leishmania 
Leishmania promastigotes were washed twice in PBS, then fixed in 200 µl of 1% 
formaldehyde/PBS for 30 min at room temperature.  The cells were permeabilised 
by adding 20 µl of 1% Triton X-100/PBS for 10 min and 20 µl of 1M glycine/PBS  
was added to neutralise free aldehyde bonds that resulted from the formaldehyde 
fixation, to diminish any background fluorescence, and incubated a further 10 min.   
During these incubations, glass slides were washed with 70% ethanol.  A small 
rectangular border of clear nail varnish was drawn onto the slide to limit the spread 
of cells and antibody solutions.  The slides were then coated with 20 µl poly-L- 
lysine (Sigma-Aldrich, Poole, UK) and air dried.  The treated cells were pipetted  
onto these slides and left to sediment and adhere to the surface for 15-30 min in a 
dark box containing PBS-soaked tissues, to prevent drying. 
2.6.5.2  Infection and fixation of PEM 
PEM were extracted from ICR mice as described in Section 2.2.1.  13 mm  
diameter coverslips (VWR International, Leicestershire, UK) were cleaned with  
70% ethanol and one placed at the bottom of the appropriate number of wells of a 
12 well plate.  500 µl of PEM at 5 x 10
5 cells/ml was added to each well.  Cells  
were left to adhere overnight at 37° C with 5% CO 2.  PEM were generally infected 
with Leishmania the day following extraction, but they could be left for up to one 
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PEM were infected with cultured promastigotes at a 7:1 ratio for L. major and 
incubated at 37° C.  Parasites were left to infect o vernight, then the wells were 
washed twice with RPMI 1640 and the macrophages were re-covered with 1 ml 
RMPI 1640 with 10% (v/v) HIFCS.  THP-1 cells, differentiated as in Section 2.1.7 
were infected and treated as PEM for immunofluorescence. 
Following the desired number of days, PEM were washed twice in PBS and then 
fixed by addition of 500 µl of 1% formaldehyde/PBS to each well for 30 min at room 
temperature.  The cells were permeabilised by adding 50 µl of 1% Triton X-100/ 
PBS for 10 min, then 50 µl of 1M glycine/PBS was added and incubated a further  
10 min.  The wells were washed twice with PBS prior to antibody addition. 
2.6.5.3  Immunofluorescence 
The primary antibody was diluted in 0.1% Triton X-100, 0.1% BSA in PBS (TB), 
added to the slide / well and incubated with the cells for at least 1 h at room 
temperature.  They were then washed with 10 ml of PBS.  The rhodamine (red) – 
conjugated secondary antibody (Calbiochem, Nottingham, UK) was diluted at  
1/1000 in TB and then added and the slide / well were incubated in the dark for 1 h 
at room temperature.  1 µg/ml of 4,6-diamidino-2-phenylindole (DAPI; Sigma, Poole, 
UK) was added for 1 min before proceeding to a 10 ml PBS wash.   
For promastigotes, as much liquid as possible was removed, as well as the nail 
varnish border, and a mounting solution (2.5% DABCO, 50% glycerol in PBS) was 
applied to the coverslip before its application to the slide.  The coverslips with 
attached PEM were lifted from their wells and applied cell-side down to a slide.  
Coverslips were sealed with nail varnish to prevent drying out.  
The fluorescence was observed with the “DAPI” (l = 457 nm), and “Rhodamine”  
(l = 617 nm) filters of the UV light microscope.  Cells were viewed with an Applied 
Precision DeltaVision microscope and SoftWoRx Suite software (Image Solutions 
Ltd, Preston, UK).  Images were prepared using Adobe Photoshop CS.   
2.6.5.4  Colocalisation of Concanavalin A with immunofluorescence 
Concanavalin A (Molecular Probes, Paisley, UK) was made up to 5 mg/ml stock as 
per manufacturer’s instructions.  500 µl of Leishmania cell suspension was Chapter 2      62 
centrifuged for 5 min at 1000 g at room temperature, washed with HOMEM medium 
and resuspended in 500 µl of HOMEM containing 5 µg Concanavalin A and 
incubated for 1 h.  The cells were washed twice in PBS and resuspended in PBS.  
The protocol for immuno-fluorescence was then followed with the stained cells from 
the fixation stage (Sections 2.6.5.1 and 2.6.5.3).  The fluorescence was observed 
with the “FITC” (l = 526 nm) filter of the UV light microscope. 
2.7 Fluorescent microscopy 
2.7.1 Assessment of Bz-R-AMC uptake into L. major 
Bz-R-AMC was made up at a stock concentration of 100 mM as per the 
manufacturer’s instructions.  1 ml of cell suspension was centrifuged for 5 min at 
1000 g, washed twice with HOMEM medium, resuspended in 500 µl of HOMEM  
with 50 µM Bz-R-AMC and incubated for 10 min.  The cells were washed three  
times in PBS and resuspended in PBS.  20 µl of poly-L-lysine (Sigma-Aldrich, Poole, 
UK) was spread on a Twin frosted 76x26 mm microscope slide (VWR International, 
Lutterworth, UK) and left to dry.  The cells were spread on this and a 22x64 mm 
coverslip (VWR International) was fixed over them with clear nail varnish. 
The fluorescence was observed with the AMC filter of the Zeiss UV microscope,  
with an exposure time of 250 ms.  Phase was observed against bright visible light 
and pictures were taken with an exposure time of 50 ms.  Images were captured  
by an Orca-ER camera (Hamamatsu Photonics, Welwyn Garden City, UK) and 
Openlab software version 4.0.3 (Improvision, Coventry, UK) and prepared for 
presentation using Adobe Photoshop CS. 
2.7.2 Assessment of FM4-64 uptake 
1 ml of cell suspension was centrifuged for 5 min at 1000 g, washed twice with 
HOMEM medium, resuspended in 1 ml of HOMEM either with or without 100 µM 
cytochalasin D and incubated for 15 min, prior to the addition of 40 µM FM4-64 
(from a 12 mM stock solution in DMSO; Invitrogen) and a further 10 min incubation 
at 4° C.  The cells were washed three times in cold  PBS and resuspended in PBS.  
20 µl of poly-L-lysine (Sigma-Aldrich) was spread on Twin frosted 76x26 mm 
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and uninhibited cells were spread on these slides and a 22x64 mm coverslip (VWR 
International) was fixed over them with clear nail varnish. 
The fluorescence was observed with the “Rhodamine” filter of the Applied Precision 
DeltaVision microscope and SoftWoRx Suite software (Image Solutions Ltd).  
Images were prepared for presentation using Adobe Photoshop CS.   
2.8 DNA Content Analysis 
2.8.1 Cell preparation 
Mid-log phase promastigotes were centrifuged at 1000 g, 4° C for 5 mins, washed 
with PBS, centrifuged again and finally resuspended in 1 ml of 70% methanol in 
PBS.  Cells were stored at 4° C for at least an hour  or overnight.  Prior to analysis, 
the cells were centrifuged at 1000 g, 4° C for 5 min, washed with 1 ml PBS once, 
centrifuged, resuspended in 1 ml of PBS with 10 µg/ml propidium iodide and  
10 µg/ml RNAse A (both Sigma-Aldrich, Poole, UK), and finally incubated at 37° C  
for 1 h, in the dark. 
2.8.2 Fluorescence Activated Cell Sorting (FACS) analysis  
FACS analysis was performed with a Becton Dickinson
 FACSCalibur using the  
FL2-A (fluorescence intensity at 585/642 nm, note l emission propidium Iodine = 620 
nm under an l excitation = 488 nm (blue, Uniphase Argon Ion laser)), the Forward 
Scatter (FSC, relative cell size) and the Side Scatter detectors (SSC, cell 
granulometry or internal complexity).  Introduction of the prepared samples into the 
cytometer was automated with a FACS Loader (Worklist manager and Loader 
manager softwares).  For each sample, 10 000 events (cells) were analysed.  Data 
was interpreted using the CellQuestPro software (BD Bioscience, Oxford, UK).  
2.9 Analysis of Luciferase Activity 
2.9.1 Generation of luciferase expressing Leishmania  
Two constructs were used to generate luciferase-expressing Leishmania; one for 
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The integrating construct was a gift of Prof. D.F. Smith (University of York, UK).  It 
was designed to integrate into the ribosomal RNA small subunit of Leishmania.   
The construct was derived from the pSSU-int construct of Dr T. Aebischer of the 
University of Edinburgh, UK (Misslitz et al., 2000).  The vector, pGL1313  
(illustrated in Figure 6.1), was prepared for transfection by enzymatic digestion  
and transfected into L. major, L. mexicana and L. infantum promastigotes, as 
described in Section 2.5.7.  Two clones were selected for each species. 
The ectopic construct was a gift of Prof. M. Ouellette (McGill University, Montreal, 
Canada).  The vector map is shown in Figure 6.2.  The ectopic construct was 
transfected into L. mexicana, L. major and L. infantum promastigotes (as  
described in Section 2.5.7), and the promastigotes maintained as populations.   
Further details of both sets of luciferase lines are given in Section 6.2.1. 
2.9.2 Using D-luciferin with promastigote Leishmania 
Leishmania promastigotes were counted and a serial dilution of cells was completed, 
with parasites diluted to the relevant concentration of cells per ml in phenol red free 
RPMI 1640 (PAA Cell Culture, Yeovil, UK).  180 µl of cell suspension was pipetted 
into the wells of a 96 well plate to which 20 µl of a 1 mM stock solution of D-luciferin 
(Promega, Southampton, UK) was added, giving a final concentration of 12.5 µM  
D-luciferin.  One or two replicates were completed for each dilution of cells per 
experiment.  Luminescence was read using an EnVision Multilabel Reader (Perkin 
Elmer), with Luminescence mirror and Luminescence <700 emission filter. 
2.9.3 Using luciferase assay kit with promastigote Leishmania  
2.9.3.1  Using Leishmania with integrated luciferase construct 
Leishmania promastigotes were counted and a serial dilution was completed, with 
promastigotes diluted to the relevant concentration in phenol red free RPMI 1640.  
100 µl of promastigote suspension was pipetted into the wells of a 96 well plate and 
100 µl of the assay solution from the Luciferase Reporter Gene Assay, constant light 
signal kit (Roche, Burgess Hill, UK) was added.  A single replicate was completed 
per experiment for each concentration of cells, with three experiments completed.  
Luminescence was read using an EnVision Reader, as described in Section 2.9.2. Chapter 2      65 
2.9.3.2  Using Leishmania with ectopic luciferase construct 
Leishmania promastigotes were counted and made up to 2 x 10
7 cells/ml in phenol 
red free RPMI 1640.  150 µl of promastigote suspension was pipetted into the  
wells of a 96 well plate, with 50 µl of the assay solution from the Luciferase  
Reporter Gene Assay, constant light signal kit was added.  Two or three replicates 
were completed per experiment.  Luminescence was read using an EnVision plate 
reader, as described in Section 2.9.1. 
2.9.4 Using luciferase assay kit with infected PEM 
PEM were harvested as described in Sections 2.2.1 and 100 µl of 5 x 10
5 /ml cell 
suspension was added to either the wells of 96-well plates, or to 16-well slides for 
control experiments, and they were incubated at 37°C, 5% CO2 overnight.  PEM 
were infected with stationary phase cultures of luciferase-expressing  
promastigotes as described in Sections 2.2.2.  PEM were infected at a 5:1 ratio  
of promastigotes:PEM.   
The slides were incubated at 37° C with 5% CO 2 for 2-3 days, with the un-engulfed 
promastigotes washed off at the 24 h time point and fresh RPMI 1640 with 10%  
(v/v) HIFCS added.   
Following incubation, the wells were washed twice with phenol red-free RPMI  
1640 medium.  The wells of the 96-well plate had 100 µl of phenol red-free RPMI 
1640 added and 100 µl of the assay solution from the Luciferase Reporter Gene 
Assay, constant light signal kit.  Plates were read in the EnVision plate reader, as 
described in Section 2.9.1.  The 16-well slides were fixed with 100% methanol for 
around 1 min and stained with 10% Giemsa’s stain for 10 min and the percentage  
of macrophages infected was determined by light microscopy.   
2.10 Statistical Analysis 
Values were expressed as means ± standard error of the mean (SEM).  Levels of 
significance were calculated by unpaired t tests using the Data Analysis add-on of 
Microsoft Excel.  Differences were considered significant at a p value <0.05. 66 
 
 
 
 
 
 
 
Chapter 3   
THE USE OF A FLUORESCENT SUBSTRATE TO 
CHARACTERISE PEPTIDASE ACTIVITY IN LIVE 
LEISHMANIA Chapter 3      67 
3.1 Introduction 
For the investigation of peptidases within cells an ability to accurately quantify their 
activity in an in vivo situation is highly desirable.  In order to do this, the catalysis 
of fluorescent molecules is commonly used (Boonacker and Van Noorden, 2001), 
either endogenous fluorescent molecules, such as NADH or FAD, or, more 
commonly, synthetic fluorogenic substrates.  In order to detect changes in 
fluorescence, microscopy, flow cytometry or fluorometers have been used (Harris 
et al., 2000; Boonacker and Van Noorden, 2001). 
3.1.1 Analysis of peptidases using fluorescent molecules 
Analyses based on various fluorescing constituents have been developed and 
examples of their use will be described both for mammalian peptidases and 
Leishmania peptidases.  A number of properties are useful for peptide substrates 
to be used in living cells, including: gaining access to the location of the enzyme 
without damage to the cell; being selectively converted by the enzyme; having 
sufficiently strong fluorescence upon release for ease of detection; accumulating 
at the site of release, rather than diffusing from the site; and being non-toxic to the 
cell (Boonacker and Van Noorden, 2001). 
3.1.1.1  Fluorescent molecules commonly used 
Many fluorochromes have been used for analysis of peptidase activity, including 
various coumarin-, rhodamine-, fluorescein- and cresyl violet-containing substrates 
(Boonacker and Van Noorden, 2001), ortho-amino-benzoyl substrates (Alves et 
al., 2001a; Judice et al., 2004; Juliano et al., 2004) and 4-methoxy-naphthylamide 
substrates (Valdivieso et al., 2007).  Their different excitation and emission 
wavelengths can be valuable for analysis of several peptidases simultaneously.  
The substrate generally consists of a peptide joined to a leaving group, which 
either only fluoresces once free of the amino acids or whose emission wavelength 
changes once released.  The specificity for a particular peptidase is mostly 
provided by the amino acid sequence, through its interaction with the enzyme 
active site, although the chemical properties of the fluorophore can also be 
important, particularly due to steric hindrances preventing binding in the ligand 
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3.1.1.2  Fluorescent molecules for study of mammalian peptidases 
Coumarin-containing compounds are some of the most widely used fluorophores 
and have been often used to determine mammalian peptidase activities, though 
more regularly for study of peptidases in vitro rather than in live cell assays.  As an 
example of a live cell assay, a 7-amino-4-chloromethylcoumarin (ACMC) linked 
calpain substrate was used for the determination of calpain activity in Rat-1 
fibroblasts and HL60 myelomonocytes.  This substrate fluoresces at a different 
wavelength when cleaved, allowing simultaneous measurement of the substrate 
and product and the use of flow cytometry to measure the rate of degradation of 
the substrate (Niapour and Berger, 2007).  The specificity of the substrate was 
confirmed as inhibition of activity was only achieved using calpain inhibitors.  The 
use of flow cytometry was advantageous as the calpain activity could be measured 
in several cell types simultaneously by co-staining with cell-specific markers.  
A related compound, 7-amino-4-carbamoylmethylcoumarin (ACC), has been 
linked to a variety of peptides to evaluate the substrate specificities of a number of 
recombinant peptidases.  A fluorogenic library was prepared with ACC linked to 
both a peptide and a solid resin support.  The optimal P1 amino acid for a series of 
cysteine peptidases and serine peptidases was determined, followed by the 
optimal P2, P3 and P4 amino acids (Harris et al., 2000).  7-amino-4-methylcoumarin 
(AMC)-linked peptides have been used as substrates for recombinant cathepsins 
K, L, B, S, F, V, H, C and Z to assay the IC50 of two cathepsin inhibitors 
(Falgueyret et al., 2004). 
A method has also been developed using two fluorophores in conjunction, 7-
amino-4-fluorocoumarin (AFC) and rhodamine 110, to selectively detect peptidase 
activity in intact, viable cells or non-viable cells with a loss of membrane integrity, 
respectively, for use as a measure of cytotoxicity following treatment of cells (Niles 
et al., 2007).  Using cultured mammalian cells, the substrate preferences of live 
and lysed cell peptidases were determined with a variety of peptides linked to the 
fluorophores.  Peptidase inhibitors were used to further evaluate the peptidase 
activity in both live and lysed cell fractions.  The ability to differentiate live cells 
from lysed cells was found to correlate with other measures of cytotoxicity.   
In contrast to coumarin-based substrates, rhodamine-based substrates have the 
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following cleavage (Van Noorden et al., 1997).  Rhodamine substrates are also  
bi-substituted, meaning two peptides must be cleaved for full fluorescence of the 
molecule to be exhibited; the mono-substituted form is only intermediately 
fluorescent (Boonacker and Van Noorden, 2001). 
Measurement of the activity of two enzyme groups has been completed using 
laser scanning cytometry, which allows for repeated measurement of single cells 
as identified by their co-ordinates on a microscope slide (Bedner et al., 1998).   
Di-(leucyl)-rhodamine 110 was used for the determination of the activity of  
L-aminopeptidases in HL-60 cells and human peripheral blood cells, whilst 
fluorescein diacetate was used to determine the activity of esterase in HL-60 cells.  
Individual cells were found to have wide variation in L-aminopeptidase and 
esterase activities, with subpopulations of cells in peripheral blood distinguishable 
by their varying enzymatic activities.  The determination of esterase activity was 
hampered by the fluorescence of the released fluorescein fading upon repeated 
measurement of individual cells, meaning fluorescein diacetate was less suitable 
for this method. 
Cresyl violet has been used since the 19
th Century as a histology stain and 
recently was developed to act as a fluorescent leaving group for analysis of 
peptidase activity (Boonacker and Van Noorden, 2001).  Cresyl violet rapidly 
diffuses from its site of release in lysed cells, so it is dependent on intact cells to 
be useful (Van Noorden et al., 1997).  As both conjugated cresyl violet and the 
free molecule are fluorescent, but at differing wavelengths, the substrate and 
product can be simultaneously measured (Boonacker et al., 2003).  Cresyl violet 
has been used to investigate the activity of dipeptidyl peptidase IV (DPPIV) in rat 
hepatocytes.  In this case, the substrate was [Ala-Pro]
2-cresyl violet and DPPIV 
was localised using confocal microscopy with its activity measured using flow 
cytometry (Van Noorden et al., 1997).  This cresyl violet-containing substrate has 
also been compared with another fluorescence releasing substrate, Ala-Pro-
Rhodamine 110, for measurement of the activity of DPPIV (Boonacker et al., 
2003).  Using Jurkat cells, which have DPPIV-like peptidases but not DPPIV itself, 
and CD26/DPPIV-transfected Jurkat cells, the specificity of the two fluorophores 
were compared.  Ala-Pro-rhodamine 110 was found to be cleaved by peptidases 
other than DPPIV, whereas [Ala-Pro]
2-cresyl violet was specific to DPPIV.  This 
illustrates that the choice of fluorescent leaving group can be crucial for 
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Cresyl violet has also been used for the measurement of cysteine cathepsin 
activity in mouse splenic B and T cells and J774 macrophage cells (Creasy et al., 
2007), with flow cytometry used to detect the activity.  The cresyl violet was bi-
substituted with a peptide sequence selected for the cathepsin under study.  Such 
peptides were used to measure the activity of cathepsins B, L and S, with 
cathepsin specific inhibitors used to confirm the cleavage selectivity.  Cathepsin 
activity could be measured in individual cells via the use of flow cytometry. 
3.1.1.3  Fluorescent molecules for study of Leishmania peptidases 
Several studies have been undertaken looking at the substrate specificity and 
activity of Leishmania peptidases.  For these, fluorescent molecules have been 
used with both recombinant proteins and cell lysates. 
The fluorophore Abz (ortho-aminobenzoic acid) has been extensively used for 
analysis of the activity of recombinant cysteine peptidase B (CPB) isomers.  In the 
first study, a series of fluorogenic substrates related to Abz-KLRFSKQ-EDDnp, 
(where EDDnp is N-[2,4-dinitrophenyl]-ethylenediamine, acting to quench the 
fluorescence of Abz), were used as a combinatorial fluorescence quenched library 
to assay the activity of a recombinant isoform of CPB, CPB2.8DCTE, (Alves et al., 
2001a).  The lead substrate, Abz-KLRFSKQ-EDDnp, was cleaved at the R-F 
bond, so alteration of the P1 amino acid was investigated.  Peptides with charged 
side chains were hydrolysed and the basic amino acids had the highest catalytic 
efficiency.  The P3, P2, and P’1-P’3 specificity were also then determined. 
In the second study, a series of tetrapeptides were linked to both Abz and K* ([2,4-
dinitrophenyl]-e-NH2 lysine, which quenches the fluorescence of the Abz).  An 
arginine residue was held constant in the antepenultimate position of the peptide, 
but the other amino acids were varied.  The substrate preference of CPB2.8DCTE 
was compared to that of cathepsin L (Judice et al., 2004).  Both enzymes were 
found to have carboxydipeptidase activity, cleaving the substrates after the 
arginine residue, with CPB2.8DCTE very similar in its specificity to cathepsin L.  
The peptide FRAK* was the best substrate, in both its free C-terminal carboxyl 
group form (Abz-FRAK*-OH) and its amidate form (Abz-FRAK*-NH2), with higher 
substrate affinity found using the amidate form.  Chapter 3      71 
In the third study, the activity of recombinant cysteine peptidase B isoforms, 
CPB2.8DCTE and rCPB3, were compared.  CPB3 differs from CPB2.8 in only 3 
amino acids and from another isoform, CPB18, in only two, but these changes 
lead to different substrate preferences (Mottram et al., 1997; Juliano et al., 2004).  
The amino acids in CPB3 were altered to match those in both CPB2.8 and CPB18 
and the substrate specificity of the mutant recombinant proteins was compared to 
that of the wild-type enzymes, using fluorescent substrates based on Abz-
KLRFSKQ-EDDnp (Juliano et al., 2004).  The limited amino acid changes led to 
modifications in the activity of substrate hydrolysis and the S1 binding site was 
influenced by the changes between CPB2.8 and CPB3 particularly.  In this third 
study, a 7-amino-4-methylcoumarin (AMC) peptide, Suc-LY-AMC, was also used 
to determine the activity of the mutated recombinant CPB3 proteins in SDS-PAGE 
gels (Juliano et al., 2004).  This activity is missing from CPB3, but has previously 
been shown to be present in both CPB2.8 and CPB18, using the substrates Suc-
FVR-AMC and Suc-LY-AMC (Mottram et al., 1997).   
4-methylcoumarin-7-amide (MCA)-based peptides have been used to investigate 
the S2 subsite specificity of recombinant CPB2.8DCTE of L. mexicana.  A variety 
of substrates based on Bz-FR-MCA were compared (Alves et al., 2001b).  A 
benzoyl (Bz) blocking group was found to give a better substrate with a 10-fold 
higher rate of degradation than the commercially available benzoyloxycarbonyl (Z) 
group-based substrate.  The fluorophores were used to determine that 
CPB2.8DCTE has a particularly restrictive subsite, more so than cathepsin L. 
AMC based substrates have been used to investigate the activity of other 
peptidases.  Firstly, the activity of the L. major cathepsin B-like (LmajcatB-like) 
cysteine peptidase has been investigated with Z-RR-AMC, a cathepsin B 
substrate, and Z-FR-AMC, a cathepsin B and cathepsin L substrate.  LmajcatB-
like does not hydrolyse Z-RR-AMC readily, but does hydrolyse Z-FR-AMC, which 
was postulated to be due to the alteration of a Glu residue in mammalian 
cathepsin B to a Gly in L. major (Chan et al., 1999).  This was confirmed by 
generating a mutated protein with the Glu residue of mammalian enzymes which 
easily hydrolysed Z-RR-AMC, whilst continuing to hydrolyse Z-FR-AMC. 
AMC-containing substrates have also been used to investigate the substrate 
specificity of recombinant leucyl aminopeptidases (Lap) of L. amazonensis,  
L. donovani and L. major, using a spectrofluorometer (Morty and Morehead, Chapter 3      72 
2002).  L-Leu-AMC was determined to be the best substrate for all three 
Leishmania Lap enzymes.  Both metal ion chelators and anti-Lap IgG were found 
to inhibit the activity of the Lap peptidases against L-Leu-AMC. 
Two AMC-linked peptides, Suc-LLVY-AMC and Boc-LRR-AMC, have also been 
used to test the activity of the purified L. chagasi proteasome (Silva-Jardim et al., 
2004).  The proteasome exhibited higher trypsin-like activity (hydrolysis of Boc-
LRR-AMC), than chymotrypsin activity (hydrolysis of Suc-LLVY-AMC), with the 
proteasome inhibitor lactacystin successfully inhibiting both activities. 
Finally, AMC-linked peptides have been used to investigate the L. major 
metacaspase gene expressed in S. cerevisiae cells lacking the yeast 
metacaspase gene.  The activity was measured using cell lysates of cells 
expressing either the full length metacaspase gene or expressing only the catalytic 
domain or with purified recombinant protein (Gonzalez et al., 2007).  Caspase 
substrates were initially tested, but no significant cleavage of these substrates was 
detectable, so a number of potential metacaspase substrates were studied, Boc-
GRR-AMC, Z-RR-AMC, Z-R-AMC, Z-GGR-AMC and Boc-VLK-AMC.  The Z-GGR-
AMC substrate was especially highly hydrolysed by the lysate of the catalytic 
domain-expressing cells, and the activity could be removed by mutating the 
catalytic dyad amino acids in both the full length and the catalytic-domain proteins.   
Bz-RGFFL-4-methyl-b-naphthylamine has been used to investigate aspartyl 
peptidase activity in L. mexicana, where 4-methyl-b-naphthylamine is the 
fluorescent moiety.  The soluble and particulate fractions of lysed promastigotes 
were assayed for activity (Valdivieso et al., 2007).  Peptidase inhibitors were 
successfully used to determine that the hydrolysis was due to an aspartic 
peptidase present in the soluble fraction.   
3.1.2 AMC-peptides for the investigation of peptidases in live 
Leishmania 
On the basis of the preceding studies, it was decided to attempt to analyse 
peptidase activity using fluorescent peptides, since, although they have not been 
used for investigation of peptidase activity in live Leishmania, their use has been 
established in a variety of mammalian cells.  Recombinant Leishmania peptidases 
and Leishmania lysates have been successfully analysed with fluorescent Chapter 3      73 
peptides.  It was hoped it would be possible to identify a single peptidase activity in 
Leishmania promastigotes if a small peptide molecule, linked to a fluorophore, 
were used due to their being fewer possible cleavage sites in a peptide compared 
to a protein. 
Since AMC-containing peptidases have been used for both mammalian live cell 
assays and Leishmania peptidase analysis, peptides using this fluorophore were 
chosen for the analysis.   
3.2 Results 
3.2.1 Cleavage of AMC-linked peptide 
3.2.1.1  Determination of a suitable AMC-linked peptide for use 
The ability of live Leishmania to degrade fluorescent peptides was investigated.   
L. mexicana were able to cleave Bz-R-AMC, but unable to cleave Suc-AAPV-AMC 
or Suc-AAPF-AMC (Figure 3.1).  The rate was dependent on the number of 
promastigotes present.  The plateau in the cleavage rate of Bz-R-AMC after 
approximately 40 minutes was due to the fluorescence reaching the saturation 
point of the plate reader.  The starting fluorescence levels for the three AMC-linked 
peptides are different as the three have slightly different inherent levels of baseline 
fluorescence prior to cleavage. 
3.2.1.2  Cleavage of Bz-R-AMC by wild-type and mutant parasites 
The cleavage of Bz-R-AMC by several Leishmania lines was examined.  Both  
L. mexicana and L. major wild-type (WT) promastigotes were used, as well as  
L. mexicana mutants lacking cysteine peptidases (CPs, Dcpb, Dcpa/Dcpb and 
Dcpc cells) and L. major over-expressing VPS4
E235Q, which causes a defect in 
transport to the lysosome (Besteiro et al., 2006).  Both log phase cells and 
stationary phase cells were evaluated to determine if the developmental stage of 
the parasites determined the mean rate of cleavage.  Deletion of the CPs was 
found to have no effect on the hydrolysis of Bz-R-AMC and it was also found that 
lysosomal trafficking defects were only potentially important in stationary phase 
promastigotes, with a p value of 0.01 for the comparison between L. major WT and 
VPS4
E235Q mutant (Figure 3.2). Chapter 3      74 
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Figure   3.1 Comparison of cleavage of AMC from three peptide-AMC molecules by  
L. mexicana promastigotes.  1 x 10
6 cells were used with 5 µM peptide-AMC.  
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Figure   3.2 Effect of deletion of CP genes or over-expression of a mutated VPS4 on the 
cleavage rate of 5 µM Bz-R-AMC by Leishmania promastigotes.  Values are the mean of 
between 11 and 50 experiments ± SEM.  Each experiment was run using 6 x 10
5 cells.   
* = p = 0.01 compared to L. major WT stationary phase promastigotes, by an unpaired t-test. 
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3.2.2 Inhibition of degradation using peptidase inhibitors 
No difference in the cleavage rate of Bz-R-AMC between WT and mutant 
Leishmania was seen.  Peptidase inhibitors were used in an attempt to determine 
the enzyme responsible for Bz-R-AMC hydrolysis.  The following peptidase 
inhibitors were tested: E-64d, K11777, 1,10 phenanthroline, EDTA, pepstatin A, 
PMSF, AEBSF, antipain and leupeptin.  The structures of the inhibitors are shown 
in Table 3.1 and the concentrations used are given in Section 2.4.2. 
Only antipain, leupeptin and AEBSF were effective inhibitors of Bz-R-AMC 
degradation (Figure 3.3).  This was true for both L. major (as shown) and  
L. mexicana. 
The IC50 values for inhibition of Bz-R-AMC hydrolysis were determined for the 
three effective inhibitors.  Antipain and leupeptin were used to inhibit hydrolysis in 
log and stationary phase promastigotes of L. major and L. mexicana WT,  
L. mexicana CP mutants and L. major VPS4
E235Q mutant cells.  AEBSF was only 
used to inhibit L. major stationary phase promastigotes. 
The IC50 value for antipain was lower for the L. mexicana lines than the L. major 
lines, for both log and stationary phase cells.  The mutations in the lines had little 
effect on the IC50 values (Figure 3.4).  In contrast, the IC50 value for leupeptin was 
lower for the L. major lines than the L. mexicana lines, for both log and stationary 
phase cells.  As with antipain, any mutation had little effect on the IC50 values 
(Figure 3.4).   
AEBSF had a higher IC50 than antipain and leupeptin, being 14.4 µM (± a SEM of 
0.6), rather than in the nM range as with the former inhibitors. 
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Table   3.1 Structures of inhibitors used to inhibit degradation of Bz-R-AMC. 
Inhibitor  Structure 
E-64d 
 
K11777 
 
1,10 Phenanthroline 
 
EDTA 
 
Pepstatin A 
 
PMSF 
 
AEBSF 
 
Antipain 
 
Leupeptin 
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Figure   3.3 Effect of peptidase inhibitors on the cleavage of 5 µM Bz-R-AMC.  Peptidase 
inhibitors were used at the concentrations stated in Section 2.4.2.  6 x 10
5 L. major WT stationary 
phase promastigotes were used for each experiment.  A representative graph of at least 3 
experiments is shown. 
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Figure   3.4 Mean IC50 values for inhibition of cleavage of 5 µM Bz-R-AMC by antipain and 
leupeptin.  A = inhibition by antipain, B = inhibition by leupeptin.  30 minute assays were 
performed per experiment.  A mean of 5-10 experiments ± SEM is shown.  For each experiment  
6 x 10
5 Leishmania promastigotes were used. 
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3.2.3 Analysis of Bz-R-AMC uptake 
Having determined the inhibitory profile of Bz-R-AMC cleavage, the mechanism of 
uptake of the peptide was studied.  The presence of a transporter was investigated 
by competition assays.  A role for endocytosis was studied via actin inhibition. 
3.2.3.1  Arginine transporter 
A high affinity arginine transporter has been identified in Leishmania (Shaked-
Mishan et al., 2006).  Since Bz-R-AMC could potentially be taken up through this 
transporter, an attempt was made to block the uptake of Bz-R-AMC using 
increasing concentrations of both arginine and pentamidine.  The pentamidine was 
included to preclude the possibility that the arginine was interfering directly with 
the enzymatic degradation by binding the enzyme active site.  Pentamidine was 
thought to be a substrate of the transporter, but to be unlikely to inhibit the 
enzyme, following preliminary work in the Mottram laboratory. 
Arginine only had an effect at very high concentrations, having an IC50 value of 
29.7 mM (± a SEM of 4.0).   
Pentamidine had a much lower IC50 value for blocking the degradation of Bz-R-
AMC by live cells, only 47.1 µM (± 16.3).  To determine if pentamidine was acting 
on the peptidase itself, sonicated L. major cells were used to cleave Bz-R-AMC, 
with the lysis removing any role for a transporter in the analysis. 
As similar IC50 values, given the standard errors, were found for both live cells 
(47.1  ± 16.3 µM) and sonicated cells (70.7 ± 5.5 µM), it suggests that the 
pentamidine had an effect on the enzyme itself in both cases and was not affecting 
the uptake in live cells.  The higher IC50 in the sonicated cells may be due to other 
enzymes present in the sonicate which are precluded from hydrolysing Bz-R-AMC 
normally due to its subcellular location.   
3.2.3.2  Endocytosis 
To determine whether endocytosis had a role in the uptake of Bz-R-AMC, the 
inhibitor cytochalasin D was used.  This inhibits endocytosis by blocking actin 
polymerisation via the disruption of actin microfilaments.  High concentrations of Chapter 3      80 
cytochalasin D had no significant effect on the cleavage of Bz-R-AMC, with no 
dose response (Figure 3.5).  This suggests that endocytosis is not the primary 
method by which AMC enters the cell. 
To ensure that the concentration of cytochalasin D used was blocking endocytosis, 
microscopic analysis was carried out.  L. major stationary phase cells were 
incubated with either cytochalasin D or DMSO as a control, then FM4-64 was 
added to both, which is known to be taken up via endocytosis (Besteiro et al., 
2006).  It was seen that in the presence of cytochalasin D no endocytosis of  
FM4-64 occurred (Figure 3.6). 
3.2.4 Identification of candidate enzymes 
The profile of inhibition found suggested that the enzyme(s) potentially responsible 
for the cleavage of Bz-R-AMC was a serine peptidase.  Therefore, an analysis was 
carried out on the serine peptidases identified by the L. major genome project 
(Ivens et al., 2005).  The known inhibitors and the preferred P1 position amino 
acids of all the peptidases were compared using the MEROPS Database 
(http://merops.sanger.ac.uk; Rawlings et al. 2006) and also compared with the 
profile of Bz-R-AMC hydrolysis.   
The results of this analysis (Table 3.2) suggest that oligopeptidase B (OPB, 
LmjF09.0770) and the other two related oligopeptidase family members 
(LmjF06.0340 and LmjF35.4020) are likely to be the only enzymes to cleave Bz-R-
AMC.  The only other possibility is the 26S protease regulatory subunit 
(LmjF03.0540), since, though these enzymes tend to show preference for larger, 
polyubiquitinated substrates, they do cleave with a trypsin-like specificity.  To test 
whether the 26S protease was involved, an attempt was made to block cleavage 
of Bz-R-AMC with the proteasome inhibitors MG132 and lactacystin (Silva-Jardim 
et al., 2004). 
There was no dose response effect of the proteasome specific inhibitors, MG132 
and lactacystin, on the hydrolysis of Bz-R-AMC, suggesting that the 26S protease 
is not responsible for the cleavage (Figure 3.7). 
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Figure   3.5 Effect of cytochalasin D on cleavage of 5 µM Bz-R-AMC.  3 experiments were 
completed for both stationary and log phase L. major promastigotes, with the mean ± SEM shown.  
The activity was calculated relative to the uninhibited cells in each particular experiment.  6 x 10
5 
cells were used per experiment.   
 
 
 
Figure   3.6 Uptake of FM4-64 by L. major WT promastigotes.  A & B treated with 100 µg/ml 
cytochalasin D; C & D untreated.  A & C = merge of phase and FM4-64, B & D = FM4-64 alone.  
Scale = 5 µm. 
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26S protease preferentially cleaves longer peptide chains 
covalently conjugated to polyubiquitin chains, but can 
cleave with trypsin-like specificity (depends on species)
Unlikely S16 SJ 26S protease regulatory subunit, putative LmjF03.0540
Cleaves after phenylalanine, not arginine X S59 SP Nucleosporin, putative LmjF27.0380
Stimulated by metal ion chelators X S26B SF Mitochondrial inner membrane signal peptidase, putative LmjF36.0200
Prefers small residues at P1 X S26A SF Signal peptidase type I, putative LmjF08.0450
Inhibited by PMSF and post proline-cleaving X S15 SC X-pro, dipeptidyl-peptidase, serine peptidase, putative LmjF28.1950
Preference for cleaving after hydrophobic groups X S10 SC Serine carboxypeptidase (CBP1), putative LmjF18.0450
X S9D SC ATP-dependent Clp protease subunit, heat shock protein LmjF33.0400
X Putative ATP-dependent Clp protease subunit, heat shock protein LmjF30.1700
X Putative ATP-dependent Clp protease subunit, HSP100 LmjF29.1270
X Putative ATP-dependent Clp protease subunit, HSP78 LmjF27.2630
Clp inhibited by EDTA
X Putative ATP-dependent Clp protease subunit, HSP78 LmjF02.0710
Closely related to LmjF09.0770  Possible S9X SC Bem46-like serine peptidase LmjF35.4020
Closely related to LmjF09.0770 Possible S9A-like SC Oligopeptidase B-like protein LmjF06.0340
Post arginine cleavage, homologues in T. brucei inhibited 
by antipain and leupeptin Possible S9A-like SC Oligopeptidase B LmjF09.0770
Cleaves after proline, not arginine X S9A SC Prolyl oligopeptidase, putative LmjF36.6750
Related peptidases prefer cleaving after proline, or less 
well alanine or hydroxyproline
X S9B SC Dipeptidyl-peptidase 8-like serine peptidase, putative LmjF36.2420
Homologues have preference for cleaving after proline X S9D SC Serine peptidase, putative LmjF12.1330
X S8-like SB Subtilisin-like serine peptidase LmjF28.2380
Inhibited by PMSF
X S8-like SB Subtilisin-like serine peptidase LmjF13.1040
X S54 S- Rhomboid-like LmjF04.0850
Prefer membrane bound, larger substrates.
X S54 S- Rhomboid-like LmjF02.0430
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likely?
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Figure   3.7 Effect of MG132 and lactacystin on the cleavage of 5 µM Bz-R-AMC by L. major 
WT stationary promastigotes.  Relative activities compared to no inhibitor are shown.   
A = MG132, B = lactacystin.  Mean of four experiments ± SEM.  The activity was calculated relative 
to the uninhibited cells in each particular experiment.  6 x 10
5 cells were used per experiment. 
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3.3 Discussion 
Leishmania peptidases have been identified as being important virulence factors 
and as such peptidase activity was investigated in live cells. 
Bz-R-AMC was the only peptide tested that was successfully hydrolysed by 
Leishmania promastigotes (Figure 3.1).  The rate of hydrolysis of Bz-R-AMC by 
both L. mexicana and L. major wild-type promastigotes were determined and 
compared to mutant lines previously described (Mottram et al., 1996b; Bart et al., 
1997; Besteiro et al., 2006), to investigate whether any of the three main clan CA 
cysteine peptidases present in Leishmania were responsible for the cleavage of 
Bz-R-AMC or if mis-trafficking to the lysosome would interfere with the hydrolysis.  
There was a significant difference between the two species, with L. mexicana 
having higher activity compared to L. major in both log and stationary phase 
promastigotes (with p values of 0.03 and 0.00001 respectively, by unpaired t-test), 
but there was no difference between the log and stationary phase cells for all lines 
(Figure 3.2).  This difference between the two species is interesting; there are 
several possible reasons.  There could be a difference in either the uptake or 
degradation of the substrate, as both are being measured at once.  Potentially, 
there could be a difference in the membrane properties between the species that 
affects uptake.  If the difference is due to the degradative properties of the species 
it could be that the peptidase(s) responsible may be more highly expressed in  
L. mexicana, or different proportions of peptidases capable of cleaving Bz-R-AMC 
(as identified in Table 3.2), could be expressed in the two species. 
Deletion of cysteine peptidases did not result in an alteration of the hydrolysis and, 
as such, these peptidases cannot be responsible for the cleavage.  On the other 
hand, the VPS4
E235Q mutant stationary phase cells had a significantly higher rate 
of cleavage than the L. major WT stationary phase cells, with a p value of 0.01 
(Figure 3.2).  However, VPS4
E235Q mutant promastigotes do not differentiate to 
metacyclic promastigotes in culture (Besteiro et al., 2006) and so a stationary 
phase culture of this line is not comparable to a metacyclic-containing, stationary 
phase culture of the WT line.  It is likely that the difference found in the stationary 
cultures is due to the differences in the cells that compose the culture, especially 
given that the VPS4
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of culture, with a p value of 0.82.  This finding suggests that the peptidase cleaving 
Bz-R-AMC is not present in the lysosomal system.   
Since the major cysteine peptidases were not hydrolysing Bz-R-AMC, a series of 
general peptidase inhibitors were used to investigate the type of peptidase that 
was involved.  The activity was determined to be due to a peptidase susceptible to 
antipain, leupeptin and AEBSF (Figure 3.3).  Antipain and leupeptin affect both 
cysteine peptidases and serine peptidases which have a trypsin-like specificity for 
basic residues in the P1 site.  Specific cysteine peptidase inhibitors were 
ineffective, whereas, the serine peptidase inhibitor AEBSF did inhibit this activity, 
although with a high IC50.  These data indicate that the peptidase involved is a 
serine peptidase with trypsin-like specificity.   
The IC50 values for antipain and leupeptin were determined for L. mexicana and  
L. major WT, CP mutants and the VPS4
E235Q mutant, and neither the mutations 
nor the cell growth phase had an effect on the IC50 values (Figure 3.4).  The IC50 
values were different between the two species however, with antipain having a 
lower IC50 for L. mexicana and leupeptin a lower IC50 with L. major.  Leupeptin has 
a modified tripeptide structure, whereas antipain contains a tripeptide linked to a 
large [carboxy-phenylethyl]-carbamoyl structure (Table 3.1).  This suggests that 
the difference may be due to the size of the inhibitor, and perhaps, as with the 
difference in rate of cleavage between the two species, it is due to a difference in 
ease of uptake of the inhibitor through the membrane in each species.  
Alternatively, more than one peptidase could be involved, each of which is affected 
by leupeptin and antipain to different degrees and which could be expressed at 
different levels in the two species.  
The IC50 value for AEBSF inhibition of the cleavage in L. major stationary 
promastigotes was found to be higher than that of antipain or leupeptin, being in 
the low µM range rather than nM.  AEBSF is a very similar inhibitor to PMSF 
(Barrett and Rawlings, 1995), an inhibitor that had no effect on the cleavage 
(Figure 3.3).  It is likely that the differences in their activity are due to the small 
differences in their structures, viz. PMSF having an extra methyl group between 
the benzyl ring and the sulfonylfluoride compared to AEBSF and AEBSF having an 
additional aminoethyl group attached to the benzyl ring, which PMSF lacks (Table 
3.1).  These differences are likely to determine that AEBSF, but not PMSF, can 
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The method by which Bz-R-AMC entered Leishmania was also investigated.  An 
arginine transporter, LdAAP3, which mediated high affinity transport of arginine 
across membrane was described in L. donovani in 2006 (Shaked-Mishan et al., 
2006).  This transport was inhibited by the anti-Leishmania drug pentamidine, 
which is a diamidine.  It was hypothesised that it could be the means by which Bz-
R-AMC was entering the cell.  However, arginine was not found to be a very good 
inhibitor of hydrolysis, only affecting cleavage with an IC50 of 29.7 mM.  LdAAP3 
was inhibited over 80% by arginine at a concentration of 100 µM (Shaked-Mishan 
et al., 2006), suggesting that it is very unlikely that the transporter is responsible 
for uptake of Bz-R-AMC.  The IC50 value is therefore likely to be of arginine 
inhibiting the peptidase itself.  As it is such a high value, this suggests that the 
active site pocket of the peptidase is not simply binding the arginine residue after 
which it cleaves; interactions between the S2 or S3 sites, or more, and the ligand 
are also important. 
Pentamidine was also used to inhibit the cleavage of Bz-R-AMC.  The IC50 value 
for pentamidine was far lower than that of arginine, suggesting it was also affecting 
the peptidase itself.  Pentamidine was used to inhibit cells lysed by sonication and 
was found to inhibit the cleavage of Bz-R-AMC.  Pentamidine was therefore 
inhibiting the peptidase rather than inhibiting uptake of the substrate, further 
corroborating that the arginine transporter is not the mode of uptake for Bz-R-AMC.  
Pentamidine is also a larger molecule than arginine and the lowered IC50 value of 
pentamidine compared to arginine suggests that it fits into the active site pocket 
and interacts more suitably, assuming that it is inhibiting the activity competitively.
In addition, the potential for endocytosis to be the route of uptake of Bz-R-AMC 
was investigated, using cytochalasin D.  This inhibitor is commonly used to 
prevent endocytosis but was found to be ineffective at interfering with hydrolysis of 
Bz-R-AMC, implying that the lack of endocytosis was not preventing uptake of the 
substrate (Figure 3.5).  Cytochalasin D inhibition of endocytosis was confirmed 
using the lipophilic dye FM4-64, which previously has been shown to be taken up 
through the flagellar pocket and trafficked through the endosomal system to the 
lysosome (Besteiro et al., 2006).  It was confirmed that FM4-64 entered the cell 
when uninhibited, but the uptake was prevented when cytochalasin D was applied 
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Bz-R-AMC has been found not to enter through the arginine transporter nor via 
endocytosis, although it is inevitable that some would be taken up by endocytosis 
when present in the extracellular milieu.  It seems likely that the Bz-R-AMC is 
entering Leishmania by simple diffusion through the cell membrane.  It is a small 
molecule, which is likely to cross membranes, especially as its stock is dissolved 
in dimethylformamide, which aids entry of even lipophilic substrates into cells 
(Boonacker and Van Noorden, 2001).  However the involvement of a different 
transporter has not been formally ruled out. 
The mode of entry suggests that the peptidase responsible for the cleavage is 
unlikely to be located within the endosomal system or lysosome, which would 
correlate with the unimpaired degradation found with the VPS4 mutant line, which 
has a defect in transport to the lysosome and thus alterations in the peptidases 
found in that compartment.  The peptidase involved is likely to be cytosolic. 
An analysis of the serine peptidases of L. major (Ivens et al., 2005), together with 
the profile of inhibition and the fact that the enzyme cleaves post arginine, led to 
the conclusion that OPB and its related family members were the peptidases most 
likely to be responsible for the activity observed (Table 3.2).  The possibility that 
the 26S protease could be involved was excluded by the use of the specific 
inhibitors MG132 and lactacystin (Figure 3.7). 
3.3.1 Conclusions 
Leishmania promastigotes provide an excellent system for the characterisation of 
peptidases in living cells.  Bz-R-AMC was found to be a good substrate for 
hydrolysis by Leishmania.  It is suggested that the substrate may be entering the 
cell by diffusion, as it is not entering through the endosomal system nor the 
arginine transporter. 
The inhibitory profile of this activity was determined using standard peptidase and 
proteasome inhibitors.  The inhibition by antipain, leupeptin and AEBSF is 
indicative of a trypsin-like serine peptidase.  Genomic data identified OPB and two 
other related peptidases as the most likely candidate peptidases and so OPB will 
be investigated to determine whether the correct identification has been made.       88 
 
 
 
 
 
 
 
Chapter 4   
OLIGOPEPTIDASE B OF L. MAJOR  Chapter 4      89 
4.1 Introduction 
Oligopeptidase B (OPB) is a member of the S9 family of serine peptidases, the 
prolyl oligopeptidase (POP) family, which is part of clan SC.  Oligopeptidase B is 
restricted taxonomically, being found only in bacteria, plants and trypanosomatids.  
All OPBs cleave post-basic residues, preferring arginine, in a trypsin-like activity 
(Rea and Fulop, 2006). 
4.1.1 Peptidases of the POP family 
The POP family contains prolyl oligopeptidase, dipeptidyl peptidase IV, 
acylaminoacyl peptidase and oligopeptidase B (Polgar, 2002).  The POP family 
have a conserved Ser/Asp/His catalytic triad, found in their carboxy terminal 
regions, and are restricted to hydrolysing peptides up to around 30 amino acids in 
length.   
4.1.1.1  Structure of POP and OPB 
POP has been demonstrated to be monomeric (Fulop et al., 1998).  The restriction 
in the length of substrates cleaved is due to the conserved peptidase structure: the 
carboxy terminal region of the peptidase is a catalytic domain and the amino 
terminal region is a seven-bladed b-propeller that restricts access to the active site 
through the central tunnel (Fulop et al., 1998; Polgar, 2002).  The active site of 
POP is in a cavity in the interface between the two domains, covered by the 
central tunnel of the b-propeller (Fulop et al., 1998).  The b-propeller is not 
covalently closed and may oscillate between open and closed forms for substrate 
binding and catalysis (Fulop et al., 2000).   
There is only 22% amino acid identity between human POP and E. coli OPB 
(Venalainen et al., 2004), but there is seemingly high structural similarity.  A model 
of E. coli OPB was constructed based on porcine POP.  The two were very similar, 
though the binding site of E. coli OPB was more negatively charged than that of 
POP.  Two OPB substrates were docked into the active site and it was found that 
the best substrate, Z-Arg-Arg, was a better fit into a hydrophilic region (Gerczei et 
al., 2000).  L. amazonensis OPB has also been modelled based on porcine POP 
and has a very similar structure, though again with a more negative surface and 
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L. major OPB has been crystallised by Prof. Neil Isaacs’ group at the University of 
Glasgow and its structure solved.  It was found to be very similar in structure to 
porcine POP, with 86% similarity in the secondary structures.  Analysis and 
comparison of the OPB and POP structures is ongoing.  The structures are shown 
in Figure 4.1. 
4.1.2 Bacterial Oligopeptidase B 
Oligopeptidase B was identified in Escherichia coli as a cytosolic enzyme, 
originally designated as Protease II (Pacaud and Richaud, 1975).  Purified E. coli 
OPB has optimal activity at pH 7.5 and was competitively inhibited by the serine 
peptidase inhibitors N-tosyl-L-lysyl-chloromethylketone (TLCK) and diisopropyl 
phosphorofluoridate (DFP), but not by phenylmethylsulfonyl fluoride (PMSF).  The 
trypsin inhibitors benzamidine and p-aminobenzamidine also inhibited OPB.   
L-arginine also competitively inhibited activity.   
Kanatani et al. sequenced E. coli OPB and calculated a predicted molecular 
weight for the corresponding protein of 81.9 kDa.  The expressed recombinant  
E. coli OPB was inhibited by DFP, TLCK and antipain.  E. coli OPB was found to 
have 25.3% homology to porcine brain prolyl oligopeptidase, which led to its 
inclusion in the prolyl oligopeptidase family (Kanatani et al., 1991).  It was also 
found to be inhibited by protamine, a basic peptide containing polyarginine 
sequences (Tsuji et al., 2006).  E. coli OPB was subsequently found to have a 
preference for di-arginine containing compounds over single arginine containing 
substrates and to cleave peptides up to 30 amino acids in length (Polgar, 1997). 
OPBs from Rhodococcus erythropolis, Moraxella lacunata, Treponema denticola 
and Salmonella enterica have also been characterised, and OPB genes are 
present in the genomes of other bacterial species (Venalainen et al., 2004).   
R. erythropolis OPB was purified and estimated to have a molecular weight of  
82 kDa by SDS-PAGE, a similar size to E. coli OPB (Shannon et al., 1982).  It was 
inhibited by DFP, TLCK, p-aminobenzamidine and antipain, similarly to E. coli 
OPB, and also by leupeptin, ovomucoid and gramicidin S.  PMSF was ineffective 
at inhibiting R. erythropolis OPB. 
OPB from M. lacunata was also originally designated as protease II (Yoshimoto et 
al., 1995).  The gene was expressed in E. coli and the nucleotide sequence found,  Chapter 4      91 
 
 
 
Figure   4.1 Structure of L. major OPB and porcine brain POP.  A and C = L. major OPB, B and 
D = porcine brain POP.  Cyan = β-propeller, magenta = catalytic domain.  A and B show the view 
down the pore of the β-propeller onto the catalytic domain, C and D show a side view.  The 
inhibitor antipain was co-crystallised with OPB and is shown in yellow, blue and red in C, bound 
into the active site.  The diagrams were constructed using PyMol (Delano Scientific) by Dr. 
Nicholas D. Bland (University of Glasgow), using data provided by Prof. N. Isaacs (University of 
Glasgow; A and C) and of structure 1h2w from RCSB Protein Data Bank (B and D). 
A  B 
C  D Chapter 4      92 
to give a predicted molecular weight for the encoded protein of 79.5 kDa and 38% 
identity to E. coli OPB.  Recombinant M. lacunata OPB was also inhibited by DFP, 
TLCK and p-chloromercuribenzoic acid (PCMB). 
T. denticola OPB was purified, partially sequenced and found to have a molecular 
weight of 78 kDa by SDS-PAGE.  Purified T. denticola OPB hydrolysed peptide 
substrates, but not proteins (Makinen et al., 1995).  The gene encoding  
T. denticola OPB was subsequently isolated and was found to have significant 
homology to E. coli OPB and other POP family members (Fenno et al., 2001).  An 
OPB mutant was generated, truncating OPB, resulting in an inability to hydrolyse 
the OPB substrate N-a-benzoyl-L-arginine-p-nitroanilide (BApNA), showing OPB 
was responsible for all the trypsin-like activity in T. denticola. 
S. enterica OPB has 75% identity to E. coli OPB.  Recombinant S. enterica OPB 
cleaved a number of 7-amino-4-methylcoumarin (AMC)-linked peptides, with the 
best substrate being Cbz-RR-AMC (Morty et al., 2002), as with E. coli OPB 
(Polgar, 1997).  S. enterica OPB was inhibited by the serine peptidase inhibitors 
PMSF (unlike E. coli OPB), 4-(2-aminoethyl) benzenesulfonyl fluoride (AEBSF or 
pefabloc), 2,3-dichloroisocoumarin, antipain and leupeptin.  Limited post-arginine 
hydrolysis of histone proteins was found, but only in regions of protein lacking 
secondary structure. 
S. enterica OPB was used to investigate the substrate recognition properties of 
OPB enzymes (Morty et al., 2002).  The amino acids of the catalytic domain of 
POP and OPB have been compared and nine residues varying between the two 
were mutated.  For P1 substrate specificity Glu
576 and Glu
578 were important, with 
mutation of either alone to alanine reducing hydrolysis of Cbz-R-AMC and 
mutation of both (to alanines, arginines or tryptophan and threonine respectively) 
abolished it completely.  For P2 substrate specificity, the mutations Asp
460Thr and 
Asp
462Asn reduced hydrolysis of Cbz-RR-AMC and Cbz-FR-AMC, though the 
effect was lower with Cbz-FR-AMC, suggesting involvement in the preference for 
cleavage after two basic amino acid residues.  Mutation of both residues had a 
larger effect on hydrolysis than either single mutation (Morty et al., 2002). Chapter 4      93 
4.1.3 Oligopeptidase B in plants 
Trypsin-like peptidases with the characteristics of OPB have been described in 
plants, in soy (Glycine max), ragweed (Ambrosia artemisiifolia) and wheat 
(Triticum aestivum), although only the last enzyme has been designated OPB.   
Soybean seed trypsin-like peptidase was found to be inhibited by DFP, PCMB, 
antipain and leupeptin, but not PMSF (Nishikata, 1984).  Cultured soybean cells 
had a trypsin-like peptidase with a molecular weight of 90 kDa (Guo et al., 1998).  
As with the soybean seed peptidase, it was inhibited by DFP, 3,4-
dichloroisocoumarin (DCI), AEBSF, antipain and leupeptin, but not PMSF.  
Sequenced peptides had homology to both E. coli OPB and human and pig POP. 
Ragweed trypsin-like peptidase was purified from pollen extract and found to have 
a molecular weight of 80 kDa by SDS-PAGE (Bagarozzi et al., 1998).  It was 
inhibited by DFP, TLCK, DCI and a number of synthetic serine inhibitors, but not 
by leupeptin.  It preferentially cleaved peptides post Arg-Arg or Gly-Arg residues 
and was found to cleave a number of biologically active peptides involved in 
maintaining bronchial function.  Ragweed OPB may thus be at least partially 
responsible for the known role of ragweed pollen in stimulating respiratory 
symptoms in hay fever and asthma sufferers. 
Wheat OPB was inhibited by DFP, TLCK, leupeptin, antipain and benzamidine 
(Tsuji et al., 2004).  OPB activity increased in germinating cells.  Wheat OPB 
peptides were sequenced and found to have high homology to E. coli OPB.  It was 
also inhibited by protamine, as with E. coli OPB (Tsuji et al., 2006). 
4.1.4 Oligopeptidase B in Trypanosoma cruzi 
T. cruzi OPB (TcOPB) was described in 1997 as a cytosolic serine endopeptidase, 
present in all life cycle stages, with significant homology to E. coli and M. lacunata 
OPBs (Burleigh et al., 1997).  Recombinant TcOPB had a molecular weight of  
81 kDa by SDS-PAGE, but a weight of ~120 kDa by non-reducing gel 
electrophoresis.  When purified, OPB activity was found in elutions from columns 
where proteins around 180 kDa were expected, suggesting OPB is dimeric.  
TcOPB was inhibited in a similar manner to E. coli OPB, being inhibited by PCMB, 
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by anti-recombinant TcOPB antibodies.  Longer peptides, with several binding 
sites in the active site filled, were cleaved most efficiently, with di-basic residues in 
P1 and P2 and hydrogen donors in the P1’ positions preferred (Hemerly et al., 
2003).  17-mer peptides could be hydrolysed, but not 21-mer peptides. 
TcOPB in trypomastigote soluble extract (TSE) had been previously postulated to 
induce Ca
2+ transients in host cells (Burleigh and Andrews, 1995).  This was 
confirmed when anti-OPB antibodies led to significant delay in the induction of the 
transients.  TcOPB does not signal directly for Ca
2+ release, but is responsible for 
generating a Ca
2+-signalling factor (Burleigh et al., 1997).  T. cruzi Dopb mutants 
were generated with a gene dosage effect found; heterozygote extracts had 50% 
OPB activity and Dopb none (Caler et al., 1998).  Heterozygotes were 
approximately 40% less infective to mammalian host cells than wild type 
trypomastigotes; Dopb trypomastigotes were 75% less infective.  Addition of 
recombinant OPB to Dopb TSE restored Ca
2+ signalling ability, whilst addition of 
an inactive recombinant active site mutant (Ser
565Thr) OPB did not.  Parasitaemia 
of infected mice was also reduced when heterozygote or Dopb trypomastigotes 
were used as the infectants. 
The presence of anti-OPB antibodies in infected animals and patients was 
investigated using purified TcOPB.  Approximately 72% of infected animals had 
antibodies cross-reactive with TcOPB, whilst mock infected animals did not.  
Similarly, 86% of chagasic patients, 90% of mucocutaneous leishmaniasis patients 
and 55% of visceral leishmaniasis patients had sera reactive to TcOPB, but control 
malarial patients did not (Fernandes et al., 2005).  Antibodies from chagasic 
patients did not inhibit the activity of purified TcOPB, with the OPB activity 
enhanced by human sera, by an unknown mechanism.  Non-chagasic patient sera 
also enhanced OPB activity. 
Trypomastigotes, but not epimastigotes, were found to release TcOPB, as OPB 
activity increased in the culture supernatant over a 1 hour period.  The control 
activity of cathepsin D or cruzipain did not increase over the same time period, 
indicating no cell lysis occurred (Fernandes et al., 2005).  This contrasts with the 
results of Caler et al. who only found TcOPB in the cytosol by EM immuno-
localisation, with none in the flagellar pocket, the route of exocytosis from 
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4.1.5 Oligopeptidase B in African trypanosomes 
Trypanosoma brucei brucei OPB (TbOPB) was initially characterised as an 80 kDa 
endopeptidase in 1992.  It cleaved post basic residues and was inhibited by DFP.  
Dithiothreitol (DTT) increased the stability of the peptidase, and the thiol blocking 
agents iodoacetamide and N-ethylmaleidide led to loss of activity, suggesting a 
thiol group is necessary for activity (Kornblatt et al., 1992).  TbOPB was confirmed 
as a member of the POP family by sequence comparison with T. cruzi and 
bacterial OPBs (Morty et al., 1999b).  TbOPB was also recognised by antibodies 
raised against TcOPB. 
Activation of TbOPB by a number of thiol reducing agents, particularly DTT, has 
been confirmed (Troeberg et al., 1996; Morty et al., 1999b).  By mutation of the 
cysteine residues in TbOPB to serine residues, C
256 was found to be necessary for 
inhibition by iodoacetamide and N-ethylmaleidide and C
559 and C
597, with possibly 
C
256, were necessary for thiol activation of TbOPB (Morty et al., 2005b). 
Further inhibitors of TbOPB were later determined: AEBSF, leupeptin and antipain 
(Troeberg et al., 1996), DCI and PMSF (Morty et al., 1999b).  E64 was also 
inhibitory, which is unusual for a serine peptidase and has not been reported for 
non-African trypanosome OPBs (Morty et al., 1999b).  Mammalian peptidase 
inhibitors, including serpins, did not inhibit TbOPB, probably due to their large size.  
Protein substrates were not cleaved but peptides were, up to a limit of 4 kDa, 
including a number of peptides known to be present in the host bloodstream 
(Troeberg et al., 1996).  Substrate binding was better with both P1 and P2 sites 
occupied (Morty et al., 1999b) and improved further with multiple substrate binding 
sites occupied (Hemerly et al., 2003).  As with TcOPB, 17-mer peptides could be 
hydrolysed, but not 21-mer peptides. 
The trypanocidal agents pentamidine, diminazene and suramin are inhibitors of 
TbOPB, as are a number of suramin analogues (Morty et al., 1998).  Pentamidine 
and diminazene contain arginine-like motifs, mimicking OPB substrates, whilst 
suramin has been shown to inhibit other serine peptidases.  TbOPB may be a 
target of suramin as significant correlation between OPB inhibition and 
trypanocidal efficacy of the suramin analogues has been found (Morty et al., 
1998).  Other inhibitors of TbOPB, containing arginine at the P1 position, have also 
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survival rates of T. brucei infected mice, although they were toxic in high doses 
(Morty et al., 2000).   
TbOPB activity was detected in the bloodstream of infected rats, based on the 
inhibitory profile found (Troeberg et al., 1996), western immunoblotting of rat 
plasma and the ability of anti-TbOPB antibodies to block most cleavage of Cbz-
RR-AMC by the plasma (Morty et al., 2001).  TbOPB was purified from rat plasma, 
identified by sequence analysis and found to be fully active against a range of 
AMC-linked peptides.  TbOPB was not released into the culture supernatant, 
indicating that cell lysis is responsible for its presence in plasma.  
OPBs have also been purified from T. congolense (Morty et al., 1999a) and  
T. evansi (Morty et al., 2005a).  Both T. congolense OPB (TcgOPB) and T. evansi 
OPB (TeOPB) are cytosolic, as with TbOPB, and both were similar in their activity 
to TbOPB, preferring substrates which filled both the P1 and P2 binding sites, 
particularly Gly, Lys, Arg, Phe or Leu as the P2 amino acid.  Thiol reducing agents 
also enhanced the activity of TcgOPB, thiol blocking agents inhibited it, and the 
same inhibitors were active as with TbOPB: DCI, AEBSF, DFP, PMSF, E64, 
antipain and leupeptin.  DCI, AEBSF, PMSF, antipain and leupeptin also inhibit 
TeOPB. 
TeOPB has been found in the bloodstream of infected rats, released from lysed 
parasites.  As was found with TbOPB (Troeberg et al., 1996), TeOPB can cleave 
atrial natriuretic factor (ANF) after four arginine residues (Morty et al., 2005a).  A 
correlation was found between reduced levels of ANF in infected rats over the 
course of infection and increased TeOPB activity.  TeOPB led to a 300-fold 
reduction in the half life of ANF in plasma from infected rats.  ANF controls blood 
volume and reduced levels in infected animals may contribute to the pathogenesis 
of trypanosomiasis (Morty et al., 2005a). 
4.1.6 Leishmania Oligopeptidase B 
A serine oligopeptidase, likely to be OPB, was described in L. amazonensis in 
1998, though the peptidase had a molecular weight of 101 kDa, higher than OPBs 
so far described.  It was inhibited by similar serine peptidase inhibitors (DIC, 
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substrates, post-basic amino acids, but not cleaving proteins (de Andrade et al., 
1998). 
OPB was identified in L. major in 1999 (Morty et al., 1999a) and was subsequently 
annotated in the genomes of L. major, L. infantum and L. braziliensis (Ivens et al., 
2005; Peacock et al., 2007). 
OPB from L. amazonensis (LaOPB) was later cloned based on the sequence of  
L. major OPB (de Matos Guedes et al., 2007).  It was sequenced and found to be 
90% identical to L. major and L. infantum OPB and 84% identical to L. braziliensis, 
67% identical to trypanosome OPBs and 37% identical to bacterial OPBs.  As 
detailed above, C
256 in T. brucei OPB is responsible for inhibition by thiol activating 
agents.  This cysteine is a glycine residue in Leishmania OPBs as in TcOPB, 
suggesting that Leishmania OPBs will be resistant to iodoacetic acid and N-
ethylmaleimide, as with TcOPB (de Matos Guedes et al., 2007).   
4.1.6.1  Expression of OPB in Leishmania 
OPB is a putative marker for the amastigote stage of the life cycle in  
L. braziliensis, having been found to be upregulated in amastigotes by a 
differential display screening and by quantitative PCR analysis of cDNA from the 
three life cycle stages of L. braziliensis (Gamboa et al., 2007).  OPB was also 
found to have increased expression in amastigotes in a proteomic screen of  
L. donovani differentiating from metacyclic promastigotes to axenic amastigotes, 
reaching a peak of expression 24 hours after differentiation was initiated; physical 
transformation to the amastigote form occurs from around 15 hours after initiation 
(Rosenzweig et al., 2008). 
4.1.7 Overview 
The substrate preferences and inhibitory profile of OPBs from several species 
have been described above.  It has been shown in these studies that cleavage of 
peptides post-arginine residues is a distinguishing feature of OPBs and they are 
inhibited by a number of serine peptidases, although often not by PMSF.  This 
activity is exactly as was demonstrated for the cleavage of Bz-R-AMC by live 
Leishmania as described in Chapter 3, which suggests that the identification of 
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correct.  However, as there are two other OPB-like peptidases in L. major, detailed 
characterisation of OPB is necessary to validate this suggestion. 
4.2 Results 
4.2.1 Expression of OPB in Leishmania species 
Recombinant OPB was produced in E. coli and used to produce polyclonal 
antibodies in a sheep, which were then affinity purified (as described in Section 
2.6.2).  These antibodies were used for a western immunoblot using cell lysate of 
all three of the life cycle stages of L. major i.e., replicative promastigotes, infective 
metacyclic promastigotes and amastigotes purified from a lesion on an infected 
BALB/c mouse.  OPB protein was found in all three stages (Figure 4.2).  
OPB was also investigated in other Leishmania species.  A western immunoblot 
was completed with cell lysate of both log and stationary phase promastigotes of 
L. mexicana, L. infantum and L. donovani.  The anti-L. major OPB antibody 
successfully recognised the expression of OPB in the other species (Figure 4.3). 
4.2.2 Localisation of OPB in fractionated cells 
Purified anti-OPB antibody was used for western immunoblotting to identify the 
fraction containing OPB.  L. major cells were sonicated with inhibitors that did not 
affect the cleavage of Bz-R-AMC by live cells, to prevent excessive degradation in 
the sonicate from peptidases released from organelles (E64-d, EDTA, 1,10 
Phenanthroline and Pepstatin A).  The supernatant, containing the soluble fraction, 
and the pellet, containing the membrane fraction, were separated as described in 
Section 2.1.6 and immunoblotted (Figure 4.4).  The antibodies used were affinity 
purified anti-OPB, anti-EF-1a (a soluble protein) and anti-GP63 (a membrane 
protein).  OPB was found to be in the soluble fraction of L. major (Figure 4.4). 
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Figure   4.2 Western immunoblot showing the expression of OPB in the three life cycle stages 
of L. major. 1 = procyclic promastigotes, 2 = metacyclic promastigotes, 3 = amastigotes.  A lysate 
of 5 x 10
6 cells was run in each lane.  Purified anti-OPB antibody was applied at a 1 in 20,000 
dilution and anti-T. brucei elongation factor 1a (EF-1a) antibody was applied at a 1 in 10,000 
dilution.  HRP-conjugated anti-sheep and anti-mouse secondary antibodies were applied at a 1 in 
5,000 concentration.  The chemiluminescence was detected in an Xomat processor.   
 
 
 
 
 
Figure   4.3 Western immunoblot showing expression of OPB in L. mexicana, L. infantum and 
L. donovani promastigotes.  1 = L. mexicana log phase, 2 = L. mexicana stationary phase, 3 =  
L. infantum log phase, 4 = L. infantum stationary phase, 5 = L. donovani log phase, 6 = L. donovani 
stationary phase.  A lysate of 5 x 10
6 cells were run in each lane.  Purified anti-OPB antibody was 
applied at a 1 in 20,000 dilution and anti-EF-1a antibody was applied at a 1 in 10,000 dilution.  
HRP-conjugated anti-sheep and anti-mouse secondary antibodies were applied at a 1 in 5,000 
concentration.  The chemiluminescence was detected in an Xomat processor.   
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Figure   4.4 Western immunoblot to determine the location of OPB.  OPB was localised to either 
soluble or membrane fraction of L. major.  1 = soluble fraction, 2 = pelleted fraction.  Purified anti-
OPB antibody was applied at a concentration of 1 in 20,000, with anti-EF-1a used at a 
concentration of 1 in 10,000 (as a control for the soluble fraction) and anti-GP63 used at a 
concentration of 1 in 100 (as a control for the membrane fraction).  HRP-conjugated anti-sheep and 
anti-mouse secondary antibodies were applied at a 1 in 5,000 concentration.  The 
chemiluminescence was detected in an Xomat processor.   
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4.2.3 Localisation of OPB by immunofluorescence analysis 
For localisation, immunofluorescence analysis was undertaken on L. major 
promastigotes and L. major infected mouse macrophages and infected THP-1 
cells. 
4.2.3.1  Localisation in promastigotes  
Purified anti-OPB antibody was used at two concentrations and co-localisation 
was carried out with concanavalin A as a marker for the flagellar pocket. 
A 1 in 200 dilution of purified anti-OPB antibody was used initially, detecting the 
OPB with a rhodamine-conjugated secondary antibody, with DAPI staining to 
determine the location of DNA.  OPB was apparently cytosolic, with a potential 
focus at the base of the flagellum, perhaps indicating the flagellar pocket.  OPB 
was found in the flagellum, but appears to be excluded from the nucleus (Figure 
4.5).  A lower concentration of anti-OPB antibody was then used, a 1 in 500 
dilution of primary antibody, which also appeared to have a slight focus in the 
region of the flagellar pocket (Figure 4.5C and D). 
Only diffuse staining was found in secondary antibody only controls (Figure 4.5E) 
and the addition of exogenous recombinant OPB effectively blocked immuno-
fluorescence using anti-OPB antibodies (Figure 4.5F). 
Promastigotes were incubated with concanavalin A for 1 hour, the concanavalin A 
was washed off and the cells fixed and prepared for immunofluorescence as 
detailed in Sections 2.6.5.4.  There was no co-localisation of the green 
concanavalin A with any focus of the rhodamine-detected OPB (Figure 4.6).   
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Figure   4.5 Localisation of OPB in L. major.  1 in 200 dilution of primary antibody was used for A, 
B and F, 1 in 500 dilution for C and D, rhodamine secondary antibody alone for E and recombinant 
OPB was added to promastigotes prior to immunofluorescence analysis for F.  A and C = anti-OPB 
antibody stained with rhodamine secondary antibody at a 1 in 1000 dilution, B, D, E and F = anti-
OPB antibody staining merged with DAPI staining of nucleus and kinetoplast. 100 ms exposure 
was used.  Scale = 5 µm. 
 
Figure   4.6 Comparison of OPB localisation with concanavalin A staining of flagellar pocket.  
A and B = 1 in 200 dilution of primary antibody, C and D = 1 in 500 dilution of primary antibody.  A 
and C = anti-OPB antibody stained with rhodamine secondary antibody merged with DAPI staining 
of nucleus and kinetoplast, B and D = anti-OPB antibody merged with DAPI and co-localised with 
concanavalin A.  100 ms exposure used for rhodamine and DAPI and 45 ms for concanavalin A.  
Scale = 5 µm. 
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4.2.3.2  Localisation in intracellular amastigotes 
Release of OPB from the cell was investigated using immunofluorescence of PEM 
infected with L. major.  The amastigotes could be detected through the use of 
DAPI staining of the nucleus and kinetoplast, but the localisation of Leishmania 
OPB could not be determined as there was cross-reaction of the OPB antibody 
with proteins in the macrophage, with fluorescent signal throughout the cell.  This 
was confirmed by controls using uninfected macrophages, where the same 
distribution of fluorescence was found (Figure 4.7A and B). 
The monocyte line THP-1 was differentiated to attached cells (as detailed in 
Section 2.1.7) and cells were also used for immunofluorescence, either infected or 
uninfected with L. major.  As with the infected PEM the amastigotes could be 
detected through the DAPI staining of DNA.  However, proteins within the THP-1 
cell were also detected by the anti-OPB antibody, with fluorescence throughout the 
cell.  Again, this was confirmed as the uninfected cells had the same pattern of 
fluorescence (Figure 4.7C and D). 
The cross-reactive protein detected by immunofluorescence in PEM was also 
detected by western immunoblotting at over 175 kDa, though no extra protein was 
detected in the THP-1 cells (Figure 4.8).  L. major OPB was just detected in the 
infected PEM (lane 1).  A protein of the correct size for L. major OPB was detected 
in the infected THP-1 cells (lane 3), with the cells presumably more heavily 
infected than the PEM given the relative strengths of the signal (lane 3 versus  
lane 1). 
4.2.4 Localisation of the site of cleavage of Bz-R-AMC 
To investigate further whether OPB could be responsible for the cleavage of Bz-R-
AMC in live promastigotes, the hydrolysis was localised by visualisation on a 
fluorescence microscope.  Bz-R-AMC was added to promastigotes for a period of 
10 minutes, then the cells were washed with PBS and the AMC was visualised 
using an excitation wavelength of 365 nm and an emission wavelength of 450 nm.  
The AMC was shown to appear in the cytosol following cleavage (Figure 4.9). 
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Figure   4.7 Immunofluorescence of PEM and THP-1 cells, using anti-OPB antibody.  A = PEM 
infected with L. major for 4 days, B = uninfected PEM.  For A and B a 1 in 200 dilution of primary 
antibody was used, with DAPI staining of DNA and an exposure time of 100 ms for both.  C = THP-
1 cells infected with L. major for 4 days, D = uninfected THP-1 cells.  For C and D a 1 in 1000 
dilution of primary antibody was used, with DAPI staining of DNA and an exposure time of 50 ms 
for both.  White arrowheads indicate position of amastigotes.  Scale = 5 µm. 
 
 
Figure   4.8 Western immunoblot of PEM and THP-1 cells infected and uninfected with  
L. major stationary phase promastigotes. 1 = PEM infected with L. major for 5 days,  
2 = uninfected PEM, 3 = THP-1 cells infected with L. major for 6 days, 4 = uninfected THP-1 cells.  
Purified anti-OPB antibody was used.  8 x 10
4 macrophage cells were run per lane.  Anti-OPB 
antibody was applied at a concentration of 1 in 20,000.  HRP-conjugated anti-sheep secondary 
antibody was applied at a 1 in 5,000 concentration.  The chemiluminescence was detected in an 
Xomat processor.  Arrow marks position of L. major OPB on blot. 
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Figure   4.9 Cleavage of 50 µM Bz-R-AMC localised by fluorescent microscopy.  Two examples 
of representative promastigotes.  A and D = AMC fluorescence alone, B and E = AMC fluorescence 
merged with phase, C and F = phase alone.  50 ms exposure was used for the AMC.   
Scale = 5 µm. 
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4.2.5 Immunoprecipitation of OPB from sonicated L. major  
L. major cells were sonicated with the inhibitors that did not affect the cleavage of 
Bz-R-AMC by live cells (E64-d, EDTA, 1,10 Phenanthroline and Pepstatin A), to 
prevent excessive cleavage in the sonicate from peptidases released from 
organelles.  The L. major sonicate was incubated overnight with either anti-OPB 
antibody or pre-immune serum (P.I.S.), as a control.  The mixtures were run 
through protein G columns and three fractions collected: the flow-through from the 
column and two elutions.  The flow-through should contain all proteins not bound 
by the antibody and the elutions from the columns contain the antibody and any 
protein they have bound.  These fractions, the sonicate bound to either anti-OPB 
antibody or P.I.S. and the sonicate alone were used to investigate the cleavage of 
Bz-R-AMC and for western immunoblotting, using anti-OPB antibody, to identify 
the fraction containing OPB.  
The sonicate alone, prior to binding of either antibody or serum, was able to cleave 
Bz-R-AMC effectively.  Using the fractions from the column with the anti-OPB 
antibody-bound sonicate run through it, there was no cleavage of Bz-R-AMC by 
the flow-through from the column.  The peptidase which cleaves Bz-R-AMC was 
thus retained on the column.  There was also no cleavage activity in either of the 
two elutions or the sonicate that had been bound to the anti-OPB antibody, but not 
run through the column (Figure 4.10A), given this, the anti-OPB antibody must 
bind OPB in such a way as to inhibit its activity. 
With the column with the P.I.S.-bound sonicate run through it, both the flow-
through from the column and the sonicate bound to serum but not put through the 
column were still able to cleave Bz-R-AMC.  Neither elution from the column 
cleaved Bz-R-AMC (Figure 4.10B).  This shows the P.I.S. was not able to bind to 
the peptidase which cleaves Bz-R-AMC. 
A western immunoblot to show presence of OPB was completed by Dr Nicholas D. 
Bland (University of Glasgow), using the fractions from the columns and the 
sonicate bound overnight to antibody or pre-immune serum (Figure 4.11).  With 
the fractions from the column which had anti-OPB antibody-bound sonicate run 
through it, OPB was found in the sonicate bound to antibody fraction and in the 
first elution.   Chapter 4      107 
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Figure   4.10 OPB Activity after immuno-precipitation.  A = activity after immuno-precipitation of 
sonicate bound to anti-OPB antibody, B = activity after immuno-precipitation of sonicate bound to 
pre-immune serum (P.I.S.).  Flow-through = run through of sonicate from column, 1st and 2nd 
elutions = elutions from column, sonicate + anti-OPB antibody = L. major sonicate bound overnight 
to anti-OPB antibody, sonicate + P.I.S. = L. major sonicate bound overnight to pre-immune serum, 
and sonicate alone = sonicate not bound to anything.  A volume of liquid equivalent to the sonicate 
of 3 x 10
5 stationary phase cells were assayed for each fraction.  Representative graphs of two 
experiments are shown. 
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Figure   4.11 Western blot of fractions from immuno-precipitation with anti-OPB antibody.  
Fractions are: sonicate bound to serum (S), flow-through from column (FT), elution 1 from column 
(E1) and elution 2 (E2).  Anti-OPB antibody was applied at a concentration of 1 in 20,000.  HRP-
conjugated anti-sheep secondary antibody was applied at a 1 in 5,000 concentration.  The 
chemiluminescence was detected in an Xomat processor.   
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This confirms that the anti-OPB antibody had bound the OPB in the L. major 
sonicate and that the antibodies were retained by the protein G column, as there 
was no OPB present in the flow-through fraction.  In contrast, the fractions from 
the column which had pre-immune serum-bound sonicate run through it only 
contained OPB in the sonicate bound to serum fraction and in the flow-through.  
The antibodies in the pre-immune serum were not specific to OPB and so the OPB 
was not retained on the column.   
4.2.6 Inhibitors of recombinant OPB in live cell tests 
Polyamine compounds (CMR compounds) were designed within the Chemistry 
Department at the University of Glasgow as potential anti-cancer agents.  The 
members of this series of compounds with side chains with similarity to arginine, 
the preferred P1 amino acid for OPB, were identified as potential OPB inhibitors.  
In addition, other compound in this series with the same polyamine ring structure 
but with different side chains, were identified as useful controls.  Their structures 
and their Kis against recombinant OPB are shown in Figure 4.12.  Their Kis were 
determined by Dr. Nicholas D. Bland of the University of Glasgow. 
 
Figure   4.12 Structures of polyamine compounds (CMR compounds), compared to the amino 
acid arginine.  These were tested for inhibition of recombinant OPB and the resultant Kis are 
shown. 
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The best inhibitor of recombinant OPB was CMR370, one of the compounds with 
the arginine-like side chain.  However, other compounds without this side chain 
were as good or better inhibitors of recombinant OPB than compound CMR372, 
which also has an arginine-like side chain.  This suggests that the compounds 
may not be inhibiting simply via binding the active site that accepts arginine.  
The effect of the CMR compounds on the growth of L. major promastigotes was 
determined by alamar blue assay (Table 4.1).  CMR inhibitors affected the growth 
of parasites.  Although CMR370 was one of the best inhibitors, other compounds 
without arginine-like side chains were also as effective anti-leishmanial 
compounds. 
The LD50 values were also determined for mouse PEM and the human cell line 
HEK, by alamar blue assays, prior to being used for infected macrophage assays 
(Table 4.1).  The HEK cell LD50 values were generated by Dr. Charles Ebikeme 
(University of Glasgow). 
Table   4.1 Mean LD50 found for CMR compounds against L. major promastigotes and 
mammalian cells by alamar blue assay. 
Inhibitor  LD50 for L. major 
promastigotes  
LD50 for  
mouse PEM  LD50 for HEK cells 
CMR32  5.4 µM ± 1.3  21.9 µM  26.0 µM 
CMR330  8.4 µM ± 0.3  104 µM  181.2 µM 
CMR95  10.1 µM ± 1.0  33.2 µM  24.9 µM 
CMR370  11.0 µM ± 1.1  133 µM  >200 µM 
CMR91  27.8 µM ± 4.5  56.6 µM  >200 µM 
CMR3  33.9 µM ± 4.5   104 µM  5.0 µM 
CMR372  115.3 µM ± 29.6  >1000 µM  >200 µM 
CMR94  >1 mM  nd  >200 µM 
 
Several of the CMR compounds had very similar LD50 values for both L. major and 
mammalian cells, the difference being only between 2- and 3-fold.  However, the 
best anti-recombinant OPB compound, CMR370, had a 10-fold higher LD50 value 
against PEM compared to L. major and so this compound was chosen for infected 
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Since CMR 370 also affected the growth of macrophages, concentrations from 
100 µM down to 2.5 µM were used for infected PEM assays.  However, at this 
concentration the amastigotes appeared to disintegrate, but not to be removed 
(Figure 4.13 A).  The disintegration also occurred at lower concentrations (Figure 
4.13 B), though not with untreated cells (Figure 4.13 C).  The macrophage 
cytoplasm was obscured to such an extent that it was impossible to determine if 
whole amastigotes were also present. 
CMR3 and CMR370 were used to inhibit the cleavage of Bz-R-AMC by  
L. mexicana and L. major WT promastigotes.  CMR3 had no effect on activity of 
the enzyme (Figure 4.14), whilst CMR370 did inhibit (Figure 4.15 and Table 4.2).  
Due to the inherent fluorescence of CMR370 the AMC values released are 
artificially high for the three highest concentrations used.  
4.3 Discussion 
Western blot analysis with specific anti-OPB antibody has shown that OPB is 
equally expressed in all life cycle stages in L. major (Figure 4.2).  The amastigote 
expression was corroborated as OPB has previously been shown to be present in 
L. braziliensis and L. donovani amastigotes (Gamboa et al., 2007; Rosenzweig et 
al., 2008).  OPB has also been found to be expressed in both promastigotes and 
axenic amastigotes of L. amazonensis (de Matos Guedes et al., 2007). 
Anti-L. major OPB antibodies can also successfully recognise OPB from other 
species (Figure 4.3), which is unsurprising given that the Leishmania OPB protein 
sequences currently known are at least 94% identical to one another. 
OPB was localised to the soluble fraction (Figure 4.4) and subsequently to the 
cytosol by immunofluorescence (Figure 4.5).  This apparent cytosolic location is 
consistent with that found for other kinetoplastid OPBs (Burleigh et al., 1997; Morty 
et al., 2005a; Rea and Fulop, 2006).  A focus at the base of the flagellum 
suggested that OPB might be located in the flagellar pocket and so secreted, but 
failure to co-localise with the flagellar pocket marker, concanavalin A, suggests 
this may be an artefact of the immunofluorescence staining (Figure 4.6).  
However, even though OPB does not contain a signal sequence for secretion it 
has been found in the secretome of L. donovani (Silverman et al., 2008).  One  Chapter 4      112 
 
 
 
 
 
 
 
Figure   4.13 Effect of CMR 370 on PEM infected with L. major.  A = cells treated with 100 µM 
CMR 370; B = cells treated with 22 µM CMR 370; C = untreated control cells.  Cells were infected 
at a ratio of 8 promastigotes to one macrophage overnight, treated the following day and Giemsa’s 
stained 5 days later.  Example disintegrated amastigotes are indicated by thin arrows, whole 
amastigotes by thick arrows.  Scale = 10 µm. 
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Figure   4.14 Effect of CMR 3 on the cleavage of 5 µM Bz-R-AMC.  A = L. major WT stationary 
phase promastigotes, B = L. mexicana WT stationary phase promastigotes.  Legend indicates 
concentration of CMR3 used (µM).  6 x 10
5 cells were used per experiment.  Representative 
graphs of 3 experiments are shown. 
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Figure   4.15 Effect of CMR 370 on the cleavage of 5 µM Bz-R-AMC.  A = L. major WT stationary 
phase promastigotes, B = L. mexicana WT stationary phase promastigotes.  At high concentrations 
CMR370 is fluorescent, affecting the values for AMC release.  Legend indicates concentration of 
CMR370 used (µM).  6 x 10
5 cells were used per experiment.  Representative graphs of 3 
experiments are shown. 
 
Table   4.2 IC50 values for inhibition of Bz-R-AMC cleavage by CMR 370.   
  Mean IC50 ± ± ± ± SEM 
L. major stationary phase promastigotes  7.41 µM ± 1.62 
L. mexicana stationary phase promastigotes  11.19 µM ± 2.75 
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other report of an OPB being released has been made, for T. cruzi OPB 
(Fernandes et al., 2005), though there is no evidence for secretion of other OPBs, 
including African trypanosome OPBs (Morty et al., 2001; Morty et al., 2005a). 
Localisation of OPB in amastigotes within macrophages, or of potential secretion 
of OPB into the macrophage, was not possible due to cross reaction of the anti-
OPB antibody with a protein within the macrophages (Figure 4.7), but it is not 
unreasonable to predict that it is cytosolic as well.  The cross reactive protein 
could be another member of the POP family, which is expressed in mammalian 
cells, as the family appear to show structural similarity (Gerczei et al., 2000) and 
the POP family member prolyl endopeptidase has been found to be present 
cytosolically, in the perinuclear region and in association with the microtubule 
cytoskeleton in cultured glioma cell lines (Schulz et al., 2005).   
The cytosolic location of OPB suggests that it could be responsible for the 
cleavage of Bz-R-AMC.  This substrate probably enters L. major by diffusion 
through the membrane, which would lead to it being located in the cytosol and 
therefore available to the enzyme.  The apparent co-localisation of OPB and  
Bz-R-AMC to the cytosol was confirmed by visualising the appearance of AMC 
fluorescence in the cell upon application of Bz-R-AMC to promastigotes (Figure 
4.9).   
Cleavage of Bz-R-AMC occurring in the same location as OPB was consistent with 
OPB being responsible for the cleavage.  This was confirmed when 
immunoprecipitation of L. major sonicate with anti-OPB antibody removed 
peptidase activity from the sonicate (Figure 4.10).  The anti-OPB antibody also 
prevented hydrolysis, as has previously been shown to occur with anti-T. cruzi, 
anti-T. brucei and anti-T. evansi OPB antibodies (Burleigh et al., 1997; Morty et al., 
2001; Morty et al., 2005a).  As antibodies are large multidomain proteins, they 
would be unable to access the active site of OPB due to the b-propeller and so are 
unlikely to block the active site directly, meaning it is more likely that one of the 
epitopes recognised by the polyclonal antibody is around the entrance of the  
b-propeller pore, thus preventing substrate access and catalysis. 
Since OPB inhibitors have previously been shown to have trypanocidal activity 
(Morty et al., 2000), a number of potential OPB inhibitors were screened for OPB 
inhibitory activity and for anti-leishmanial activity.  OPB is a promising drug target, Chapter 4      116 
being absent from mammalian genomes and with antipain, an inhibitor of OPB, 
being recognised as an anti-leishmanial agent (Coombs et al., 1982; Coombs and 
Baxter, 1984). 
The most active polyamine compound against recombinant OPB, CMR370 (Figure 
4.12), had a low micromolar LD50 against L. major promastigotes (Table 4.1).  
However, several of the other polyamine compounds, of varying effectiveness at 
inhibiting recombinant OPB, were as effective or even more effective as anti-
leishmanials.  This suggests that there are other targets for these compounds 
within promastigotes, which, in hindsight, may not be unexpected as they were not 
designed specifically to inhibit OPB, but for testing as anti-cancer agents. 
Many of the polyamine compounds were not specific in their anti-leishmanial 
properties.  The compounds killed mouse PEM and HEK cells with LD50 values 
only 2 to 4-fold higher than those against L. major promastigotes (Table 4.1).  Only 
CMR370 showed significant selectivity, with a 10-fold difference between its anti-
leishmanial activity over its anti-mammalian cell activity.  As such, amastigote 
killing assays were attempted in infected macrophages.  CMR370 appears to 
affect the ability of macrophages to completely remove amastigotes, as drugged 
macrophages had what appeared to be large numbers of disintegrated 
amastigotes within their cytoplasm, even with levels of drug 6-fold lower than the 
PEM LD50 (Figure 4.13).  This suggests that there is a target of CMR370 within the 
macrophage whose disruption leads to an inadequate clearing of amastigotes.  
The obscuring of the macrophage cytoplasm by disintegrated amastigotes meant it 
was impossible to be sure that whole amastigotes were not present, but assuming 
complete disintegration of amastigotes was occurring at high levels of CMR370 
then this may be sufficient for anti-leishmanial action. 
CMR370 was an inhibitor of the activity of OPB in live cell Bz-R-AMC cleavage 
assays (Figure 4.15), with a similar micromolar IC50 value as that of the anti-
leishmanial LD50 (Table 4.2).  Given this similarity, this compound may therefore 
be acting directly as an anti-OPB agent in promastigotes. 
 Chapter 4      117 
4.3.1 Conclusions 
OPB has been demonstrated to be a cytosolic protein present throughout the life 
cycle in Leishmania.  Localisation of OPB and the site of cleavage of Bz-R-AMC 
suggested OPB was the enzyme responsible for this activity.  This was confirmed 
by determining that no cleavage occurred when OPB was immunoprecipitated 
from L. major sonicate. 
OPB appears to be suitable as a drug target, being absent from mammalian 
species and with OPB inhibitors being able to kill promastigote L. major, and 
appearing to lead to disintegration of amastigotes within infected macrophages.  
Genetic manipulation of OPB in L. major to evaluate it as a drug target has been 
carried out and will be discussed in Chapter 5.       118 
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GENETIC MANIPULATION OF L. MAJOR OPB Chapter 5      119 
5.1 Introduction 
5.1.1 Targeted gene replacement in Leishmania  
Genetic manipulation involves the replacement of specific genes using constructs 
designed to exploit homologous recombination in Leishmania.  These typically 
contain an antibiotic resistance gene (for examples, see Section 5.1.3), to allow 
selection, flanked by regions of DNA specific to the gene under study.  The gene 
specific DNA either flanks or includes part of the open reading frame of the gene 
of interest in order to target the construct to the desired locus to replace or disrupt 
the gene (Clayton, 1999; Beverley, 2003).  DNA is digested to leave just the flanks 
and the resistance gene, then introduced into Leishmania by electroporation.  As 
Leishmania is a diploid organism two rounds of homologous recombination using 
different selectable markers are necessary to delete both alleles of a gene (Cruz et 
al., 1991). 
Early studies indicated that a flank of around 200 bp was sufficient for gene 
replacement to occur successfully in L. enriettii (Tobin and Wirth, 1992).  
Subsequent work in L. tarentolae found that flanks of around 1 kb had the highest 
efficiency of replacement, with a minimum size of 150-200 bp being required for 
recombination.  The successful integration of constructs designed for L. tarentolae 
into either L. donovani or L. major or from either of the latter two into L. tarentolae 
were highly dependent on the homology of the sequences in the three species; 
sequences with 86 or 87% homology could not recombine (Papadopoulou and 
Dumas, 1997). 
For targeted gene replacement to work in Leishmania, homologous recombination 
is necessary.  This was proven to occur in Leishmania in 1991 by the Wirth 
laboratory with L. enriettii.  They transfected L. enriettii with two plasmids with 
independent mutations in different regions of the chloramphenicol acetyl-
transferase (CAT) gene, which each caused a lack of activity.  Recombination 
between the plasmids was shown, when CAT activity was found.  The 
recombination was confirmed by Southern blotting and PCR.  Recombination was 
also demonstrated between a different pair of plasmids as well, one carrying the 
NEO gene and the other the CAT gene (Tobin et al., 1991).   Chapter 5      120 
Targeted gene replacement in Leishmania was first illustrated in avirulent L. major 
in 1990, when a construct containing the neomycin phosphotransferase (NEO) 
gene was introduced into the dihydrofolate reductase-thymidine synthase (DHFR-
TS) gene locus by homologous recombination using a construct containing the 
flanking sequences of DHFR-TS (Cruz and Beverley, 1990).  Both alleles could be 
sequentially replaced using this construct and one containing hygromycin B 
phosphotransferase (HYG), if thymidine was added for growth (Cruz et al., 1991). 
Targeted gene replacement was then demonstrated in L. enriettii by integration of 
a construct containing NEO, flanked by a-tubulin intergenic regions and coding 
sequences, into the a-tubulin locus (Tobin and Wirth, 1992).  Subsequently, either 
of the two arrays of a-tubulin genes present in L. enriettii could be deleted either 
singly or together, provided an ectopic copy was added to maintain the viability of 
the parasites (Curotto de Lafaille and Wirth, 1992).  
Targeted gene replacement has subsequently been used extensively by many 
laboratories to disrupt or remove both single genes and multi-copy gene arrays.  
Individual genes targeted within the Coombs and Mottram laboratories include the 
cysteine peptidases CPA and CPC (Souza et al., 1994; Bart et al., 1997) and GPI8 
(GPI:protein transamidase 8; Hilley et al., 2000).  The gene array of the 19-copy 
cysteine peptidase CPB was also deleted by this method (Mottram et al., 1996b). 
Essential genes can be identified by this technique as the gene will be retained by 
the parasite post-transfection.  Leishmania have been found to use several 
mechanisms to survive selection with two antibiotics and maintain a copy of the 
original gene.  Attempts to knock out DHFR-TS in virulent L. major had three 
results: i) the DNA content was doubled in some cells, to tetraploidy, maintaining 
two wild-type chromosomes and two chromosomes each with one resistance 
gene; ii) aneuploid lines, with only one extra chromosome (containing the wild-type 
gene), were generated; and iii) diploid cells, with insertion of the antibiotic 
resistance genes without replacement of the wild-type locus were found (Cruz et 
al., 1993).  Cells with either triploid or tetraploid DNA content were also found 
when it was attempted to delete CRK1 in L. mexicana.  Both alleles could only be 
removed without altering ploidy if an ectopic gene copy was also expressed 
(Mottram et al., 1996a).  Genomic rearrangements to maintain a wild-type gene 
have been found also in L. donovani when it was attempted to knock out the Chapter 5      121 
trypanothione reductase gene, with an extra copy found on a different 
chromosome (Dumas et al., 1997). 
5.1.2 Ectopic expression of genes in Leishmania 
Extrachromosomal expression of genes in Leishmania has been possible since 
1989, when it was demonstrated that CAT could be transiently expressed on an 
extrachromosomal element in L. enriettii, L. major and L. braziliensis.  In order to 
drive expression it was necessary to include an intergenic region of the a-tubulin 
gene 5’ to the CAT sequence (Laban and Wirth, 1989).   
Stable extrachromosomal expression of NEO was also described in L. enriettii, 
with the NEO sequence flanked by a-tubulin intergenic sequences to process the 
NEO mRNA (Laban et al., 1990).  DHFR-TS intergenic regions were also used to 
drive the expression of NEO from an ectopic plasmid to produce G418-resistant  
L. major (Kapler et al., 1990). 
Intergenic regions of Leishmania genes were subsequently found to be essential 
to allow expression of active proteins from ectopic constructs.  Expression of either 
CAT or NEO was only successful when the a-tubulin intergenic region, containing 
the trans-splicing site for the downstream gene, was included on the plasmid 5’ to 
the CAT and NEO sequences (Curotto de Lafaille et al., 1992). 
A series of expression vectors, named pNUS vectors, have been designed for the 
trypanosomatids Crithidia and Leishmania, allowing expression of introduced 
genes with His- or GFP-tags or signal sequences, for purification, visualisation or 
secretion of proteins (Tetaud et al., 2002).  Proteins can also be expressed by 
these vectors with their native start and stop sites in order to obtain non-tagged 
proteins.  The pNUS vectors contain an rRNA promoter, intergenic sequences 
from the C. fasciculata phosphoglycerate kinase locus both 5’ and 3’ to the 
introduced gene, and the 3’ untranslated sequence of the C. fasciculata 
glutathionyl-spermidine synthetase locus 3’ to the antibiotic resistance gene.  A 
multiple cloning site allows for easy insertion of desired genes.  Versions of the 
vectors are available containing three different antibiotic selection genes, HYG, 
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5.1.3 Resistance markers 
To genetically manipulate Leishmania a number of antibiotic resistance genes 
have been developed and are commonly used, with several markers generally 
necessary in order to manipulate genes in Leishmania.  These genes are shown in 
Table 5.1. 
Table   5.1 Antibiotic resistance genes used for genetic manipulation of Leishmania. 
Gene  Encoded Protein  Antibiotic  Reference 
NEO  Neomycin phosphotransferase  Geneticin or 
G418  Laban et al., 1990 
SAT  Streptothricin acetyltransferase  Nourseothricin  Joshi et al., 1995 
PAC  Puromycin N-acetyltransferase  Puromycin  Freedman and 
Beverley, 1993 
HYG  Hygromycin B phosphotransferase  Hygromycin B  Lee and van der 
Ploeg, 1991 
BLE  Bleomycin hydrolase  Phleomycin / 
Bleomycin  Souza et al., 1994 
BSD  Blasticidin S deaminase  Blasticidin S  Brooks et al., 2000 
 
5.1.4 Overview 
Genetic manipulation in Leishmania is a well characterised method for establishing 
the importance of proteins.  Utilisation of this method to generate null mutants and 
ectopic over-expression mutants of OPB in L. major will allow investigation of the 
role of OPB and the determination of its role in Bz-R-AMC cleavage.  This will 
provide information on whether it is essential for parasite survival or is a potential 
drug target. 
5.2 Results 
5.2.1 Constructs for over-expression of OPB in L. major 
In order to over-express OPB in L. major, the full length gene (LmF09.0770), was 
inserted into the HcN pNUS vector (Tetaud et al., 2002), with its start and stop 
sites intact, and transfected into L. major.  As controls, two other constructs were 
transfected into L. major, one with the active site serine of OPB mutated to a 
glycine residue (OPB
S577G), and the other the empty pNUS vector. Chapter 5      123 
The two constructs used for over-expression are shown in Figure 5.1.  The full 
length gene was generated by PCR, using genomic L. major WT DNA as 
template, using the primers OL2352 and OL2353, ligated into the TOPO vector, 
and then transferred into the pNUS vector to give pGL1640.  Site directed 
mutagenesis was then completed on pGL1640, using the primers OL2550 and 
OL2551 to mutate the active site serine (residue 577) to a glycine, giving the 
active site mutant construct, pGL1714.  The empty pNUS vector, pGL1137, was 
not altered prior to use.  Details of primers used are given in Section 2.5.3.   
5.2.2 Over-expression of OPB 
5.2.2.1  Generation of lines 
Two populations of cells over-expressing OPB were produced, WT[OPB] 
populations 1 and 2, by splitting the transfected culture into two immediately 
following transfection and selecting using 50 µg/ml G418.  A single population of 
cells was generated over-expressing OPB with the active site mutation, 
WT[OPB
S577G], by selection with 25 µg/ml G418.  The cells were maintained in  
50 µg/ml G418.  A single population of cells with the empty pNUS vector was also 
produced, by selection with 50 µg/ml G418. 
The ectopic constructs were shown to be present in the transfected populations by 
PCR analysis.  A PCR product of 1.2 kb, amplified using the primers M13 Forward 
and OL2456, shows the construct is present in the WT[OPB] populations.  A  
1.7 kb PCR product, amplified using the primers M13 Reverse and OL816, shows 
the construct is present in the WT[OPB
S577G] and empty pNUS vector lines (Figure 
5.2).  In both, a product of the correct size was not found in the WT population. 
 
A western immunoblot was carried out using anti-OPB antibody and anti-EF-1a 
antibody as a loading control.  An increased level of the 83 kDa protein 
corresponding to OPB was detected in the two WT[OPB] lysates (lanes 2 and 3, 
Figure 5.3A), compared to the L. major WT lysate (lane 1, Figure 5.3A).  There 
was also an increase of the OPB protein detected in the WT[OPB
S577G] lysate 
(lane 3, Figure 5.3B), with no increase in the level of protein expressed in the 
empty vector lysate (lane 2, Figure 5.3B), compared to the L. major WT lysate 
(lane 1, Figure 5.3B).  In contrast, the same level of expression of the control 
protein, EF-1a, was found in all the lysates compared to L. major WT. Chapter 5      124 
 
                     
pGL1640
8542 bp
Neomycin phosphotransferase
OPB
Eco RV (2861)
KpnI (582)
OL2352 (100.0%)
OL2353 (100.0%)
M13 Forward (-20) (100.0%)
OL2456 (100.0%)
 
 
pGL1714
8542 bp
Neomycin phosphotransferase
OPB S577G
Eco RV (2861)
KpnI (582)
M13 Reverse (100.0%)
OL816 (100.0%)
OL2352 (100.0%)
OL2353 (100.0%)
OL2550 (100.0%)
 
Figure   5.1 Constructs for the over-expression of OPB in L. major.  A = OPB, B = OPB
S557G.    
In A, OPB denotes L. major OPB gene, LmF09.0770, and M13 Forward and OL2456 are the 
primers used to check for presence of the construct.  In B, OPB S577G denotes L. major OPB with 
the serine residue at 577 mutated to glycine, and M13 Reverse and OL816 are the primers used to 
check for presence of the construct.  In both, KpnI and EcoRV are the restriction enzymes used to 
digest the OPB from the TOPO vector to insert it into the pNUS vector and OL2352 and OL2353 
are the primers used to generate the gene by PCR. 
 
A 
B 
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Figure   5.2 PCR analysis of OPB over-expressers.  DNA was used from both over-expresser 
populations and L. major WT to determine presence of pGL1640 construct.  A = PCR using 
genomic DNA from both WT OPB over-expressers. 1 = WT[OPB] population 1, 2 = WT[OPB] 
population 2, 3 = L. major WT and MW = 1 kb ladder.  B = PCR using genomic DNA from active 
site mutant OPB over-expresser population and empty vector population, 1 and 3 = L. major WT, 2 
= WT[OPB
S577G] population and 4 = empty vector population and MW = 1 kb ladder.  The relevant 
size bands of the ladders are marked. 
 
   
 
Figure   5.3 Demonstration of over-expression of OPB in L. major cells by western 
immunoblot.  In A, 1 = L. major WT cells, 2 = WT[OPB] population 1 and 3 = WT[OPB] population 
2.  In B, 1 = L. major WT cells, 2 = empty pNUS vector population and 3 = WT[OPB
S577G] 
population.  A lysate of 5 x 10
6 cells was run per lane, anti-OPB antibody was applied at a 
concentration of 1 in 20,000 and anti-EF-1a antibody was applied at a concentration of 1 in 10,000.  
HRP-conjugated anti-sheep and anti-mouse secondary antibodies were applied at a 1 in 5,000 
concentration and the chemiluminescence was detected using a Molecular Imager ChemiDoc 
System. 
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5.2.2.2  Phenotype analysis 
The growth of the WT[OPB] promastigote populations was compared to that of  
L. major WT, the WT[OPB
S577G] and the empty pNUS vector.  The presence of the 
constructs in the promastigotes led to a slightly lower stationary phase population 
level being reached, but as this was the same for the OPB over-expressing lines 
and the empty vector it is likely that this is due to the antibiotic pressure in the 
culture.  There was also an initial lag in the growth of the empty vector population, 
but this was not replicated in the OPB over-expressing lines.  The rate of growth of 
the logarithmic phase was very similar for all the lines (Figure 5.4).   
FACS analysis was performed to investigate the ploidy of the over-expresser lines.  
Over-expression of OPB had no effect on the ploidy of the L. major (Figure 5.5), as 
the cells all had normal proportions of 2N and 4N cells, representing normal cells 
and cells in the process of dividing, having already duplicated their DNA.   
The level of peptidase activity towards Bz-R-AMC was determined in the various 
cell lines.  The WT[OPB] promastigotes had over 20 times the enzymatic activity of 
the wild type cells or the empty vector control.  The WT[OPB
S577G] promastigotes 
had an activity that was approximately half that of the wild-type (Figure 5.6). 
The effect of over-expressing OPB in L. major on the IC50 value for antipain, 
leupeptin and pefabloc inhibition of peptidase activity towards Bz-R-AMC was 
measured.  Over-expression of OPB caused a small increase in the IC50 for 
antipain compared to both L. major WT and empty vector promastigotes, whilst the 
IC50 for pefabloc was only higher for the WT[OPB] populations compared to  
L. major WT promastigotes, though only the difference between the L. major WT 
and the WT[OPB] population 2 was significant, with a p value of 0.04 by an 
unpaired t-test.  There was no difference between the IC50 values of leupeptin for 
any of the lines (Table 5.2).  
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Figure   5.4 Effect of over-expression of OPB on growth of L. major promastigotes.  Cells were 
counted over 8 days in culture.  Three cultures were counted of each line to generate a mean, with 
values ± SEM. 
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Figure   5.5 Effect of over-expression of OPB on ploidy of promastigotes.  FACS analysis was 
performed on L. major WT and promastigotes containing pNUS empty vector and OPB over-
expressing populations.  A = L. major WT, B = pNUS empty vector, C = WT[OPB] population 1,  
D = WT[OPB] population 2 and E = WT[OPB
S577G].  Peaks at 200 FL2-Area represent 2N cells and 
peaks at 400 FL2-Area represent 4N cells. 
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Figure   5.6 Effect of over-expression of OPB in L. major promastigotes on the cleavage of  
5 µM Bz-R-AMC.  Over-expressers were compared to wild-type (taken as 100%) and empty vector 
control promastigotes.  For each assay, 6 x 10
6 cells were used.  Relative activity was calculated 
compared to WT for each individual experiment.  The mean of between 4 and 11 experiments is 
shown ± SEM. 
 
Table   5.2 Effect of over-expression of OPB in L. major promastigotes on the mean IC50 value 
for inhibition of cleavage of Bz-R-AMC, compared to wild-type and empty vector cells. 
  L. major WT  WT[OPB] 
pop
n 1 
WT[OPB] 
pop
n 2 
empty pNUS 
vector 
Mean antipain 
IC50 ± SEM (nM)  9.3 ± 1.6  23.6 ± 9.2  18.1 ± 5.9  12.5 ± 3.7 
Mean leupeptin 
IC50 ± SEM (nM)  48.1 ± 5.8  57.2 ± 14.4  53.3 ± 8.3  55.9 ± 7.3 
Mean pefabloc 
IC50 ± SEM (µM) 
14.4 ± 0.6  25.5 ± 6.4  25.4 ± 2.3  20.9 ± 3.9 
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Antipain has previously been shown to have anti-leishmanial activity (Coombs et 
al., 1982; Coombs and Baxter, 1984).  As an inhibitor of OPB, it was hypothesised 
that OPB could be its intracellular target.  Therefore, the effect of over-expression 
of OPB on the LD50 of antipain against promastigotes was analysed.  A serially 
diluted drug assay was completed and the growth of parasites analysed by the 
reduction of alamar blue, to give the LD50 values.  A slightly higher LD50 was found 
in the OPB over-expressing lines when compared to the wild-type (Figure 5.7), 
though only the increase in LD50 for the WT[OPB] population 2 compared to wild-
type was significant, with a p value of 0.05, by an unpaired t-test.   
5.2.3 Constructs for generating OPB null mutants in L. major 
The constructs used for deleting the OPB gene in L. major are shown in Figure 5.8 
and a schematic of the OPB locus and the constructs is shown in Figure 5.9.  The 
5’ flanking region of OPB was generated by PCR using the primers OL2395 and 
OL2415, giving a flank of 872 bp and the 3’ flanking region of OPB was generated 
by PCR using the primers OL2356 and OL2459, giving a flank of 539 bp.  Details 
of primers used are given in Section 2.5.3.  The 5’ flank was ligated into the  
PCR-Script cloning vector and the 3’ flank was ligated into the TOPO cloning 
vector, then both were inserted into the knock out construct that had previously 
been used to generate the CPB array and ICP null mutants (Mottram et al., 1996b; 
Besteiro et al., 2004), to give pGL1693.  The HYG gene in pGL1693 was then 
replaced with the streptothricin acetyltransferase (SAT) gene to give pGL1792.  
The linear null cassette was excised using the restriction enzyme Bgl II before 
transfection into L. major.  pGL1693 was used for the first round of transfection, 
with pGL1762 used for the second round. 
5.2.4 OPB null mutants 
5.2.4.1  Generation of lines 
Two independent populations of OPB heterozygote cells were generated by 
splitting the transfected culture into two immediately following transfection.  Prior to 
attempting to knock out the second allele of OPB it was necessary to first 
demonstrate that the first allele had been removed.   
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Figure   5.7 LD50 of antipain against OPB over-expressing promastigotes.  LD50 values were 
determined from 6 day serial dilution assays on promastigotes, detected by reduction of alamar 
blue.  The mean of between 4 and 8 experiments is shown ± SEM.  * = p = 0.05, compared to  
L. major WT, by an unpaired t-test.  
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pGL1693
7644 bp
Hygromycin B phosphotransferase
3' OPB
5' OPB
BglII (25)
BglII (4842)
OL13 (100.0%)
OL14 (100.0%)
OL2356 (96.3%)
OL2395 (81.5%)
OL2415 (85.2%)
OL2459 (100.0%)
OL2616 (100.0%)
OL2704 (100.0%)
OL2705 (100.0%)
 
    
pGL1762
7123 bp
Streptothricin acetyltransferase
3' OPB
5' OPB
BglII (25)
BglII (4321)
OL2356 (96.3%)
OL2395 (81.5%)
OL2415 (85.2%)
OL2459 (100.0%)
OL2702 (100.0%)
OL2703 (100.0%)
 
 
Figure   5.8 Construct for the knock out of OPB in L. major.  A = pGL1693, B = pGL1762.   
5’ OPB denotes the 5’ flanking region of the L. major OPB gene, 3’ OPB denotes the 3’ flanking 
region of the L. major OPB gene, that were used.  The primers used for PCR reactions (OL2616, 
OL14 & OL13; OL2704 & OL2705 and OL2702 &OL2703), to check for integration and presence of 
the construct, as described in Sections 5.2.3 and 5.2.4.1, are shown.  Bgl II indicates the restriction 
enzyme used to digest the construct prior to transfection into L. major. 
Hygromycin B phosphotransferase 
Streptothricin acetyltransferase 
A 
B Chapter 5      133 
 
 
 
 
Figure   5.9 Schematic representation of OPB locus and plasmid constructs used for gene 
replacement.  A = OPB locus, B = pGL1693 and C = pGL1762.  Positions of primers used for PCR 
reactions and the length of PCR products produced, as described in Sections 5.2.3 and 5.2.4.1, are 
shown. 
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PCR analysis was carried out using two sets of primers.  One set amplified a 
section of the construct from the hygromycin resistance gene to the 3’ flank, 
showing that the construct was present.  The second set amplified a section from 
the hygromycin resistance gene to outside the 5’ flank, which would only generate 
a PCR product when the construct had correctly integrated into the genome.  Both 
PCR products were only found with the DNA from the heterozygote populations 
and not with that from the L. major WT promastigotes (Figure 5.10), with both the 
heterozygote populations had the 1.9 kb PCR product amplified by primers 
OL2615 and OL13 indicating integration of the deletion construct and the 1.6 kb 
PCR product amplified by primers OL2616 and OL14 indicating presence of the 
deletion construct. 
Transfection with Bgl II digested pGL1762 was carried out on heterozygote 
population 1.  Immediately following transfection the culture was split into two, to 
ensure that if clones were generated from both cultures then they would be from 
independent transfection events.  The two cultures were serially diluted and plated 
out on 96-well plates to generate clones (as described in Section 2.5.7.2).  
Following selection with hygromycin and nourseothricin, 33 clones were 
generated, which were analysed to determine if they were null mutant clones. 
A primary screen was conducted to determine if the WT OPB locus was present in 
the clones using PCR.  Clones that were negative were then checked for the 
presence of the antibiotic selection genes, also by PCR.  The analysis was 
completed using three sets of primers.  One pair, OL2353 and OL2399, amplified 
a 1 kb section of the WT OPB locus, the second pair, OL2702 and OL2703, 
amplified the SAT resistance gene, and the third pair, OL2704 and OL2705, 
amplified the HYG resistance gene.  In OPB null mutants the WT locus should be 
missing and both the antibiotic genes should be present, with the opposite being 
true for WT cells (Figure 5.11).  By this method only two clones were found to be 
potential null mutants: clones 10 and 21.  These were the only two clones found to 
lack the 1 kb PCR product indicating presence of the WT locus.  The PCR 
products amplified by clones 11 and 20 are included to illustrate the presence of 
the WT locus in these clones, which was replicated in the remaining 29 clones 
generated by the serial dilution.  Both the 500 bp fragment amplified using primers 
for SAT and the 1 kb fragment amplified using primers for HYG were also found in 
clones 10 and 21.  These clones were named Dopb clone 10 and Dopb clone 21. Chapter 5      135 
 
 
Figure   5.10 PCR to determine presence and integration of digested pGL1693.  For lanes 1-3, 
a PCR product of 1.9 kb indicates that pGL1693 has been integrated, for lanes 4-6 a PCR product 
of 1.6 kb indicates that pGL1693 is present.  Lanes 1 & 4 = heterozygote population 1; 2 & 5 = 
heterozygote population 2; 3 & 6 = L. major WT.  MW = 1 kb ladder. 
 
 
 
Figure   5.11 PCR to determine presence of WT OPB, SAT and HYG.  DNA from potential null 
mutant clones and L. major WT promastigotes was used.  For lanes 1-5 a PCR product of 1 kb 
indicates presence of the WT OPB locus, for lanes 6-8 a PCR product of 500 bp indicates 
presence of the SAT gene and for lanes 9-11 a PCR product of 1 kb indicates presence of the HYG 
gene.  Lanes 1, 6 & 9 = clone 10; 2 = clone 11; 3 = clone 20; 4, 7 & 10 = clone 21; 5, 8 & 11=  
L. major WT.  MW = 1 kb ladder. 
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A western immunoblot was carried out using anti-OPB antibody and anti-EF-1a 
antibody as a loading control.  The 83 kDa protein corresponding to OPB was 
detected in lane 1, the WT L. major lysate, but there was no protein detected in 
either of the OPB null mutant clone lysates (lanes 2 and 3).  In contrast, the same 
level of expression of the control protein, EF-1a, was found in all three lysates 
(Figure 5.12). 
5.2.4.2  Phenotype analysis 
The growth of the two Dopb clones was compared to that of L. major WT 
promastigotes.  The clones had a slight growth defect, only reaching a stationary 
phase concentration of less than 3 x 10
7 cells/ml, whilst the WT cells reached 
approximately 3.5 x 10
7 cells/ml.  The clones also exhibited an initial lag in their 
growth and have a growth rate in log phase 20% slower than that of the wild-type 
(Figure 5.13).   
To investigate the ploidy of the OPB null mutants, FACS analysis was performed, 
with the lines all found to have normal proportions of 2N and 4N promastigotes 
(Figure 5.14).   
Since OPB had been shown to be responsible for the majority of Bz-R-AMC 
cleavage activity in L. major, the activity for the heterozygote and Dopb clones was 
investigated.  The rate of cleavage was determined for each line of promastigotes, 
as described in Section 2.4.1.  The rates for the heterozygote and null mutant 
clones were then calculated as a percentage of the rate of cleavage of the  
L. major WT.  The heterozygote was found to have around 42% of the cleavage 
compared to the WT whilst the Dopb clones only had between 1.4 and 0.7% of the 
cleavage of the WT (Figure 5.15).   
Since antipain is an inhibitor of OPB, it was hypothesised that OPB could be its 
intracellular target.  Therefore, the LD50 of antipain for heterozygote and OPB null 
mutant clones was compared to that of L. major WT promastigotes.  A serially 
diluted drug assay was completed and the growth of parasites was analysed by 
the reduction of alamar blue, to give the LD50 values.  The OPB heterozygote 
population 1 showed a small increase in sensitivity to antipain, however the 
decrease in the LD50 was not significant (p value of 0.14, by an unpaired t-test).  
There was a significant decrease in the LD50 for Dopb clone 21  Chapter 5      137 
 
 
 
Figure   5.12 Demonstration of OPB protein levels in L. major WT promastigotes and D D D Dopb by 
western immunoblot.  1 = L. major WT cells, 2 = Dopb clone 10 and 3 = Dopb clone 21.  A lysate 
of 5 x 10
6 cells was run per lane, anti-OPB antibody was applied at a concentration of 1 in 20,000 
and anti-EF-1a antibody was applied at a concentration of 1 in 10,000.  HRP-conjugated anti-
sheep and anti-mouse secondary antibodies were applied at a concentration of 1 in 5,000 and the 
chemiluminescence was detected using a Molecular Imager ChemiDoc System. 
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Figure   5.13 Effect of deleting OPB in L. major cells on growth of promastigotes.  Cells were 
counted over 8 days in culture.  No antibiotics were applied to the Dopb clones.  Three cultures 
were counted of each line to generate a mean ± SEM.   
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Figure   5.14 Comparison of FACS profiles of WT L. major and the two D D D Dopb clones.   
A = L. major WT, B = Dopb clone 10, C = Dopb clone 21.  Peaks at 200 FL2-Area represent 2N 
cells and peaks at 400 FL2-Area represent 4N cells. 
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Figure   5.15 Cleavage of 5 µM Bz-R-AMC.  Relative activities of live heterozygote and Dopb clone 
promastigotes as a percentage of L. major WT promastigotes were determined from the rate of 
increase in fluorescence.  Values are the mean of between 5 and 11 experiments, ± SEM. 
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compared to L. major WT, with a p value of 0.02 in an unpaired t-test.  However, 
the LD50 of Dopb clone 10 was not decreased and was the same as that of  
L. major WT (Figure 5.16). 
Dopb and L. major WT stationary phase cells were used to infect peritoneal 
exudate macrophages (PEM) at an 8:1 ratio of parasites to macrophages.  PEM 
were fixed after one, four and six days post infection and the numbers of infected 
macrophages were counted (Figure 5.17).  After one day both WT and Dopb cells 
infected PEM at a similar level, between 60-75%.  However, by day six only 5-10% 
of PEM were still infected with Dopb promastigotes, whereas over 80% were 
infected with L. major WT promastigotes.  The infection levels were significantly 
lower at day 6 for the null mutant clones compared to L. major WT, with p values 
of 0.001 (clone 10) and 0.002 (clone 21) by an unpaired t-test. 
A reduced ability to survive infection in macrophages can reflect a reduced 
number of metacyclic cells.  The number of metacyclic promastigotes in Dopb 
clones was compared to that of L. major WT.  Two methods were used, i) western 
immunoblotting for the surface protein HASPB (Figure 5.18), a known metacyclic 
marker (Flinn et al., 1994), and ii) comparison of peanut lectin agglutination of cells 
(Table 5.3), which agglutinates the non-metacyclic cells (Sacks et al., 1985).  
Immunoblotting of lysates of L. major WT and OPB null mutant clones stationary 
phase promastigotes determined that there was less HASPB protein, consistent 
with there being fewer metacyclic promastigotes in the two null mutant clones, but 
no reduction in the level of the control protein, EF-1a (Figure 5.18).  The reduction 
in metacyclic promastigotes was replicated by the peanut lectin agglutination of 
the lines, with a reduction in the apparent number of metacyclics of 30% for clone 
10 compared to the wild-type and 64% for clone 21 (Table 5.3). 
Table   5.3 Comparison of percentages of metacyclic promastigotes in L. major WT and D D D Dopb 
clones as determined by peanut lectin agglutination. 
Line  % 
Metacyclics 
L. major WT  35.1 ± 0.2 
Dopb clone 10  24.6 ± 2.4 
Dopb clone 21  12.6 ± 0.1 
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Figure   5.16 LD50 of antipain against heterozygote and D D D Dopb promastigotes.  LD50 values were 
determined from 6 day serial dilution assays on promastigotes, detected by reduction of alamar 
blue.  The mean of between 5 and 8 experiments is shown ± SEM.  * = p = 0.02, compared to  
L. major WT, by an unpaired t-test. 
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Figure   5.17 Infectivity of D D D Dopb clones compared to WT L. major in PEM.  PEM were infected at 
a ratio of 8 stationary phase promastigotes to 1 macrophage and were incubated for 6 days.  Each 
value is the mean of 5-8 replicates over two experiments ± SEM. * = p = 0.001 and ** = p= 0.002, 
compared to L. major WT at day 6, by unpaired t-test. 
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Figure   5.18 Western immunoblot of D D D Dopb clones and L. major WT to compare HASPB levels.  
1 = L. major WT cells, 2 = Dopb clone 10 and 3 = Dopb clone 21.  A lysate of 5 x 10
6 cells was run 
per lane, anti-HASPB antibody was applied at a concentration of 1 in 5,000 and anti-EF-1a 
antibody was applied at a concentration of 1 in 10,000.  HRP-conjugated secondary antibodies 
were applied at a concentration of 1 in 5,000 and the chemiluminescence was detected in an 
Xomat processor. 
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To assess if the null mutant clones were infective to mice and could generate 
lesions, Dopb and L. major WT stationary phase promastigotes were used to 
inoculate BALB/c mice footpads.  Footpads were measured at weekly intervals 
and mice were culled once the footpad diameter was 5 mm.  There was a lag in 
the growth of the footpads in mice inoculated with the Dopb clones compared to 
those inoculated with L. major WT.  There was also a slower rate of growth in the 
lesions of Dopb once the exponential rate of growth started at week 3 for the 
clones, compared to week 1 for L. major WT.  Dopb clone 21 had a slower rate of 
lesion development compared to Dopb clone 10 (Figure 5.19). 
5.3 Discussion 
The pNUS vector had been used previously within the Mottram laboratory to over-
express the L. major proteins VPS4, ATG4.2 and metacaspase (Besteiro et al., 
2006; Ambit et al., 2008) and was thus chosen for the over-expression of OPB.  
Over-expression of OPB was successfully achieved in L. major promastigotes, as 
shown by increased level of protein (Figure 5.3) and the higher rate of cleavage of 
Bz-R-AMC (Figure 5.6).  This confirmed that the higher level of OPB protein found 
by western immunoblotting was responsible for faster cleavage of Bz-R-AMC.  The 
increase in protein level found by western blot was not quantified, but a large 
increase is clear.  Over-expression of OPB
S577G was also confirmed by western 
immunoblot (Figure 5.6), but over-expression of the mutant led to a drop in activity 
relative to wild-type promastigotes, suggesting that the active site mutant had a 
dominant negative effect.  It may be that this is due to the OPB
S577G binding the 
substrate but being unable to cleave it, acting in a similar manner to a competitive 
inhibitor. 
It has been previously shown that non-native expression levels of proteins can be 
deleterious, as with the metacaspase cysteine peptidase.  For metacaspase 
(MCA), removal of even the first allele of the peptidase was impossible without 
expression of a MCA transgene elsewhere in the parasite’s genome, thus 
maintaining a native level of expression, and over-expression of MCA at higher 
than normal levels led to aneuploid cells with a severe growth defect (Ambit et al., 
2008).  The level of expression of OPB is not critical for L. major as the over-
expression of either the WT or the active site mutant OPB in promastigotes had no  Chapter 5      143 
 
 
 
 
 
 
 
 
Figure   5.19 Growth of footpad lesions of BALB/c mice.  Footpads infected with Dopb clones 
were compared to footpads infected with WT L. major.  5 x 10
5 stationary phase promastigotes 
were injected per footpad.  Each value is the mean of 5 or 6 mice ± SEM.  Crosses and numbers 
represent the number of mice culled at that number of weeks.  
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major growth defect compared to the empty vector control line (Figure 5.4) and 
there was no effect on their ploidy (Figure 5.5).   
As OPB activity against Bz-R-AMC was reduced by the inhibitors antipain, 
leupeptin and pefabloc, it was hypothesised that the presence of higher levels of 
OPB would lead to the IC50
 values for inhibition increasing.  The IC50 values for 
antipain and pefabloc for the over-expresser lines did increase relative to the wild-
type promastigotes, but not relative to the empty vector line (Table 5.2).  This 
suggests that it was the presence of the ectopic construct itself that was somehow 
causing the alteration in the IC50 values.  There was only approximately a 100% 
and a 50% increase in the IC50 values for antipain and pefabloc respectively, 
which is a very low difference in the values compared to the over 20-fold increase 
in the cleavage rate.  There was no change in the values for leupeptin.  However, 
an IC50 is independent of enzyme concentration.  The IC50 is based on a ratio of 
the rate of a reaction, which is itself derived from the Michaelis-Menten equation  
Enzyme concentration is not a parameter in the Michalis-Menton equation as long 
as all other reaction components are in excess, meaning the concentration of 
enzyme is not a factor in the determination of the IC50 (page 127; Cornish-
Bowden, 2004).  Thus, the lack of a large increase in IC50 despite the very large 
increase in protein level is not unusual, in hindsight.   
Creation of OPB null mutants was also successfully achieved in L. major 
promastigotes, as was shown by the lack of expression of OPB protein (Figure 
5.12), showing that the peptidase is not essential for survival of this stage of the 
parasite in vitro.  However, only two null mutant clones were produced out of a 
potential 33, a very low ratio of success.  This could be because the promastigotes 
were initially disadvantaged by deletion of OPB and so only a low number of 
successful clones were able to survive the initial antibiotic selection.  Alternatively, 
the OPB locus could be located in a section of the genome in which recombination 
was comparatively difficult, so the construct preferentially recombined into an 
alternative locus. 
A lack of OPB did lead to a growth defect, with a lag in growth, slower growth rate 
and a lower stationary phase level of parasites (Figure 5.13), suggesting that the 
lack of OPB was in some way affecting the parasites.  As would be expected with 
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there was no need to alter the ploidy in order to preserve a WT copy of the gene 
(Figure 5.14).   
OPB was confirmed to be responsible for almost all cleavage of Bz-R-AMC, as the 
∆opb clones had only 0.7 to 1.4% of the activity of L. major WT promastigotes 
(Figure 5.15).  There was a gene-dose response found, with the heterozygote 
having approximately half of the activity of the WT.  This finding is in agreement 
with the dose response in enzymatic activity found when OPB was knocked out in 
T. cruzi (Caler et al., 1998).  The ~1% of activity that was detected even in the 
Dopb clones is most probably due to other enzymes with a very low level of ability 
to cleave this substrate or enzymes that are not present in the same compartment, 
the cytosol.  The two other OPB-like peptidases present in L. major, OPB-like 
(LmjF06.0340) and Bem-46 (LmjF35.4020), could be responsible for the remaining 
activity.  It is unknown what substrate specificity these peptidases have or where 
they are located within the parasite.  Other potential enzymes involved are the 
cathepsin L-like peptidases CPB or CPC, which are located in the lysosome but 
should be able to cleave Bz-R-AMC, as the CPB isoform CPB2.8 has been found 
to preferentially cleave fluorogenic substrates after an arginine residue (Alves et 
al., 2001a).  Only a very small amount of substrate may be delivered to this 
compartment through the endosomal system after being taken up by endocytosis.   
As antipain had been previously found to be an anti-leishmanial compound 
(Coombs et al., 1982) and it was an inhibitor of the cleavage of Bz-R-AMC by OPB 
(Figure 3.3), it was hypothesised that the anti-leishmanial action could be due to 
the inhibition of OPB.  A higher concentration of antipain was needed to kill the 
over-expresser lines, suggesting that more antipain was necessary to inhibit the 
extra OPB that was present (Figure 5.7).  However, as it was possible to knock out 
OPB in L. major, it was unlikely that OPB would be the only target of antipain.  It 
was indeed found that antipain could kill Dopb clones, with the heterozygotes and 
Dopb clone 21 having a lower LD50 than L. major WT, but Dopb clone 10 having a 
very similar LD50 (Figure 5.16).  This suggests that the other targets of antipain 
that are present in Leishmania may be expressed at a higher concentration in 
clone 10 to account for the increased LD50 of antipain when compared to the 
heterozygote population 1 from which it was derived. 
The Dopb clones were found to be similarly infective to PEM as L. major WT after 
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macrophages.  However, the percentages of infected cells declined over the 6 day 
infection period, with only around 5-10% infected by the end point of the 
experiment (Figure 5.17).  This is a promising finding, suggesting there may be a 
defect in metacyclogenesis or differentiation to amastigotes associated with loss of 
OPB, or perhaps a reduced ability of amastigotes to survive.  Metacyclic 
promastigotes are acknowledged as the infective stage of Leishmania (da Silva 
and Sacks, 1987) and so a decreased ability to survive in macrophages is 
indicative of a lower proportion of metacyclic promastigotes in the Dopb clones.  It 
was indeed found that there was a reduction in the number of metacyclic 
promastigotes in the Dopb clones using two different methods: peanut lectin 
agglutination of non-metacyclic promastigotes and HASPB expression as 
assessed by western immunoblots (Table 5.3 and Figure 5.18).  Dopb clone 10 
had a slightly higher number of macrophages still infected at day 6 post infection 
compared to Dopb clone 21, and this was corroborated by the numbers of 
metacyclic promastigotes found using both methods, with Dopb clone 10 having 
higher levels of metacyclics.  However, since some metacylic promastigotes are 
produced by both null mutant clones, the very poor survival of amastigotes in 
macrophages suggests that OPB also has a role in either differentiation to 
amastigotes or in amastigote survival itself. 
A few other genes known to be involved in metacyclogenesis have been 
described, including two cysteine peptidases.  L. major promastigotes which lack 
sphingolipids cannot complete metacyclogenesis (Zhang et al., 2003; Denny et al., 
2004).  L. mexicana double null mutants for the cysteine peptidases CPA and CPB 
fail to transform to metacyclic cells, with inhibition of autophagosome degradation, 
and have a defect in infection of macrophages (Williams et al., 2006).  A reduced 
ability to infect mice was also associated with lack of both sphingolipids and the 
cysteine peptidases, suggesting this is also associated with fewer metacyclics.   
The Dopb clones were also initially less infective to mice, with lesions developing 
in infected footpads with a lag period compared to wild-type parasites (Figure 
5.19).  Additionally, lesions developed at a slightly slower rate, with the lesions 
reaching a size of 5 mm between one and four weeks later than the mice infected 
with L. major WT.  Lesions of Dopb clone 10 were faster to develop than those of 
clone 21, echoing the infectivity to macrophages.  This suggests that a lag in 
initiation of a lesion may be due to fewer metacyclic promastigotes being injected Chapter 5      147 
or also to a reduced ability to differentiate to amastigotes, given that OPB has 
been shown to be upregulated in L. braziliensis and L. donovani amastigotes 
(Gamboa et al., 2007; Rosenzweig et al., 2008).  To determine which is correct it 
would be necessary to repeat the macrophage and mice experiments infecting 
with isolated metacyclic promastigotes.  Dopb clones re-expressing OPB are also 
needed to confirm the results are due to lack of OPB. 
5.3.1 Conclusions 
OPB can be over-expressed in L. major and the over-expressing lines show a 
highly increased rate of cleavage of Bz-R-AMC.  OPB can also be knocked out in 
promastigotes, showing it is not an essential gene in this life cycle stage.  OPB is 
the enzyme responsible for the vast majority of Bz-R-AMC cleavage since a 99% 
reduction in cleavage activity was found in the Dopb clones compared to the wild-
type.   
Dopb clones showed reduced ability to survive in macrophages and a lower level 
of metacyclic promastigotes in stationary phase cultures.  Lack of OPB is thus 
inhibiting the ability of the parasite to transform into the mammalian-infective stage 
of the parasite.  Dopb clones also had a lag in the growth of lesions in BALB/c 
mice, corroborating there being a deficiency in the ability to produce infective-
stage parasites.  That this result is due to the lack of OPB will have to be 
confirmed using Dopb clones re-expressing OPB.       148 
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6.1 Introduction 
Any experimental study on Leishmania depends on accurate detection of the 
parasites in some form.  In particular, any inaccuracy in determination of the 
number of Leishmania-infected macrophages presents a major hurdle to i) the 
development of anti-parasite drugs, ii) the determination of the effect of natural 
resistance or purposely inserted mutations on drug efficacy, and iii) the evaluation 
of the influence on macrophage infectivity of gene mutations and deletions (Croft 
et al., 2006).  In order to test the effectiveness of potential anti-Leishmania drugs, 
a quick, quantitative and realistic assay is clearly desirable (Sereno et al., 2007). 
6.1.1 Traditional methods for detection of Leishmania 
In many drug screening studies, cultured promastigotes have been used for 
primary screens as these are amenable to a high throughput system with plate-
based assays to determine viability, for example assays with MTT (Dutta et al., 
2005; Tanaka et al., 2007) and alamar blue (Mikus and Steverding, 2000; Dutta et 
al., 2005).  Such assays utilising promastigotes are advantageous due to their 
speed, accuracy and ease of use.  However, the promastigote stage is not the 
human infective life-cycle stage (Neal and Croft, 1984) and so using promastigotes 
may result in potentially useful compounds being missed.  For example, the 
pentavalent antimonial compounds used against Leishmania, sodium 
stibogluconate and meglumine antimoniate, are inactive against promastigotes 
(Neal and Croft, 1984).   
Assays using axenically grown amastigotes have also been developed (Callahan 
et al., 1997; Sereno and Lemesre, 1997; Sereno et al., 2005).  These have the 
advantage over promastigotes of being the human infective life-cycle stage, whilst 
still being quick, amenable to high throughput and easy to work with (Sereno et al., 
2007).  However, using axenic amastigotes obviously does not mimic the 
intracellular environment of Leishmania infection, with any role played by the host 
cell left unevaluated (Buckner and Wilson, 2005).  Therefore, although axenic 
amastigotes have many advantages, it is still common practice to test anti-
leishmanial compounds on infected macrophages (Yardley et al., 2006).   
In most studies using macrophages, to determine the activity of anti-leishmanial 
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percentage of infected macrophages and number of amastigotes per macrophage 
are determined by manual counting; a labour intensive and somewhat subjective 
method (Neal and Croft, 1984; Sereno et al., 2007).  Staining may also give 
inaccurate results as it can be very difficult to determine the viability of the 
amastigotes, and dead parasites may be included in the count (Sereno et al., 
2007).  Therefore, the development of alternative methods for the evaluation of the 
infection rates of Leishmania in macrophages has been an important area of study 
over recent years.  Within this area, reporter gene systems have been extensively 
investigated (Naylor, 1999; Sereno et al., 2007). 
6.1.2 Reporter gene systems 
A reporter gene is defined as a gene with a measurable phenotype, allowing 
detection above a background of endogenous proteins (Naylor, 1999).  Reporter 
gene systems are generally more sensitive than classical methods of screening 
Leishmania (Sereno et al., 2007).  Reporter systems have been designed which 
use several different proteins, including b-galactosidase and b-lactamase (Buckner 
and Wilson, 2005), green fluorescent protein (Naylor, 1999), and luciferase, 
typically firefly (Photinus pyralis) luciferase (Gould and Subramani, 1988; Naylor, 
1999).   
6.1.2.1  b b b b-galactosidase and b b b b-lactamase 
The bacterial enzyme b-galactosidase can be used in simple colorimetric and 
chemiluminescent assays (Naylor, 1999) and E. coli b-galactosidase has been 
stably expressed in L. major (LeBowitz et al., 1990).  b-galactosidase has been 
reported to have high background activity in eukaryotic cells, including 
macrophages (Buckner and Wilson, 2005), so it may be unsuitable for evaluating 
Leishmania-infected macrophages.  However, b-galactosidase has been 
expressed in L. amazonensis, by ectopic transfection, and detected by a change in 
absorbance upon cleavage of the b-galactosidase substrate CPRG (chlorophenol 
red b-D-galactopyranoside).  Correlations were found both between numbers of 
promastigotes present and the absorbance recorded upon breakdown of CPRG 
and between the number of amastigotes in infected macrophages and the 
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b-lactamase has been suggested to be a better reporter gene than b-galactosidase 
as it is suitable for use in live cell assays and catalyses the degradation of various 
coloured substrates, meaning colorimetric assays are possible, with no problem of 
background enzymatic activity in eukaryotic cells (Moore et al., 1997; Campbell, 
2004).  L. major and L. amazonensis have been generated with b-lactamase 
integrated into their genomes and these cells were used to test anti-leishmanial 
compounds on infected murine macrophages, with a correlation found between 
both manual counts of the infections obtained and with published accounts of LD50 
values for sodium stibogluconate and amphotericin B (Buckner and Wilson, 2005).
6.1.2.2  Green fluorescent protein 
Green fluorescent protein (GFP), isolated from the Aequorea victoria jellyfish, is 
autofluorescent, which provides for easy measurement of its activity in living cells, 
and GFP has been used as a reporter in many species (Naylor, 1999).  GFP has 
the advantage of its fluorescence range being highly sensitive and specific and 
also of being suitable for macrophage infection assays, as there is very little auto-
fluorescence in the host cell (Zhao et al., 2006).   
GFP has been extensively used for many purposes in Leishmania, including using 
GFP-expressing L. donovani promastigotes for anti-leishmanial drug testing (Singh 
and Dube, 2004).  In this study clinical isolates were transfected with a 
cytoplasmic GFP expression vector and the effectiveness of anti-leishmanial drugs 
was evaluated by detecting the living cells using fluorescence-activated cell sorting 
(FACS) analysis.  Also, GFP expressing L. infantum amastigotes have been used 
to test for the effect of HIV-1 infection on parasite ability to infect macrophages 
and grow intracellularly (Zhao et al., 2006), with the infectivity also evaluated using 
FACS analysis.  The necessity of the use of FACS for detection of fluorescence 
from GFP-expressing Leishmania does, however, mean that there is a limited 
scope to use GFP as a reporter gene for fast, simple assays of the infectivity to 
macrophages as the fluorescence is not high enough for microplate reader 
detection (Sereno et al., 2007).  Fluorescence signals from L. amazonensis 
expressing enhanced GFP (eGFP) have, however, been detected using a 
microplate reader, with a correlation found between numbers of promastigotes 
present and fluorescence and between amastigotes in infected macrophages and 
fluorescence (Okuno et al., 2003).  This suggests that the stronger signal 
produced with eGFP is more applicable for monitoring Leishmania numbers. Chapter 6      152 
6.1.2.3  Use of luciferase to detect pathogens 
Firefly luciferase has been extensively used as a reporter system with many 
pathogens, including intracellular bacteria and other parasitic species.  Since its 
luminescence depends on the presence of ATP in live cells, it is suitable as a test 
of cellular viability (Deb et al., 2000).  Firefly luciferase is particularly suitable for 
intracellular detection because its substrate, luciferin, can rapidly diffuse into cells 
and tissues (Hutchens and Luker, 2007). 
The survival of Mycobacterium species within macrophages upon administration of 
antimycobacterial agents, or stimulation of the macrophages, has been extensively 
studied with luciferase reporters.  The intracellular survival of luciferase-expressing 
M. tuberculosis and M. bovis was investigated using THP-1 cells and 
antimycobacterial drugs (Arain et al., 1996).  The results were validated by 
comparison to those obtained using traditional assessment methods (i.e., the 
assessment of colony forming units (CFU) of the bacteria released from 
macrophages, following drug treatment).  The stimulatory effect of 19 cytokines 
applied to monocyte-derived macrophages pre-infection has also been 
successfully evaluated, using luciferase-expressing M. bovis (Bonay et al., 1999).  
The assay was validated by finding a linear relationship between the numbers of 
bacteria found by CFU measurement and the luminescence recorded.  It was 
found to be both simple, and very sensitive to the viability of the mycobacteria.   
M. aurum expressing firefly luciferase have also been used to screen anti-
mycobacterial drugs, at their reported minimum inhibitory concentrations, using 
infected J774A.1 macrophage cells, with a strong correlation between the 
luminescence and CFU measurement (Deb et al., 2000). 
In the case of parasitic species, firefly luciferase has been used for in vivo imaging 
of Plasmodium bergei and Toxoplasma gondii.  P. bergei expressing the luciferase 
gene were used to visualise the sequestration of infected erythrocytes in mice 
using both whole body and isolated organ imaging and with luciferin administered 
to generate luminescence (Franke-Fayard et al., 2005; Franke-Fayard et al., 
2006).  A novel site for sequestration was found, adipose tissue, with the 
sequestrations confirmed by comparison with histological slides, thus 
demonstrating the usefulness of luciferase in visualising host-parasite interactions 
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T. gondii was transfected with both firefly luciferase and click beetle luciferase, in 
order to investigate differences in the disease progression and dissemination of 
parasites in mice upon variation of the oral infection method (Boyle et al., 2007).  
Firefly luciferase-expressing T. gondii have also been used to demonstrate the 
difference in growth and dissemination of parasites with high or low virulence, with 
parasite presence determined from non-invasive images produced after injection 
of luciferin into live mice (Saeij et al., 2005).  In this study the use of an anti-
Toxoplasma compound, sulfadiazine, to control infection with virulent T. gondii 
was also investigated.  The progress of infection was compared to untreated mice, 
demonstrating that drug effectiveness could be analysed using luciferase in an in 
vivo setting. 
6.1.2.4  Use of luciferase to detect Leishmania 
In Leishmania, firefly luciferase has been employed by using constructs that 
introduce the protein via both integration of the gene into the parasite genome at a 
defined locus and also having it as an ectopic copy (Sereno et al., 2007).  The use 
of luciferase for parasite detection has so far been reported for six Leishmania 
species, both visceral and cutaneous, i.e., L. donovani, L. infantum, L. major,  
L. panamensis, L. tropica and L. amazonensis. 
In 2000, both ectopic and integrated copies of firefly luciferase were introduced 
into L. major and L. donovani promastigotes and L. infantum axenic amastigotes, 
to allow the accurate quantification of amastigotes within macrophages (Roy et al., 
2000).  By using serially diluted parasites, a linear correlation was found between 
the number of L. major or L. donovani promastigotes present and the 
luminescence.  Notably, promastigotes containing the ectopic luciferase had 
higher luminescence readings and required fewer parasites for detection (Roy et 
al., 2000).  L. infantum axenic amastigotes expressing luciferase ectopically were 
also used to test the effect of antimonial drugs and pentamidine, and similar 50% 
inhibition concentration (IC50) values were found using luciferase as have 
previously been reported using such tests as the MTT assay (Sereno et al., 2001).  
L. donovani promastigotes have been generated that express a form of luciferase 
mutated at the C-terminal, so that it is retained in the cytosol rather than being 
transported into the glycosome – which results in a higher level of luciferase 
activity in the cells (Luque-Ortega et al., 2001).  The luminescence activity was Chapter 6      154 
again found to be consistent with the numbers of promastigotes present.  These 
promastigotes were then used to evaluate the effect of naphthoquinones on 
intracellular ATP concentrations, as a measure of their effect on mitochondrial 
ATP production, with two of the three drugs found to have similar 50% effective 
dose (ED50) concentrations when recorded via luminescence readings, 
mitochondrial membrane potential and parasite proliferation as assessed by MTT 
assay.  Another 14 drugs were also tested with six found to inhibit luminescence, 
again with a good correlation with the parasite proliferation and mitochondrial 
membrane potential.  Luminescence inhibition was found to correspond well with 
published data for anti-leishmanial activity for the effective drugs and the assay 
was postulated to be useful for investigating drugs with activity against ATP 
metabolism (Luque-Ortega et al., 2001). 
6.1.2.4.1 Use of luciferase in infected macrophages 
Over the last eight years, luciferase has been expressed in four species of 
Leishmania to evaluate the value of luminescence parasites for use in infected 
macrophage assays.  In 2000, L. infantum axenic amastigotes, expressing 
luciferase from an ectopic construct, were used to infect THP-1 cells and a good 
correlation was found between the numbers of infected macrophages, and the 
parasites present, and the luminescence, as long as the loss of macrophages due 
to high parasitaemia was taken into account (Roy et al., 2000).  If lower ratios of 
parasites to macrophages were used then the problem of loss of macrophages 
could be removed, but it was suggested by Roy et al. that to be confident that the 
numbers of parasites present were accurately determined it would be preferable to 
quantify the numbers of host cells using a second marker protein.   
The same L. infantum axenic amastigotes have also been used to test the effect of 
antimonial drugs against infected THP-1 cells, with the luminescence levels 
detected compared to counting of the percentages of infected cells.  The resulting 
IC50 values were similar to those previously reported in the literature (Sereno et al., 
2001).   
L. donovani promastigotes have been transfected with luciferase in several 
laboratories and used to test the usefulness of the cells for determining the 
infections in macrophages.  For example, in 2000 L. donovani promastigotes, with 
the same ectopic construct expressing luciferase as in the above two studies with Chapter 6      155 
L. infantum, were used to infect J774 macrophages and the numbers of parasites 
present were compared by manual counting and luminescence activity (Roy et al., 
2000).  With the L. donovani infected macrophages, a correlation between parasite 
number and luminescence was found, without any revision being necessary to 
account for macrophage loss.   
An ectopic construct containing luciferase has also been transfected into  
L. donovani field isolates, both sodium stibogluconate-resistant and -sensitive, and 
a reference strain for comparison (Ashutosh et al., 2005).  The luminescence of 
these parasites was compared to the numbers of parasites and found to correlate, 
with a minimum of 10 parasites needed for detection.  The luminescence was 
maintained for up to 30 days without antibiotic pressure and a correlation was also 
found between the numbers of amastigotes counted in infected J774 
macrophages and the luminescence.  Infected macrophages were then used to 
compare the effectiveness of potassium antimony tartrate trihydrate (SbIII) against 
the resistant and sensitive strains, compared to the reference strain.  The resistant 
strains were found to have threefold higher resistance compared to the sensitive 
strains and the reference strain, mirroring the clinical findings (Ashutosh et al., 
2005).   
In 2006, in another study using L. donovani,  promastigotes expressing the ectopic 
construct of Roy et al. (Roy et al., 2000) were generated and used to investigate 
the effectiveness of topoisomerase inhibitors and standard anti-leishmanials in 
infected U-937 macrophage assays (Jean-Moreno et al., 2006).  Luminescence 
was recorded and compared to counted parasite numbers, with a linear correlation 
found.  ED50 values were then calculated for the compounds by luminescence 
activity, again with correlation to those found by counting of infected cells. 
The ectopic construct of Roy et al. (Roy et al., 2000) has also been used to 
produce L. panamensis which express luciferase.  These were used to infect  
U-937 macrophages and the ED50 of seven fluoroquinolones against intracellular 
amastigotes were determined by reading luciferase activity, to compare to the 
ED50 against macrophages as a measure of selectivity.  The ED50 values 
determined by luminescence were found to be in good agreement with those 
determined by microscopical analysis of infected cells (Romero et al., 2005).   Chapter 6      156 
Finally, L. tropica promastigotes expressing luciferase have also been used in 
infected macrophages, using luminescence readings to compare the effectiveness 
of meglumine antimoniate against resistant and sensitive field isolates.  THP-1 
cells were infected with a number of sensitive and resistant parasites containing a 
luciferase ectopic construct and the ED50 values were determined for meglumine 
antimoniate.  These were compared to those already determined by counting of 
parasite numbers and found to be very similar (Hadighi et al., 2006) and it was 
confirmed that clinically-resistant isolates had higher ED50 values than clinically-
sensitive isolates. 
6.1.2.4.2 Use of luciferase in infected mice 
L. major promastigotes, containing ectopically-expressed luciferase, were used to 
investigate footpad infection of BALB/c mice.  The luminescence of pulverised 
footpad tissue was compared to an estimation of the numbers of parasites by a 
limiting dilution assay.  A correlation was found between parasite number and 
luminescence for two weeks post-infection.  However, by four weeks, the 
luminescence was underestimating the number of parasites due to the loss of the 
ectopic construct containing the luciferase when antibiotic pressure could not be 
maintained in vivo, since copy numbers of the ectopic construct were found to 
decrease over time.  L. major promastigotes, with luciferase integrated into the 
ribosomal locus, have also been used for footpad infection of BALB/c mice to 
compare with the ectopically expressing L. major.  With these parasites, a 
correlation was found between parasite number and luminescence for eight weeks 
post-infection (Roy et al., 2000). 
L. donovani promastigotes, containing ectopic luciferase, have also been used in 
animal experiments, using BALB/c mice, with the luminescence of pulverised liver 
compared to the number of parasites, estimated from counting parasites on 
impression smears, over an eight week period.  A slight underestimation of 
numbers was again found by luminescence, with the underestimation increasing 
from week 2 to week 6 of infection, which again was ascribed to the loss of the 
ectopic construct containing the luciferase when there was no antibiotic pressure 
(Roy et al., 2000).   
Luciferase has also been used for in vivo imaging of infected mice.  In this study,  
1 x 10
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the 18S rRNA locus of the genome, were inoculated into the ear of BALB/c mice 
and over a two week period the luminescence recorded was compared to limiting 
dilution assays.  The luminescence was induced by the injection of luciferin into 
the mice.  Parasites could be detected by one day post-infection.  The number of 
parasites found by limiting dilution assays increased over the period, particularly 
quickly after 1 week.  This was replicated in the luminescence readings, with a 
large increase in luminescence at day 16 compared to day 8.  It was found that 
inoculating with 1 x 10
5 parasites was also detectable, but when only 1 x 10
4 
parasites were used no luminescence was found (Lang et al., 2005).  The 
luminescence readings correlated with the numbers of parasites found by limiting 
dilution.  It was also found that it was possible to use standard curves for 
luminescence of purified amastigotes in order to quantify the number of parasites 
present in either infected macrophages or mouse tissues (Lang et al., 2005). 
6.1.2.5  General consensus on the effectiveness of luciferase for detection of 
Leishmania  
All the published studies which have been reviewed suggest that the use of firefly 
luciferase as a reporter for the presence of Leishmania in infected macrophages is 
a viable prospect and that the speed and accuracy of evaluation of both anti-
leishmanial compounds and infectivity of genetically altered parasites could be 
improved by the use of luminescent Leishmania.  It should also potentially be 
useful for more accurate determination of whether amastigotes are alive within 
macrophages, which is not always possible using traditional staining methods. 
For this reason a short digression was made from the main research here reported 
to examine the potential value of luciferase-expressing Leishmania for monitoring 
differences in parasite infectivity to macrophages in the main work. 
6.2 Results 
6.2.1 Luciferase lines used 
Two constructs were used to generate luciferase-expressing Leishmania; one was 
for integration into the Leishmania genome and the other was for ectopic 
expression.   Chapter 6      158 
6.2.1.1  Construct for integration of luciferase reporter 
The integrating construct was a gift of Prof. D.F. Smith (University of York, UK).  It 
was designed to integrate into the ribosomal RNA small subunit of Leishmania.  
The construct was derived from the pSSU-int construct of Dr T. Aebischer of the 
University of Edinburgh, UK, as described in Misslitz et al., 2000.   
The vector, pGL1313 (Figure 6.1), was prepared for transfection by enzymatic 
digestion using the restriction enzymes Ase I and Pme I by Dr Lesley Morrison, 
University of Glasgow.  L. major, L. mexicana and L. infantum parasites were 
species-checked by the PCR method (also by Dr Lesley Morrison, University of 
Glasgow), and then transfected with the digested pGL1313 DNA, as described in 
Section 2.5.7. 
Transfectants were selected with hygromycin, as described in Section 2.1.1, and 
the parasites were then diluted down and plated in three 96 well plates, to give an 
average of 0.1 parasites per well in order to generate clones.  Two clones were 
selected for each species and tested for luminescence. 
6.2.1.2  Construct for ectopic expression of luciferase reporter 
The ectopic construct was a gift of Prof. M. Ouellette (McGill University, Montreal, 
Canada).  It had been used previously in L. major, L. donovani and  
L. infantum (Roy et al., 2000; Sereno et al., 2001; Jean-Moreno et al., 2006), with 
the neomycin resistance gene, and in L. tropica with the hygromycin resistance 
gene (Hadighi et al., 2006).  The vector map is shown in Figure 6.2.  The 
intergenic region of the alpha tubulin gene is included to control the maturation of 
the luciferase transcript (Roy et al., 2000) and the 3' UTR of L. infantum amastin is 
included in the construct to induce reporter-gene expression
 specifically in 
amastigotes (Boucher et al., 2002).  The ectopic construct was transfected into  
L. mexicana, L. major and L. infantum cells.  Selection of clonal cell lines was not 
necessary since the luciferase reporter was ectopic; as such the cells were kept as 
populations.   
The Leishmania parasites containing the luciferase ectopic construct will hereafter 
be referred to as LUC cells. Chapter 6      159 
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Figure   6.1 Integrating construct for the expression of luciferase in Leishmania.  Map of the 
integrating construct, pGL1313.  The 5’ and 3’ rRNA small subunit sections are included for 
integration into this locus, the CPB 2.8 intergenic regions (IR) are to ensure high level of 
expression in the amastigote stage and the SAS is the splice acceptor site and Ase I and Pme I 
indicate the sites where digestion occurs with these restriction enzymes.  
 
         
pSP-HYG-LUC1.2
9719 bp
HygR
LUC
1.2 kb
alpha-tubIR
alpha-tubIR
 
Figure   6.2 Ectopic construct for the expression of luciferase in Leishmania.  Map of the 
ectopic construct, pSP-HYG-LUC1.2.  Luciferase indicates the luciferase gene, 1.2kb is the last  
1.2 kb of the amastin 3’ untranslated region and alpha-tubIR is the intergenic region of the a-tubulin 
gene. 
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6.2.2 Detection of Leishmania using integrating construct 
6.2.2.1  Validation of luciferase expression 
After the generation of hygromycin resistant clonal lines they were investigated to 
determine whether, or not, they expressed the luciferase gene and were thus 
luminescent. 
A final concentration of 12.5 µM D-luciferin was administered to the two clonal 
lines of each species and it was found that luciferase was being expressed by five 
of the Leishmania promastigote clonal lines: both of the L. mexicana and  
L. infantum clones, and clone 2 of L. major, since increasing luminescence was 
recorded with increasing numbers of these cells (Figure 6.3). 
6.2.2.2  Validation of detection of promastigotes 
Two methods were compared for the detection of promastigotes, i) the addition of 
D-luciferin to cells to a final concentration of 12.5 µM, and ii) Roche’s Luciferase 
Reporter Gene Assay, constant light signal, kit (hereafter referred to as the 
luciferase assay kit). 
There was a linear correlation between increasing numbers of cells and the 
increase in luminescence (Figures 6.4 and 6.5).  The clonal lines were in the same 
order of luminescence with both detection methods: the two L. infantum clones 
and L. mexicana clone 2 with the highest luminescence, followed by L. mexicana 
clone 1 and lastly L. major clone 2. 
The luciferase assay kit was found to be more sensitive, generating luminescence 
readings around 25-40 times higher than those obtained with D-luciferin. 
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Figure   6.3 Use of D-luciferin to detect the luminescence of Leishmania promastigotes.   
20 µl of a 1 mM stock solution of D-luciferin was administered to 180 µl of log phase promastigotes, 
giving a final concentration of 12.5 µM D-luciferin.  Luminescence was recorded for two replicates 
per concentration of cells and a mean of these is presented.  cl. = clone. 
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Figure   6.4 Use of D-luciferin to detect luminescence of Leishmania luciferase clonal log 
phase promastigotes.  20 µl of a 1 mM stock solution of D-luciferin was administered to 180 µl of 
log phase promastigotes, giving a final concentration of 12.5 µM D-luciferin.  Luminescence was 
recorded for three experiments (each of a single replicate), and a mean of these is presented.   
cl. = clone. 
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Figure   6.5 Use of the luciferase assay kit to detect the luminescence of Leishmania 
luciferase clonal log phase promastigotes.  100 µl of the luciferase assay kit solution was added 
to 100 µl of cells.  Luminescence was recorded for three experiments (each of a single replicate), 
and a mean of these is presented.  cl. = clone. 
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6.2.2.3  Validation of detection of amastigotes in infected peritoneal exudate 
macrophages (PEM) 
Luminescence was compared with the percentage of infected cells and the 
average number of amastigotes per macrophage, both as determined by manual 
counting (Tables 6.1 – 6.3).  The luciferase assay kit was used to analyse 
luminescence in infected macrophages since adding D-luciferin did not generate 
luminescence above background levels. 
Luminescence readings were highly variable and did not correspond to either the 
percentages of cells that were infected or to the numbers of parasites found per 
macrophage.  For example, for the L. mexicana clone 1 there was a 14-fold 
variation in the luminescence readings in the 4
th and 5
th experiments, when the 
macrophages were similarly infected, viz., 72% and 68% infected with 2.8 and 3.8 
amastigotes per macrophage respectively.   
Table   6.1 Corrected mean luminescence readings found for PEM infected with Leishmania 
luciferase clonal lines, using the luciferase assay kit.     
Exp
t 
L. mexicana 
clone 1  
(± ± ± ± SEM) 
L. mexicana 
clone 2  
(± ± ± ± SEM) 
L. major  
clone 2  
(± ± ± ± SEM) 
L. infantum 
clone 1  
(± ± ± ± SEM) 
L. infantum 
clone 2  
(± ± ± ± SEM) 
1  6,848 ± 1,260  286 ± 137  325 ± 40  76 ± 23  -12 ± 2 
2  464 ± 68  1,747 ± 420  52 ± 8  13 ± 4  743 ± 59 
3  70 ± 6  267 ± 38  67 ± 13  8 ± 6  15 ± 7 
4  29,884 ± 
2,208 
51,710 ± 
6,934  379 ± 58  357 ± 15  109 ± 19 
5  2,095 ± 243  2,014 ± 401  242 ± 33  2,046 ± 604  5,796 ± 1,956 
 
 
Table   6.2 Mean percentages of infected macrophages found for PEM infected with 
Leishmania luciferase clonal lines.     
Exp
t 
L. mexicana 
clone 1  
(± ± ± ± SEM) 
L. mexicana 
clone 2  
(± ± ± ± SEM) 
L. major  
clone 2  
(± ± ± ± SEM) 
L. infantum 
clone 1  
(± ± ± ± SEM) 
L. infantum 
clone 2  
(± ± ± ± SEM) 
1  49 ± 10  38 ± 7  74 ± 5  69 ± 4  78 ± 2 
2  33 ± 2  42 ± 7  48 ± 8  80 ± 3  41 ± 6 
3  47 ± 4  54 ± 6  56 ± 8  94 ± 2  95 ± 2 
4  72 ± 6  87 ± 3  90 ± 2  78 ± 7  77 ± 7 
5  68 ± 5  76 ± 11  78 ± 3  66 ± 4  66 ± 8 
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Table   6.3 Mean number of amastigotes found per macrophage for PEM infected with 
Leishmania luciferase clonal lines. 
Exp
t 
L. mexicana 
clone 1  
(± ± ± ± SEM) 
L. mexicana 
clone 2  
(± ± ± ± SEM) 
L. major  
clone 2  
(± ± ± ± SEM) 
L. infantum 
clone 1  
(± ± ± ± SEM) 
L. infantum 
clone 2  
(± ± ± ± SEM) 
1  2.0 ± 0.5  0.8 ± 0.1  3.0 ± 0.6  2.3 ± 0.1  3.0 ± 0.1 
2  1.1 ± 0.2  1.5 ± 0.3  1.6 ± 0.5  3.8 ± 0.6  1.2 ± 0.2 
3  1.2 ±  0.2  1.8 ± 0.2  1.4 ± 0.4  9.1 ± 1.1  8.9 ± 1.0 
4  2.8 ± 0.4  4.4 ± 0.4  3.9 ± 0.2  3.2 ± 0.7  2.3 ± 0.2 
5  3.8 ± 0.3  5.0 ± 0.6  4.4 ± 0.9  2.6 ± 0.2  2.6 ± 0.9 
 
6.2.3 Detection of Leishmania using ectopic construct 
6.2.3.1  Validation of luciferase expression 
LUC promastigote populations were investigated for expression of the luciferase 
gene and hence luminescence.  For all experiments using the LUC cells the 
luciferase assay kit was used. 
Luciferase was found to be expressed by each of the LUC populations (Table 6.4).  
The populations were thus used to determine suitability for detection of 
amastigotes within PEM.   
Table   6.4 Corrected mean luminescence readings found with 3 x 10
6 cells for Leishmania 
LUC populations, using the luciferase assay kit. 
Parasites tested  Luminescence of log     
phase cells (± SEM) 
Luminescence of stationary 
phase cells (± SEM) 
L. mexicana LUC   345,783 ± 30,890  247,018 ± 5,916 
L. major LUC   386,730 ± 19,289  556,457 ± 76,838 
L. infantum LUC   425,292  ± 23,014  248,701 ± 1,713 
 
6.2.3.2  Longevity of luminescence without antibiotic selection  
To determine the longevity of the retention of the luciferase ectopic construct and 
thus the luciferase gene, the luminescence was compared at several timepoints 
over a 24 day period using cultures with the antibiotic pressure removed and 
control cultures with the antibiotic pressure maintained. Chapter 6      165 
Luciferase activity was detectable for seven days post antibiotic removal, in all 
lines, though the L. mexicana LUC cells lost luciferase activity and presumably the 
ectopic construct very quickly after this (Figure 6.6).  Maintenance of luciferase 
activity for seven days should be sufficient for the experiments planned using 
infection of macrophages. 
6.2.3.3  Validation of detection of amastigotes in infected PEM 
PEM were infected with LUC stationary phase promastigotes and the luciferase 
assay kit was used to compare luminescence with the percentage of infected cells 
and the average number of amastigotes per macrophage, both determined by 
manual counting (Table 6.5).   
Table   6.5 Comparison of the corrected mean luminescence readings with the percentage of 
macrophages infected and the number of amastigotes per macrophage.   
Parasite and ratio 
of infection 
Luminescence  
(± SEM) 
% PEM Infected  
(± SEM) 
No. amastigotes 
per PEM (± SEM) 
L. mexicana 2:1  72.1 ± 11  80 ± 1.7  3.4 ± 0.2 
L. mexicana 5:1  70.0 ± 4  83 ± 7.8  4.7 ± 0.5 
       
L. major 5:1  4.5 ± 5  81 ± 2.7  5.5 ± 0.6 
L. major 7:1  18.0 ± 9  86 
 ± 3.1  5.7 ± 0.4 
       
L. infantum 7:1  26.0 ± 3  48 ± 3.8  0.9 ± 0.1 
L. infantum 10:1  25.0 ± 6  78 ± 3.1  3.7 ± 0.7 
 
 
Despite the macrophages being highly infected, no significant luminescence was 
recorded above background levels and no correlation was found between 
luminescence and the percentage of infected PEM and the number of amastigotes 
per macrophage.  For example, for the L. infantum LUC population, there was a 
30% difference in the percentage of macrophages infected and a 4 fold difference 
in the number of amastigotes present in the macrophages and yet no difference in 
luminescence was detected. 
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Figure   6.6 Corrected mean luminescence readings found for Leishmania LUC populations 
with or without hygromycin selective pressure.  Luminescence was measured over 24 days in 
culture using the luciferase assay kit.  + = presence of hygromycin, - = absence of hygromycin.   
50 µl of luciferase assay kit solution was added to 150 µl of cells, with 3 x 10
6 cells used per 
replicate.  Luminescence was recorded for three replicates per population and a mean of these is 
presented. 
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6.2.3.4  Determination of presence of luciferase 
Given the lack of luminescence detected for infected macrophages, the potential 
loss of the luciferase ectopic construct as the parasites transformed from 
promastigotes to amastigotes within macrophages was investigated.   
A comparison was made of luminescence readings as L. mexicana LUC 
promastigotes transformed to axenic amastigotes and back to promastigotes 
(Table 6.6).  Promastigotes transforming to axenic amastigotes (AA) are sub-
passage 0 (sp0), and were sampled over the week following inoculation into 
amastigote medium.  Fully transformed amastigotes were found by the 7
th day 
post inoculation.  The amastigotes were sub-passaged again and sampled after a 
further week (sp1) before the cells were inoculated into promastigote medium and 
sampled after one week when they had returned to promastigote form. 
Cell samples were also taken during the transformation for western immunoblot 
analysis with anti-firefly luciferase antibody, to determine levels of luciferase 
protein (Figure 6.7).   
Table   6.6 Comparison of corrected mean luminescence readings recorded for L. mexicana 
LUC cells.   
Cells used  Mean luminescence (± ± ± ± SEM) 
Promastigotes  234,231 ± 3,361 
Axenic amastigotes sp0  
2
nd day transforming  76,377 ± 240 
Axenic amastigotes sp0  
4
th day transforming  16,512 ± 53 
Axenic amastigotes sp0  
7
th day transforming  8,568 ± 138 
Axenic amastigotes sp1  4,013 ± 107 
Promastigotes transformed from 
axenic amastigotes  327,203 ± 4,846 
 
 
There was a reduction in the luminescence recorded over the period of 
transformation from promastigotes to axenic amastigotes.  However, the ectopic 
construct was not lost by the cells, as the luminescence was restored when 
transformed back from amastigotes to promastigotes.   
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A                  B 
 
Figure   6.7 Western immunoblot of luciferase presence during Leishmania differentiation.   
A = luciferase presence, using anti-firefly luciferase mouse monoclonal antibody at 1 in 1000 
dilution.  B = oligopeptidase B (OPB) presence as a loading control, using purified anti-OPB sheep 
antibody at 1 in 20,000 dilution.  HRP-conjugated anti-mouse and anti-sheep secondary antibodies 
were used at a concentration of 1 in 5,000.  The chemiluminescence was detected in an Xomat 
processor.  Promastigotes were transformed to axenic amastigotes (AAs) over one week, sub-
passaged as amastigotes and transformed back to promastigotes. 1= L. mexicana promastigotes, 
2= L. mex AA 2
nd day transforming, 3= L. mex AA 4
th day transforming, 4= L. mex AA 7
th day 
transforming, 5= L. mex AA subpassage 1, 6= L. mex promastigotes transformed back from AA. 
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The level of luciferase protein decreased as the transformation process 
proceeded, although luciferase was never fully ablated as enzyme was detected in 
the sp1 axenic amastigotes.  The enzyme was also seen to be highly expressed 
once more after the parasites transformed back to promastigotes, consistent with 
the luminescence readings obtained. 
6.3 Discussion 
Firefly luciferase has been shown to be a valuable tool for the detection of 
Leishmania, whether as promastigotes and intracellular amastigotes or in vivo 
(Roy et al., 2000; Jean-Moreno et al., 2006; Sereno et al., 2007), with six 
Leishmania species having been generated that express luciferase, by other 
laboratories.     
Both the integrative luciferase construct and the ectopically expressed luciferase 
construct were successfully used to transfect promastigotes to produce 
luminescent Leishmania parasites of L. mexicana, L. major and L. infantum 
species (Figure 6.3 and Table 6.4).  Five clones were produced using the 
integrative luciferase construct, two each for L. mexicana and L. infantum and one 
for L. major, and populations were produced of the ectopic luciferase, one per 
species (LUC cells). 
Intuitively, it was thought that an integrative luciferase construct would be the most 
useful; as clones could be produced and the levels of luciferase should be very 
similar between parasites, whereas with ectopically expressed protein the 
luciferase expressed could be very different between cells based on the copy 
number of the plasmid in individual cells.  However, the sensitivity of an integrative 
construct has previously been compared to an ectopic construct and the ectopic 
construct was found to exhibit higher luminescence and to be better suited for 
macrophage infections (Roy et al., 2000).  Interestingly, in that work it was found 
that the amount of luciferase RNA expressed was similar for the parasites with the 
integrated gene and the ectopic gene, meaning some unknown factor was 
involved in determining luminescence levels. 
Initially, a comparison was made between the use of D-luciferin and that of a lysis 
method, utilising Roche’s Luciferase Reporter Gene Assay, constant light signal, 
kit (luciferase assay kit), for detection of the integrated luciferase in promastigotes Chapter 6      170 
(Figures 6.4 and 6.5).  D-luciferin has previously been used to detect parasites in 
real time in vivo monitoring (Lang et al., 2005), and a modified luciferase ester to 
detect promastigotes (Luque-Ortega et al., 2001), whereas the luminescent cells 
have been assayed by lysis and an assay buffer in most studies, both of free living 
promastigotes (Roy et al., 2000; Sereno et al., 2001; Romero et al., 2005) and of 
infected macrophages (Ashutosh et al., 2005; Romero et al., 2005; Jean-Moreno 
et al., 2006). 
It was found that the addition of D-luciferin was acceptable for the detection of 
luciferase expressing promastigotes and that a linear correlation existed between 
promastigote numbers and luminescence recorded (Figure 6.4).  However, by 
using the luciferase assay kit much higher luminescence was recorded, with the 
same correlation of cell number and luminescence and the same order of 
luminescence activity in the 5 clonal lines (Figure 6.5). 
With macrophage infections the application of D-luciferin to generate 
luminescence was not successful, since the luminescence found was barely above 
background levels.  This was probably due to the luciferin having to cross the 
macrophage membrane into the parasitophorus vacuole and then into the 
amastigote before it could act as a substrate for the luciferase.  Therefore only 
data from the use of the luciferase assay kit was presented (Table 6.1). 
Percentages of infected macrophages were found to vary between 33% and 95%.  
There was very high variation found in the luminescence readings, even when 
there were similar numbers of amastigotes in similarly infected cells.  For example, 
for L. mexicana clone 2 the luminescence readings ranged from 267 to 51,710 and 
the similarly infected last two experiments (87% and 76% infected, with 4.4 and 
5.0 amastigotes per macrophage, respectively) had luminescence readings of 
51,710 and 2,014.  For L. infantum clone 1, two experiments had 80% and 78% 
infected macrophages, with 3.8 and 3.2 amastigotes per macrophage, but 
luminescence readings of 13 and 347 respectively.   
Overall, for intracellular parasites generally low luminescence readings were 
recorded for the L. major clone and the L. infantum clones, relative to the  
L. mexicana clones.  Although the L. major clone did have the lowest 
luminescence of all the clones when assessed as promastigotes, the low readings Chapter 6      171 
are particularly unexpected for the L. infantum clones as these had the highest 
luminescence as promastigotes. 
The L. infantum clones were also sent to the laboratory of Prof. D.F. Smith, who 
had supplied the original construct, where they were used to investigate the 
progress of mouse infections, but luminescence could not be detected above 
background in this case either.  In vivo imaging was successfully completed using 
L. donovani parasites expressing the same luciferase construct, however, so it is 
possible that there may be a difference caused by the species used, perhaps 
because the CPB 2.8 intergenic region used to ensure expression in the 
amastigote stage has variable effectiveness for this purpose in different species.   
Since there was a failure to correlate the percentage of cells infected and the 
luminescence readings (Tables 6.1 to 6.3), it was decided that there was no 
advantage in continuing with tests with these luminescent parasites as a method 
to accurately determine the number of infected macrophages.  The ectopic 
construct was thus obtained from Prof. Ouellette, as it had been used by several 
other groups and success reported in the literature (Roy et al., 2000; Sereno et al., 
2001; Romero et al., 2005; Hadighi et al., 2006; Jean-Moreno et al., 2006).  Both 
cutaneous (L. major, L. tropica and L. panamensis) and visceral (L. infantum and 
L. donovani) luciferase-expressing lines had been successfully generated, though 
the L. major parasites had not been reported to have been used in macrophage 
infections. 
Only one paper shows the calibration data used to correlate the numbers of 
amastigotes present and the luminescence (Roy et al., 2000).  Other papers 
published using the ectopic construct merely show that ED50 values could be 
calculated that were very similar to those calculated by manual counting and those 
already published (Sereno et al., 2001; Romero et al., 2005; Hadighi et al., 2006; 
Jean-Moreno et al., 2006), and state that correlation was found.   
The LUC populations were shown to express good levels of luminescence (Table 
6.4) and to maintain the luminescence for at least seven days in the absence of 
hygromycin selective pressure (Figure 6.6).  The L. mexicana and L. major 
promastigotes lost their luminescence from day 10 after the antibiotic was 
removed, whereas the L. infantum promastigotes maintained their luminescence 
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found with all three lines should be sufficient to ensure that the cells could be used 
for macrophage infections when antibiotic pressure is impossible to maintain. 
Macrophages infected with the LUC populations were found to exhibit no 
luminescence above background, despite the high levels of infection of the 
macrophages (Table 6.5) and the previous finding of luminescence in 
promastigotes (Table 6.4).  The lack of luminescence in amastigotes was 
unexpected, as the amastin 3’ UTR of L. infantum was included in the construct to 
ensure the luciferase was expressed in amastigotes, giving increased mRNA 
accumulation in amastigotes.  The last 770 bp of the amastin 3’ UTR has been 
shown to increase luciferase activity by 13-fold in axenic amastigotes and 24.5-
fold in intracellular amastigotes (Boucher et al., 2002).   
It has been described previously that higher levels of luminescence were found 
with promastigotes in culture compared to intracellular amastigotes (Roy et al., 
2000), and that a 10-fold increase in luminescence was found when axenic 
amastigotes were transformed into promastigotes.  It has also been shown that  
L. amazonensis amastigotes extracted from bone-marrow derived macrophages 
gave 10-fold higher luminescence than amastigotes from mouse lesions, but that 
promastigotes differentiated from amastigotes released from the infected bone-
marrow macrophages gave a 30-fold higher luminescence than the amastigotes 
(Lang et al., 2005).  These previous reports would correlate with the lowered 
luminescence found with intracellular amastigotes, compared to promastigotes, in 
this work.   
It has been postulated that the decrease in luminescence found in amastigotes 
could be due to degradation (Lang et al., 2005), as firefly luciferase has been 
suggested to be susceptible to proteolysis (Boucher et al., 2002).  Alternatively, 
the ectopic construct could be lost by the parasites as they transformed to 
amastigotes.  Thus the transformation process was examined with L. mexicana 
LUC axenic amastigotes, as an easier model to work with compared to 
macrophage-derived amastigotes.  The data show that the ectopic construct was 
not lost, as there was luminescence in the promastigotes that were transformed 
back from amastigotes (Table 6.6).  However the levels of luciferase protein were 
also shown to decrease over the transformation from promastigotes to 
amastigotes and to return to the original level once back in the promastigote stage 
(Figure 6.7), supporting the luminescence data obtained. Chapter 6      173 
6.3.1 Conclusions   
The integrating luciferase construct gave highly variable results with infected 
macrophages, with no consistency being found nor correlation between the 
numbers of amastigotes present and the luminescence.   
Given that five studies had successfully used the luciferase-encoding ectopic 
construct in macrophage tests, it was expected that more success would be 
obtained by using this line.  However, effectively no luminescence was detectable 
when macrophages were infected with the L. major, L. mexicana and L. infantum 
LUC cells, though good luminescence was obtained with promastigote LUC 
parasites.  The ectopic construct was retained by L. mexicana axenic amastigotes; 
even though the luminescence recorded decreased and the luciferase protein was 
found to be present at a much lower level in the amastigotes.  It can be supposed 
that the same is true of the amastigotes within infected macrophages. 
Since most of the studies published to date have used a neomycin-resistant form 
of the construct, it is possible that the construct has been altered in some way 
when the resistance markers were swapped.  This seems unlikely, however, since 
the hygromycin resistant plasmid has been successfully used to show differences 
in drug sensitivities of drug-resistant and -sensitive field isolates of  
L. tropica (Hadighi et al., 2006).  Another possibility is that there is a species 
difference that can account for the inability to successfully use LUC parasites for 
detection of amastigotes within infected macrophages, as L. major and  
L. mexicana parasites have not been previously used, and the L. infantum 
parasites reported in the literature were transfected as axenic amastigotes, rather 
than as promastigotes, which could cause the difference in success (Sereno et al., 
2001).  This may also be true for the integrative construct given the reported 
inability to use L. infantum with integrated luciferase for in vivo imaging when  
L. donovani cells were successful.   
Unfortunately, it was not possible to investigate the potential species issue in this 
study.  However, it is suggested that the use of L. donovani parasites or 
transfecting axenic amastigotes might be fruitful lines for further research.          174 
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7.1 Analysis of Peptidase Activity in Live Leishmania  
Prior to this study, the detection of peptidase activity in Leishmania using 
fluorogenic compounds had only been reported using cell lysates, although 
fluorogenic compounds had been used to investigate the peptidases in live cells of 
numerous mammalian cell lines (Boonacker and Van Noorden, 2001).  I have now 
shown that peptide-based compounds containing the fluorochrome 7-amino-4-
methylcoumarin (AMC) may successfully be used to detect the activity of 
peptidases in live Leishmania.  Bz-R-AMC was the only peptide tested that was 
successfully hydrolysed by Leishmania promastigotes (Section 3.2.1).  Bz-R-AMC 
was thus selected for this study since it is a small molecule with the potential to 
easily enter cells, with only one peptide bond able to be cleaved and the 
preliminary studies showed that it was readily hydrolysed by both L. mexicana and 
L. major. 
Cleavage of Bz-R-AMC by live Leishmania promastigotes was shown to be due to 
a peptidase which, based on analysis of the inhibition profile, is a serine peptidase 
with trypsin-like specificity for cleavage after basic residues 
(http://merops.sanger.ac.uk).  The absence of significantly different cleavage by 
the mutant line with lysosomal trafficking defects, the L. major VPS4
E235Q mutant 
(Besteiro et al., 2006), compared to equivalent wild-type promastigotes, suggested 
that the peptidase involved was unlikely to be resident in the lysosomal system, 
since in the VPS4
E235Q mutants the substrate would be unlikely to be properly 
delivered to the lysosomal compartment (Section 3.2.1).  Preventing endocytosis, 
using the actin polymerisation inhibitor cytochalasin D, had no effect on the 
hydrolysis of Bz-R-AMC.  Endocytosis is thus not the method by which Bz-R-AMC 
was entering Leishmania.  This would also seem to suggest that the Bz-R-AMC 
was unlikely to be being hydrolysed in the endosomal/lysosomal system, and if it 
was, it was not entering it directly.  It was also impossible to prevent the cleavage 
of Bz-R-AMC by blocking the arginine transporter; a transporter that perhaps could 
take up the substrate (Shaked-Mishan et al., 2006).  These results together imply 
that the substrate is most probably entering the cell via diffusion and is being 
hydrolysed by a peptidase in the cytosol (Section 3.2.3). 
As the enzyme being investigated had a trypsin-like specificity, given the likely 
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peptidase likely to be responsible for the hydrolysis was oligopeptidase B (OPB, 
LmjF.09.0770).  This hypothesis was shown to be correct when immuno-
precipitation of OPB protein from Leishmania lysate resulted in prevention of 
cleavage of the peptide (Section 4.2.5). 
OPB is present in trypanosomatids, plants and bacteria (Coetzer et al., 2008).  It 
was first shown to be present in L. major in 1999 (Morty et al., 1999b), and 
subsequently in L. amazonensis (de Matos Guedes et al., 2007).  In this study, 
OPB was found to be expressed at approximately equal levels in all three main life 
cycle stages in L. major (Section 4.2.1), whilst OPB has previously been found to 
be upregulated in amastigotes of L. braziliensis and L. donovani compared to 
promastigotes (Gamboa et al., 2007; Rosenzweig et al., 2008).  There may be a 
difference in expression levels between species, although the methods used may 
account for the different findings.  The higher expression reported for  
L. braziliensis amastigotes compared with promastigotes was based on RNA 
levels detected using differential display methodology (Gamboa et al., 2007); 
interestingly, OPB was not one of the genes found to have higher expression in  
L. major amastigotes in another differential display analysis (Ouakad et al., 2007).  
OPB was also not found in a microarray analysis of RNA expressed at differential 
levels between promastigotes and amastigotes of L. mexicana (Holzer et al., 
2006).  The analysis of L. donovani expression levels was completed using 
proteomic techniques and axenic amastigotes (Rosenzweig et al., 2008).  As well 
as using a different species, L. major, I used amastigotes isolated from an infected 
mouse, which may also account for the difference. 
The localisation of OPB to the cytosol by immunofluorescence is consistent with 
the previous localisation of the OPBs of T. cruzi, T. congolense and T. evansi 
(Caler et al., 1998; Morty et al., 1999a; Morty et al., 2005a).  The release of OPB 
by L. major was not found using the methods of this study, where potential release 
from amastigotes into macrophages was investigated by immunofluorescence, 
due to cross-reactivity of the anti-OPB antibody with proteins in the macrophage 
(Section 4.2.3).  However, T. cruzi OPB has been found to be released by 
trypomastigotes (Fernandes et al., 2005) and L. donovani OPB by promastigotes 
(Silverman et al., 2008), both by assaying OPB activity released into growth 
media.  This could indicate a role for OPB in the survival of Leishmania 
promastigotes within the sand fly gut or, if this finding was replicated in 
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This role could be in degradation of host peptides within the parasitophorus 
vacuole for the benefit of continuing infection, whether through impeding host anti-
parasite responses or parasite nutrition.  Alternatively, OPB could be secreted due 
to a role in processing exported proteins. 
7.2 Inhibition of OPB 
Anti-OPB antibodies have been found to inhibit the activity of OPB, both in this 
study for Leishmania (Section 4.2.5), and previously in studies of T. cruzi,  
T. brucei and T. evansi (Burleigh et al., 1997; Morty et al., 2001; Morty et al., 
2005a).  These antibodies are too large to inhibit the active site of the peptidase, 
since access to the active site is blocked by the pore in the b-propeller region of 
the protein which only allows the passage of small oligopeptides (Fulop et al., 
1998; Polgar, 2002).  This suggests that at least one of the polyclonal antibodies is 
possibly acting by blocking the entrance to the pore.  This raises the prospect of, 
as well as testing inhibitors of OPB chosen for their likelihood to interact with the 
active site, investigating inhibitors of OPB which act by blocking the entrance to 
the b-propeller pore.  Additionally, regions surrounding the b-propeller could be 
sites of binding for more specific inhibitors of OPB.  A number of peptidases found 
in mammals are also able to cleave following di-arginine residues, including 
cathepsins B, L, N and W, neprilysin, dipeptidyl peptidase III, trypsin, furin, 
numerous proprotein convertases and phytepsin (http://merops.sanger.ac.uk).  
These other enzymes could thus also be inhibited by inhibitors designed to interact 
with the di-arginine preference of the OPB active site, and so targeting the opening 
of the b-propeller may result in more specific inhibition. 
The effectiveness of inhibitors of OPB in killing Leishmania was investigated, since 
OPB inhibitors have previously been found to be anti-trypanosomal (Morty et al., 
2000).  Several drugs currently used to treat sleeping sickness are inhibitors of 
OPB (Morty et al., 1998), and the OPB inhibitor antipain is an antileishmanial 
compound (Coombs et al., 1982; Coombs and Baxter, 1984).  For this 
investigation a number of polyamine compounds were used.  These were chosen 
due to the similarity of the side chains of two of the compounds to arginine, the 
preferred P1 amino acid of OPB, with the remainder of the compounds intended to 
be controls.  However, when the polyamines were assayed both for their ability to 
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of the non arginine-like side chain compounds had IC50 values against 
recombinant OPB which were as low as those of the compounds with the arginine-
like side chains (Section 4.2.6).  These compounds are unlikely to be competing 
for the active site in a substrate-mimicking manner, given the dissimilarity of the 
compounds without the arginine-like side chains to OPB substrates.  It is possible 
that these compounds could be inhibiting OPB via blocking the pore of the  
b-propeller, rather than the active site itself, though this possibility requires further 
investigation. 
One of the polyamine compounds with an arginine-like side chain, CMR370, and 
three of the non arginine-like compounds were reasonable anti-leishmanials, with 
low micromolar LD50 values against promastigotes.  CMR370 was the best 
inhibitor of recombinant OPB and was also an inhibitor of Bz-R-AMC hydrolysis by 
live promastigotes.  CMR370 was also tested for its activity against L. major 
amastigotes.  However, it was not possible to determine an LD50 for this, since 
CMR370 led to apparent disintegration of the amastigotes, but not clearance of 
amastigotes from the macrophages.  It had been hoped to use luciferase-
expressing Leishmania for this testing, as then it would be possible to determine 
that the amastigotes were definitely killed.  However, although it appeared a 
promising side project, it was not possible to validate the use of luciferase-
expressing Leishmania lines for the detection of intracellular amastigotes in 
macrophages.  Therefore, the traditional method of manual counting of stained 
slides had to be used for the evaluation of the potential of CMR370 as an anti-
amastigote compound and of the infectivity of OPB null mutant lines, as detailed 
below. 
7.3 Evaluation of OPB as a Drug Target 
To evaluate the usefulness of OPB as a potential drug target, the effect of altering 
the levels of expression were investigated, with both over-expressers and null 
mutants of OPB produced.  There was no effect on the growth of promastigotes 
when OPB was over-expressed, though WT[OPB] mutants confirmed that an 
increased level of OPB led to an increase in the hydrolysis of the peptide substrate 
Bz-R-AMC (Section 5.2.2).  Ectopic expression of the active site mutant OPB in 
wild-type promastigotes, WT[OPB
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Bz-R-AMC.  This is probably explained by the mutated OPB competing for the 
substrate with the native OPB.   
OPB was not essential for promastigote stage parasites of L. major, since two null 
mutant clones were produced (Section 5.2.4).  The null mutants had a growth 
defect compared to wild-type promastigotes, with an initial growth lag and a slower 
rate of growth in log phase.  The null mutants conclusively demonstrated that OPB 
was responsible for the virtually all of the cleavage of Bz-R-AMC, since there was 
only approximately 1% of hydrolysis of the substrate with these clones, when 
compared to the wild-type.   
The Dopb null mutant clones had a defect in their ability to survive in 
macrophages, a promising finding suggesting that they are impaired in their ability 
to transform to mammalian-infective forms (Section 5.2.4.2).  A defect in 
metacyclogenesis was found, meaning fewer promastigotes than normal were 
developing into the infective promastigote form.  The fact that, despite there being 
some metacyclic promastigotes present, only low levels of amastigotes survive in 
macrophages suggests that OPB also has a role in either differentiation to 
amastigotes or in amastigote survival itself.  The latter seems likely, since the 
numbers of amastigotes fell between days 4 and 6 of infection, time points when 
the differentiation to amastigotes would be complete.  The Dopb null mutant 
promastigotes also had a defect in inducing lesions on the footpads of BALB/c 
mice, with a lag in growth of the lesion.  This lag in growth is likely to be due to 
both the defect in metacyclogenesis and also the likely additional survival of 
amastigotes in macrophages.  The additional deficiency in differentiation of 
metacyclic promastigotes to amastigotes or in survival as amastigotes is also 
suggested by OPB being found to be upregulated in amastigotes of L. braziliensis 
and in the early stages of differentiation of L. donovani to amastigotes (Gamboa et 
al., 2007; Rosenzweig et al., 2008).  In order to ascertain the effect on 
differentiation to amastigotes, purified metacyclic promastigotes should be used 
for infection of mice/macrophages.  The re-expression of OPB in the Dopb null 
mutants is also necessary to confirm the correct interpretation of the results using 
the null mutants.  Also, as it is not currently possible to differentiate L. major 
promastigotes to amastigotes axenically, it would be necessary to produce OPB 
null mutants in another species in order to investigate differentiation to 
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It is likely that there may be more effect of the lack of OPB on lesion development 
in other mice strains or in the natural host.  BALB/c mice, the strain which was 
used in this study, are particularly susceptible to infection with Leishmania (Chen 
et al., 2005).  The use of other, less susceptible, mice strains could be a more 
natural host for determining the role of OPB.  In addition, it may be that initiating 
infection of mice with numbers of promastigotes closer to those naturally egested 
upon bloodfeeding of sand flies could lead to a different result.  Up to around 
1,000 L. major promastigotes have been shown to be egested by Phlebotomus 
papatasi (Warburg and Schlein, 1986), whereas 50,000 promastigotes were 
injected into the BALB/c mice in this study. 
Even though inhibitors of OPB can kill Leishmania, it is likely that the inhibitors 
target other peptidases in Leishmania, given that Dopb null mutants can survive as 
both promastigotes and amastigotes.  This was found with antipain, which is both 
an OPB inhibitor and an antileishmanial, when the antileishmanial activity of 
antipain was tested on Dopb null mutants (Section 5.2.4.2).  Antipain was still able 
to kill these null mutant L. major, showing that other targets are involved.  The 
ability to generate null mutants of OPB and the ability of these mutants to infect 
BALB/c mice does mean that it is probably not suitable as a primary drug target, 
based on the current examination of the null mutants, though it could perhaps be 
targeted as part of a combinatorial approach.  Given that OPB appears to be 
involved in differentiation to infective parasite forms, this targeting could perhaps 
include a transmission hindering capacity or as prophylaxis to target differentiation 
to amastigotes, if OPB is confirmed to be involved in this differentiation.  
Additionally, if it is found that the secretion of OPB by promastigotes is relevant for 
survival in sand flies, it could be that treatment of the mammalian host with 
irreversible OPB inhibitors, though not curing infection in the current host, could 
reduce the ability of parasites to survive in the sand fly, thus also reducing 
transmission.  Transmission-blocking drugs have been investigated for malaria for 
several years (Butcher, 1997; Coleman et al., 2001; Ponsa et al., 2003) and could 
also be useful for leishmaniasis.  In addition, as OPB has been suggested to be a 
potential drug target for American and African trypanosomes (Fernandes et al., 
2005; Morty et al., 2005b) and for bacteria, treatments developed for other 
diseases could be investigated.  New antibacterial compounds are urgently 
needed and are being developed, with OPB being one potential target for anti-
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inhibitors of bacterial OPB have been found to successfully kill Gram-positive 
bacteria (Yu et al., 2008).  It is thus possible that drugs which have been 
developed and tested to treat bacterial diseases or trypanosomes could then be 
investigated for use as antileishmanials, with a consequently much reduced cost of 
development. 
7.4 Role of OPB  
The physiological substrates of OPB in the organisms which possess the 
peptidase are still in doubt (Coetzer et al., 2008).  However, OPB has been 
suggested to be a virulence factor of both bacteria and trypanosomatids.  The 
OPBs of various species have been found to hydrolyse a number of biologically 
active peptides rich in basic residues, including atrial natriuretic factor (Troeberg et 
al., 1996; Bagarozzi et al., 1998; Morty et al., 2005a), adrenocortotropic hormone 
(de Andrade et al., 1998; Tsuji et al., 2004), angiotensins I and II (Nishikata, 1984; 
Bagarozzi et al., 1998), neurotensin (Kanatani et al., 1991; Troeberg et al., 1996), 
serum thymic factor (Nishikata, 1984) and reduced [Arg
8] or [Lys
8] vasopressin 
(Troeberg et al., 1996).  Cleavage of atrial natriuretic factor in animals infected 
with African trypanosomes has been observed (Ndung'u et al., 1992; Morty et al., 
2005a) and shown to be due to OPB: the cleavage of atrial natriuretic factor by  
T. evansi OPB can be inhibited in infected rats using anti-OPB antibodies (Morty et 
al., 2005a).  The physiological relevance of cleavage of the other substrates is 
unknown.  Additionally, paired basic residues are abundant in the regions of 
processing of pro-peptides to peptides in biologically active molecules (Kreil, 
1990), suggesting the possibility that OPB could be involved primarily in 
processing.  
The roles of OPB in bacteria have not been determined (Polgar, 2002), though the 
enzyme is not essential for growth of Treponema denticola (Fenno et al., 2001) 
nor Salmonella enterica (Rea and Fulop, 2006).  In plants, the role of OPB 
similarly has not been fully elucidated, though it is thought to be involved in 
germination.  This has been suggested by study of wheat, Triticum aestivum, in 
which the amount of OPB increased as the wheat embryo germinated, suggesting 
a role in the processing and turnover of peptides in germination (Tsuji et al., 2004).  
Another role of the OPB of plants, though outside the plant itself, has been 
suggested by study of the OPB of the pollen of ragweed, Ambrosia artemisiifolia, Chapter 7      182 
which can cleave a number of biologically active peptides involved in maintaining 
bronchial function, including atrial natriuretic factor (ANF) and angiotensins I and 
II.  It may thus be at least partially responsible for the role of ragweed pollen in 
stimulating respiratory symptoms in hay fever and asthma sufferers (Bagarozzi et 
al., 1998). 
In trypanosomes the role of OPB has been investigated more fully.  OPB of African 
trypanosomes is released into the bloodstream of infected animals by lysis of 
dying parasites, where it is not inhibited by plasma serpins or a2-macroblobulin 
(Troeberg et al., 1996; Morty et al., 2001; Morty et al., 2005a).  OPB is thought to 
be responsible for the observed reduction in the levels of the regulatory peptide 
hormone ANF in the plasma of T. brucei-infected dogs and of T. evansi-infected 
rats (Ndung'u et al., 1992; Morty et al., 2005a), with anti-OPB antibodies leading to 
dramatically reduced hydrolysis of ANF in the blood of T. evansi-infected rats 
(Morty et al., 2005a).  The hydrolysis of ANF could result in the loss of control of 
blood volume and circulatory system lesions observed in trypanosome infections 
(Coetzer et al., 2008).  The ability of inhibitors of OPB to improve the survival rate 
of mice infected
 with T. brucei gives support for a role in the pathology of 
trypanosomiasis (Morty et al., 2000).  As there was no significant correlation
 
between the inhibition of OPB and the in vitro antitrypanosomal effect of these 
inhibitors, it has been proposed that they were actually mainly acting on the OPB 
in the host serum, thus influencing the course of the infection (Morty et al., 2000). 
In T. cruzi, OPB is involved in the invasion of non-phagocytic cells by 
trypomastigotes (Burleigh and Andrews, 1995; Burleigh et al., 1997; Caler et al., 
1998), by triggering an increase in the free intracellular calcium concentration.  
TcOPB does not signal directly for Ca
2+ release, but is responsible for generating 
a Ca
2+-signalling factor, which is exported from the trypomastigote, binds a host 
cell receptor and leads to the release of Ca
2+ from intracellular stores (Burleigh et 
al., 1997).  The Ca
2+-signalling activity was inhibited by OPB inhibitors and specific 
anti-T. cruzi OPB antibodies (Burleigh et al., 1997).  OPB null mutant T. cruzi 
trypomastigotes are 75% less infective than wild-type and the parasitaemia in mice 
was reduced when heterozygote or OPB null trypomastigotes were used as the 
infectants (Caler et al., 1998).  OPB null mutant parasites could not induce Ca
2+ 
transients and as the Ca
2+-signalling activity was restored by adding recombinant 
OPB, the central role of OPB in T. cruzi pathogenesis was confirmed (Caler et al., 
1998).  However, OPB has also been found to be released by trypomastigotes, so Chapter 7      183 
instead of cleaving an intracellular factor which is released to bind to the host cell, 
OPB could be cleaving a factor on the external surface of the parasite to enable 
uptake of T. cruzi (Fernandes et al., 2005).  Alternatively, it could interfere with 
host peptides or physiology, in a similar manner to that postulated for OPB in 
African trypanosome infections. 
As mentioned above, in Leishmania the role of OPB may be in the sand fly host, 
as it has been shown to be released from promastigotes (Silverman et al., 2008).  
It is possible that OPB is not essential for the growth of promastigotes in axenic 
culture conditions, but may have a role in survival in the sand fly gut, whether 
through degradation of peptides in the gut for nutrition or avoidance of host 
defence mechanisms.  Antimicrobial peptides (AMPs) are an important part of the 
immune response of the insect gut against both bacterial and parasitic pathogens 
(Boulanger et al., 2004).  A variety of AMPs are thought to be present in sand flies, 
with a screen of a cDNA library from Lutzomyia longipalpis identifying 43 
immunity-related genes (Dillon et al., 2006).  Although many of the AMPs of sand 
flies are yet to be determined, one, a hemolymph peptide of the insect defensin 
family, has been shown to be upregulated upon infection of Phlebotomus duboscqi 
sand flies with L. major (Boulanger et al., 2004).  It is possible that OPB secreted 
from promastigotes in the sand fly could be interfering with sand fly AMPs as a 
method of evading defence mechanisms.   
Investigation of whether amastigotes also secrete OPB is also a necessary step in 
the determination of its role in their survival in mammalian hosts.  The low survival 
of the null mutant clone amastigotes within macrophages found in this study, 
despite the presence of some metacyclic promastigotes, suggests that OPB may 
have a role in the survival of amastigotes within macrophages.  This role could 
potentially be linked to the secretion of OPB, with OPB potentially being involved 
in the degradation of host peptides in the parasitophorous vacuole. 
Alternatively, Leishmania OPB has been suggested to influence infection of 
macrophages through the activation of leishporins, which are cytosolic proteins 
which can damage macrophage membranes by forming transmembrane pores.  
They are secreted by the parasite and are thought to generate pores in either the 
parasitophorous vacuole membrane and/or the macrophage cell membrane, 
facilitating the release of amastigotes (Almeida-Campos and Horta, 2000).  OPB 
possibly releases the active leishporin by hydrolysing an oligopeptide inhibitor, Chapter 7      184 
though the activity was only generated by L. amazonensis cytosolic extract, and 
not L. guyanensis cytosolic extract (Almeida-Campos and Horta, 2000).  Whilst 
OPB from L. guyanensis has not been reported, OPB has been documented in the 
genome of the closely related species L. braziliensis (Peacock et al., 2007).  As 
OPB has been found in all trypanosomatids so far examined, it seems unlikely to 
have been completely lost from L. guyanensis.  However, as the likely OPB 
reported by de Andrade et al. from L. amazonensis (de Andrade et al., 1998) could 
activate the leishporin, it suggests that OPB is at least capable of this activation, 
though it may not be physiologically relevant.  If activation of leishporin was 
reported with L. major cytosolic extract, the role of OPB could be tested using the 
Dopb null mutants.  Investigation of the role of OPB would also require 
confirmation of the ability of the amastigote to secrete OPB, in order to activate the 
leishporin in the parasitophorous vacuole. 
The role of OPB in metacyclogenesis, or differentiation to amastigotes, is unlikely 
to be linked to secretion of the peptidase.  The role could be akin to the defect in 
metacyclogenesis caused by a lack of autophagy (Besteiro et al., 2006), a self-
digestion process whereby cells degrade proteins and organelles in the cytoplasm, 
by sequestration into a double-membrane vesicle, which normally fuses with the 
lysosome to allow the degradation of the cargo by hydrolases (Reggiori and 
Klionsky, 2005).  It is possible that OPB aids metacyclogenesis or differentiation 
through degradation of peptides in the cytosol, providing material for the 
remodelling of the parasite undertaken at this time, analogous to the degradation 
of proteins in the lysosome through autophagy.  Alternatively, OPB could be 
involved in the processing of propeptides or other regulatory peptides involved in a 
cascade leading to differentiation to infective parasite forms. 
7.5 Conclusions and Future Directions 
The detection of peptidase activity in live Leishmania using the fluorogenic 
substrate Bz-R-AMC has proved a fruitful line of study, enabling the 
characterisation of the activity of the serine peptidase OPB in live L. major 
promastigotes.  OPB is expressed in similar levels in all three main stages of the 
life cycle of L. major and also in other Leishmania species.  The inhibition profile of 
OPB was determined in live promastigotes and OPB was localised to the cytosol, 
the site of Bz-R-AMC hydrolysis.  Immunoprecipitation confirmed that OPB was Chapter 7      185 
responsible for the cleavage of Bz-R-AMC, with anti-OPB antibodies inhibiting the 
hydrolysis.  Inhibitors of OPB also killed Leishmania promastigotes. 
Genetic manipulation of OPB was successfully completed, with both mutants over-
expressing OPB and Dopb null mutants produced.  Thus, OPB was found not to be 
essential for the growth of promastigote L. major, though lack of OPB did lead to a 
defect in metacyclogenesis, a defect in the ability to survive in macrophages and a 
reduced ability to induce lesions on the footpads of BALB/c mice.   
A number of areas for future research are suggested by the findings of this study.  
Crucially, re-expression of OPB in the Dopb null mutants is necessary, in order to 
confirm the phenotypic deficiencies of the null mutants are due to the lack of OPB.   
Since it appears that OPB may have a role in either differentiation to amastigotes 
and/or in amastigote survival itself, over and above the role of OPB in 
metacyclogenesis, a full investigation of its involvement in these processes should 
be undertaken.  To investigate the amastigote-specific effects, purified metacyclic 
promastigotes could be used to infect mice and macrophages.  This would 
determine whether or not OPB indeed is important for differentiation to the 
amastigote form and/or amastigote survival.   
Additionally, confirmation of the release of OPB by promastigotes and 
investigation of its release by amastigotes are required.  Secretion by 
promastigotes suggests a role in parasite survival in the sand fly or differentiation 
through the various developmental stages that occur there; it would be interesting 
to know how important OPB is for completing the life cycle in the insect vector and 
in transmission to a mammalian hosts.  Release of OPB from amastigotes would 
suggest that OPB also plays some role in the parasite’s interaction with the 
macrophage. 
Finally, a crucial area for the future study of OPB is to establish the physiological 
substrate(s), as this would greatly aid identification of the role of OPB.  This may 
be possible using the Dopb null mutants generated in this study, perhaps by 
proteomic comparison with wild-type parasites.  Alternatively, immunoprecipitation 
of substrates could be attempted.  Discovering the role of OPB could also lead to 
further understanding of the mechanisms of differentiation of Leishmania.         186 
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